Nuo Therapeutics (AURX) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 10, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'CYTOMEDIX INC	'	'
Entity Central Index Key	'0001091596	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'CMXI	'	'
Entity Common Stock, Shares Outstanding	'	110,751,077	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$36

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets	'	'
Cash	$3,286,713	$2,615,805
Short-term investments, restricted	53,257	53,248
Accounts and other receivable, net	3,926,681	1,733,742
Inventory	1,111,507	1,170,097
Prepaid expenses and other current assets	1,258,282	737,445
Deferred costs, current portion	316,551	136,436
Total current assets	9,952,991	6,446,773
Property and equipment, net	919,469	2,440,081
Deferred costs	482,349	180,783
Intangible assets, net	33,768,954	34,135,287
Goodwill	1,128,517	1,128,517
Total assets	46,252,280	44,331,441
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable and accrued expenses	8,018,672	2,812,371
Deferred revenues, current portion	740,990	0
Note payable, current portion	1,800,000	0
Total current liabilities	10,559,662	2,812,371
Notes payable	3,620,593	2,100,000
Convertible debt	202,658	462,815
Deferred revenues	1,441,852	0
Derivative and other liabilities	3,615,521	952,344
Total liabilities	19,440,286	6,327,530
Commitments and contingencies	'	'
Conditionally redeemable common stock (909,091 issued and outstanding)	500,000	0
Stockholders' equity	'	'
Common stock; $.0001 par value, authorized 200,000,000 shares; 2013 issued and outstanding - 107,164,855 shares; 2012 issued and outstanding - 93,808,386 shares	10,626	9,381
Common stock issuable	432,100	489,100
Additional paid-in capital	117,097,844	108,485,646
Accumulated deficit	-91,228,576	-70,980,216
Total stockholders' equity	26,311,994	38,003,911
Total liabilities and stockholders' equity	$46,252,280	$44,331,441

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2013	Dec. 31, 2012
Temporary equity, shares issued	909,091	'
Temporary equity, shares outstanding	909,091	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized	200,000,000	200,000,000
Common stock, issued	107,164,855	93,808,386
Common stock, outstanding	107,164,855	93,808,386

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues	'	'
Product sales (includes excise tax of $185,767 in 2013)	$10,498,726	$7,241,392
License fees	167,657	3,154,722
Royalties	703,744	168,106
Other revenue	201,311	0
Total revenues	11,571,438	10,564,220
Cost of revenues	'	'
Cost of sales	8,363,902	3,898,162
Cost of royalties	89,290	16,380
Total cost of revenues	8,453,192	3,914,542
Gross profit	3,118,246	6,649,678
Operating expenses	'	'
Salaries and wages	7,319,407	7,106,906
Consulting expenses	2,148,983	2,275,905
Professional fees	1,156,868	1,189,734
Research, development, trials and studies	3,798,398	3,386,439
General and administrative expenses	6,789,660	5,585,419
Total operating expenses	21,213,316	19,544,403
Loss from operations	-18,095,070	-12,894,725
Other income (expense)	'	'
Interest, net	-1,680,023	-1,041,533
Change in fair value of derivative liabilities	-470,052	492,311
Change in fair value of contingent consideration	0	-4,334,932
Inducement expense	0	-1,513,371
Settlement of contingency	0	-471,250
Other	15,374	-16,558
Total other income (expenses)	-2,134,701	-6,885,333
Loss before provision for income taxes	-20,229,771	-19,780,058
Income tax provision	18,589	18,000
Net loss	-20,248,360	-19,798,058
Preferred dividends:	'	'
Net loss to common stockholders	-20,248,360	-19,811,620
Loss per common share - Basic and diluted (in dollars per share)	($0.20)	($0.24)
Weighted average shares outstanding - Basic and diluted (in shares)	103,620,046	81,859,343
Series D preferred stock [Member]	'	'
Other income (expense)	'	'
Net loss	0	0
Preferred dividends:	'	'
Preferred stock	$0	$13,562

CONSOLIDATED_STATEMENTS_OF_OPE1

CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] (USD $)	12 Months Ended
	Dec. 31, 2013
Excise and Sales Taxes	$185,767

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Issuable [Member]	Accumulated Deficit [Member]	Conditionally Redeemable Common Stock [Member]
Balance at Dec. 31, 2011	$3,281,583	$10	$7	$0	$0	$5,554	$54,458,170	$0	($51,182,158)	'
Balance (in shares) at Dec. 31, 2011	'	97,663	65,784	3,300	0	55,536,292	'	'	'	'
Common stock issued upon conversion of 4% Convertible Promissory Note	924,904	0	0	0	0	106	924,798	0	0	'
Common stock issued upon conversion of 4% Convertible Promissory Note (in shares)	'	0	0	0	0	1,062,500	'	'	'	'
Common stock issued pursuant to private offering completed in First Quarter	5,000,000	0	0	0	0	423	4,999,577	0	0	'
Common stock issued pursuant to private offering completed in First Quarter (in shares)	'	0	0	0	0	4,231,192	'	'	'	'
Common stock issued pursuant to equity purchase agreements executed in October 2010	4,493,903	0	0	0	0	453	4,493,450	0	0	'
Common stock issued pursuant to equity purchase agreements executed in October 2010 (in shares)	'	0	0	0	0	4,529,701	'	'	'	'
Cash redemption of Series A stock	-101,569	-10	0	0	0	0	-101,559	0	0	'
Cash redemption of Series A stock (in shares)	'	-97,663	0	0	0	0	'	'	'	'
Cash redemption of Series B stock	-68,416	0	-7	0	0	0	-68,409	0	0	'
Cash redemption of Series B stock (in shares)	'	0	-65,784	0	0	0	'	'	'	'
Preferred stock and warrants issued pursuant to Aldagen acquisition completed in First Quarter	1,883,765	0	0	0	14	0	1,883,751	0	0	'
Preferred stock and warrants issued pursuant to Aldagen acquisition completed in First Quarter (in shares)	'	0	0	0	135,398	0	'	'	'	'
Common stock and warrants issued upon conversion of outstanding Series D stock	1,051,371	0	0	0	0	746	1,050,625	0	0	'
Common stock and warrants issued upon conversion of outstanding Series D stock (in shares)	'	0	0	-3,300	0	7,460,350	'	'	'	'
Common stock issued to Series D shareholders as inducement to convert outstanding shares	462,000	0	0	0	0	33	461,967	0	0	'
Common stock issued to Series D shareholders as inducement to convert outstanding shares (in shares)	'	0	0	0	0	330,000	'	'	'	'
Common stock issued upon conversion of Series E stock	34,204,548	0	0	0	-14	1,340	34,203,222	0	0	'
Common stock issued upon conversion of Series E stock (in shares)	'	0	0	'	-135,398	13,399,986	'	'	'	'
Dividends accrued on Preferred stock	-13,562	0	0	0	0	0	-13,562	0	0	'
Dividends on Series D stock, paid in Common shares	82,500	0	0	0	0	8	82,492	0	0	'
Dividends on Series D stock, paid in Common shares (in shares)	'	0	0	0	0	76,461	'	'	'	'
Common stock issued upon exercise of Long-term Incentive Plan options	15,185	0	0	0	0	4	15,181	0	0	'
Common stock issued upon exercise of Long-term Incentive Plan options (in shares)	'	0	0	0	0	35,602	'	'	'	'
Common stock issued upon exercise of August 2008 warrants	584,672	0	0	0	0	58	584,614	0	0	'
Common stock issued upon exercise of August 2008 warrants (in shares)	'	0	0	0	0	584,672	'	'	'	'
Common stock issued upon exercise of August 2009 warrants	213,674	0	0	0	0	42	213,632	0	0	'
Common stock issued upon exercise of August 2009 warrants (in shares)	'	0	0	0	0	418,968	'	'	'	'
Common stock issued upon exercise of April 2010 warrants	1,521,028	0	0	0	0	283	1,520,745	0	0	'
Common stock issued upon exercise of April 2010 warrants (in shares)	'	0	0	0	0	2,833,493	'	'	'	'
Common stock issued upon exercise of Guarantor 2010 warrants	715,734	0	0	0	0	133	715,601	0	0	'
Common stock issued upon exercise of Guarantor 2010 warrants (in shares)	'	0	0	0	0	1,333,334	'	'	'	'
Common stock issued upon exercise of October 2010 warrants	225,001	0	0	0	0	38	224,963	0	0	'
Common stock issued upon exercise of October 2010 warrants (in shares)	'	0	0	0	0	375,000	'	'	'	'
Common stock issued upon exercise of Guarantor 2011 warrants	791,667	0	0	0	0	158	791,509	0	0	'
Common stock issued upon exercise of Guarantor 2011 warrants (in shares)	'	0	0	0	0	1,583,335	'	'	'	'
Common stock issued in lieu of cash for fees earned by consultant	17,850	0	0	0	0	2	17,848	0	0	'
Common stock issued in lieu of cash for fees earned by consultant (in shares)	'	0	0	0	0	17,500	'	'	'	'
Common stock issuable in lieu of cash for fees earned by consultant	17,850	0	0	0	0	0	0	17,850	0	'
Common stock issuable to holders of pre-bankruptcy Series A Preferred stock, pursuant to reorganization plan	471,250	0	0	0	0	0	0	471,250	0	'
Stock-based compensation related to stock options and warrants issued for services rendered by -	'	'	'	'	'	'	'	'	'	'
Employees and Directors	1,751,107	0	0	0	0	0	1,751,107	0	0	'
Other parties	275,924	0	0	0	0	0	275,924	0	0	'
Net loss	-19,798,058	0	0	0	0	0	0	0	-19,798,058	'
Balance at Dec. 31, 2012	38,003,911	0	0	0	0	9,381	108,485,646	489,100	-70,980,216	'
Balance (in shares) at Dec. 31, 2012	'	0	0	0	0	93,808,386	'	'	'	'
Amendment to contingent consideration for Aldagen acquisition	1,006,159	0	0	0	0	0	1,006,159	0	0	0
Warrants issued for credit and security agreement	580,394	0	0	0	0	0	580,394	0	0	0
Warrants issued for term loan modification	455,275	0	0	0	0	0	455,275	0	0	0
Common stock issued for release of security interest in patents	325,693	0	0	0	0	25	325,668	0	0	0
Common stock issued for release of security interest in patents (in shares)	'	0	0	0	0	250,000	'	'	'	'
Common stock issued upon conversion of 4% Convertible Promissory Note	523,927	0	0	0	0	160	523,767	0	0	0
Common stock issued upon conversion of 4% Convertible Promissory Note (in shares)	'	0	0	0	0	1,600,219	'	'	'	'
Common stock issued pursuant to private offering completed in First Quarter	4,557,188	0	0	0	0	818	4,056,370	0	0	500,000
Common stock issued pursuant to private offering completed in First Quarter (in shares)	'	0	0	0	0	9,090,911	'	'	'	'
Common stock issued pursuant to equity purchase agreements executed in October 2010	303,000	0	0	0	0	45	302,955	0	0	0
Common stock issued pursuant to equity purchase agreements executed in October 2010 (in shares)	'	0	0	0	0	450,000	'	'	'	'
Common stock issued pursuant to equity purchase agreements executed in February 2013	601,945	0	0	0	0	189	601,756	0	0	0
Common stock issued pursuant to equity purchase agreements executed in February 2013 (in shares)	'	0	0	0	0	1,890,261	'	'	'	'
Common stock issued to holder of pre-bankruptcy Series A Preferred stock, pursuant to reorganization plan	0	0	0	0	0	3	39,147	-39,150	0	0
Common stock issued to holder of pre-bankruptcy Series A Preferred stock, pursuant to reorganization plan (in shares)	'	0	0	0	0	27,000	'	'	'	'
Stock-based compensation related to stock options and warrants issued for services rendered by -	'	'	'	'	'	'	'	'	'	'
Employees and Directors	676,185	0	0	0	0	0	676,185	0	0	0
Other parties	26,678	0	0	0	0	4	44,524	-17,850	0	0
Other parties (in shares)	'	0	0	0	0	37,500	'	'	'	'
Other changes	-1	0	0	0	0	1	-2	0	0	0
Other changes (in shares)	'	0	0	0	0	10,578	'	'	'	'
Net loss	-20,248,360	0	0	0	0	0	0	0	-20,248,360	0
Balance at Dec. 31, 2013	$26,311,994	$0	$0	$0	$0	$10,626	$117,097,844	$432,100	($91,228,576)	$500,000
Balance (in shares) at Dec. 31, 2013	'	0	0	0	0	107,164,855	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($20,248,360)	($19,798,058)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Bad debt expense, net of recoveries	75,165	42,625
Depreciation and amortization	1,092,143	1,179,160
Stock-based compensation	717,863	2,047,731
Change in fair value of derivative liabilities	470,052	-492,311
Change in fair value of contingent consideration	0	4,334,932
Settlement of contingency	0	471,250
Amortization of deferred costs	248,606	136,436
Non-cash interest expense - amortization of debt discount	323,146	614,450
Deferred income tax provision	18,589	18,000
Loss (Gain) on disposal of assets	-594,173	84,336
Effect of amendment to contingent consideration	1,006,159	0
Loss on extinguishment of debt	19,868	0
Effect of issuance of warrants for term loan modification	303,517	0
Inducement expense	0	1,513,371
Change in operating assets and liabilities, net of those acquired:	'	'
Accounts and other receivable, net	-2,268,104	-260,510
Inventory	58,590	-602,108
Prepaid expenses and other current assets	-210,153	60,105
Accounts payable and accrued expenses	5,206,301	-83,767
Deferred revenues	2,182,842	-654,721
Other liabilities	196,953	-3,740
Net cash used in operating activities	-11,400,996	-11,392,819
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Property and equipment acquisitions	-750,697	-2,087,562
Cash acquired in business combination	0	24,563
Proceeds from sale of equipment	2,139,672	471,289
Net cash provided by (used in) investing activities	1,388,975	-1,591,710
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from issuance of debt	6,240,797	0
Proceeds from issuance of common stock, net	5,462,132	9,493,906
Redemption of preferred stock	0	-169,986
Repayment of note payable	-1,020,000	0
Proceeds from option and warrant exercises	0	4,066,959
Dividends paid on preferred stock	0	-36,595
Net cash provided by financing activities	10,682,929	13,354,284
Net increase in cash	670,908	369,755
Cash, beginning of period	2,615,805	2,246,050
Cash, end of period	$3,286,713	$2,615,805

Description_of_the_Business

Description of the Business	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	Note 1 — Description of the Business
	Cytomedix, Inc. (“Cytomedix,” the “Company,” “we,” “us,” or “our”) is a regenerative therapies company marketing products within the U.S. and internationally. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous from self biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long term recovery in complex chronic conditions with significant unmet medical needs.
	Our current commercial offerings consist of point of care technologies for the safe and efficient separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates. Today, we have two distinct platelet rich plasma (“PRP”) devices, the AutoloGelTM System for wound care and the Angel® concentrated Platelet Rich Plasma (“cPRP”) System for orthopedics markets. Our sales are predominantly (approximately 91%) in the United States, where we sell our products through direct sales representatives and distributors. In 2013, Arthrex accounted for 48% of total product sales. Since August 8, 2013, Arthrex accounted for 100% of our Angel sales. This customer’s receivable balance at December 31, 2013 represented approximately 92% of the Company’s total accounts receivable. There were no other customers that represented a concentration in either revenue or receivables at December 31, 2013 or 2012.
	Growth drivers in the U.S. include Medicare coverage for the treatment of chronic wounds under a National Coverage Determination when registry data is collected under Coverage with Evidence Development (“CED”), and a worldwide distribution and licensing agreement that allows our partner to promote the Angel System for all uses other than wound care.

Liquidity_Risks_and_Management

Liquidity Risks and Management's Plans	12 Months Ended
	Dec. 31, 2013
Liquidity Risks And Managementbs Plans [Abstract]	'
Liquidity Risks And Managementbs Plans [Text Block]	'
	Note 2 — Liquidity Risks and Management’s Plans
	Since inception we have financed our operations through capital infusions, licensing, royalty, and product revenues and have incurred recurring losses and negative cash flows. At December 31, 2013, we had approximately $3.3 million of cash.
	On March 31, 2014, the Company was provided with a $35,000,000 credit facility, of which $9,000,000 was disbursed to the Company on March 31, 2014, and the remaining $26,000,000 will be disbursed to the Company upon the authorization of the Company’s shareholders to increase the Company’s authorized capital stock. In addition, the Company entered into a subscription agreement which provided the Company with gross proceeds of $2,000,000. The net proceeds of these infusions were used by the Company to retire the term loan with MidCap and the remainder will be utilized for general corporate and working capital purposes. See Note 23 for additional details.
	As a result, the Company believes that our current resources will be sufficient to fund our operations beyond 2014.
	If we continue to incur negative cash flow from sources of operating activities for longer than expected, our ability to continue as a going concern could be in substantial doubt and we will require additional funds through debt facilities, and/or public or private equity or debt financings to continue operations. We cannot provide any assurance that we will be able to obtain the capital we require on a timely basis or on terms acceptable to us.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 3 — Summary of Significant Accounting Policies
	Basis of Presentation and Consolidation
	The Company’s financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. They include the accounts of the company and our subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation with no impact to net loss.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.
	Business Combinations
	The Company accounts for business combinations using the acquisition method. Under this method the Company allocates the purchase price to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition, including intangible assets that arise from contractual or other legal rights or are separable (i.e. capable of being sold, transferred, licensed, rented, or exchanged separately from the entity). Determination of fair value is based on certain estimates and assumptions regarding such things as forecasted future revenues and expenses, customer attrition, prevailing royalty rates, required rates of return, etc. The purchase price in excess of the fair value of the net assets and liabilities is recorded as goodwill.
	Concentration of Risk
	Approximately $613,000 and $40,000 held in financial institutions was in excess of FDIC insurance at December 31, 2013 and 2012, respectively. Approximately $2,667,000 and $1,754,000 held in money market accounts at brokerage firms was in excess of Securities Investor Protection Corporation (“SIPC”) at December 31, 2013 and 2012, respectively. The amount not covered by SIPC is insured by the Company’s brokerage firm through additional “excess of SIPC” coverage from third party insurers. These third party insurers would cover losses in the event of the financial failure and liquidation of the financial institution that holds the Company’s institutional money market investments, however they do not insure against losses due to market fluctuations.
	The Company currently has two commercially marketed products, both using PRP technology, that are presently marketed. Significant changes in technology could lead to new products or services that compete with the product offered by the Company. These changes could materially affect the price of the Company’s product or render it obsolete. The Company outsources manufacturing for all the components of its offerings.
	Company utilizes single suppliers for several components of the Angel and AutoloGel product lines. We outsource the manufacturing of various products, including component parts, composing the Angel line to contract manufacturers. While we believe these manufacturers to be of sufficient competency, quality, reliability, and stability, there is no assurance that one or more of them will not experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of AutoloGel are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom the Company has an established vendor relationship.
	Cash Equivalents
	The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.
	Accounts Receivable
	Cytomedix generates accounts receivable from the sale of its products. Cytomedix provides for a reserve against receivables for estimated losses that may result from a customer’s inability or unwillingness to pay. The allowance for doubtful accounts is estimated primarily based upon historical write-off percentages, known problem accounts, and current economic conditions. Accounts are written off against the allowance for doubtful accounts when the Company determines that amounts are not collectable. Recoveries of previously written-off accounts are recorded when collected. At December 31, 2013 and 2012 the Company maintained an allowance for doubtful accounts of $16,000 and $43,000, respectively.
	Inventory
	The Company’s inventory is produced by third party manufacturers and consists primarily of finished goods. Inventory cost is determined on a first-in, first-out basis and is stated at the lower of cost or net realizable value. The Company’s primary product is the Angel Processing set which has a shelf life of three years. The Company also maintains an inventory of kits, reagents, and other disposables that have shelf lives that generally range from ten months to five years. Expired products are segregated and used for demonstration purposes only; the Company writes off expired inventory through cost of sales.
	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over its estimated useful life ranging from three to five years for all assets except for furniture, lab, and manufacturing equipment which is depreciated over seven and ten years, respectively. Leasehold improvements are stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over the lesser of the expected lease term or its estimated useful life ranging from three to six years. Amortization of leasehold improvements is included in depreciation expense. Maintenance and repairs are charged to operations as incurred. When assets are disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income (expense).
	Centrifuges may be sold, leased, or placed at no charge with customers. Depreciation expense for centrifuges that are available for sale, leased, or placed at no charge with customers are charged to cost of sales. Depreciation expense for centrifuges used for sales and marketing and other internal purposes are charged to operations. When the centrifuges are sold the net book value is charged to cost of sales.
	Goodwill
	The Company is required to perform a review for impairment of goodwill in accordance with FASB ASC 350, Intangibles — Goodwill and Other. Goodwill is considered to be impaired if it is determined that the carrying value of the Company exceeds its fair value. The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year. In addition to the annual review, an interim review is required if an event occurs or circumstances change that would more likely than not reduce the fair value of the Company below its carrying amount. Examples of such events or circumstances include:
		•	a significant adverse change in legal factors or in the business climate;
		•	a significant decline in Cytomedix’s stock price or the stock price of comparable companies;
		•	a significant decline in the Company’s projected revenue or cash flows;
		•	an adverse action or assessment by a regulator;
		•	unanticipated competition;
		•	a loss of key personnel;
		•	a more-likely-than-not expectation that the Company will be sold or otherwise disposed of;
		•	a substantial doubt about the Company’s ability to continue as a going concern.
	Intangible Assets
	The Company capitalizes the costs of purchased patents, trademarks, customer, and technology related intangibles.
	Indefinite lived intangible assets consist of in-process research and development (IPR&D) acquired in the acquisition of Aldagen. The acquired IPR&D consists of specific cell populations (that are related to a specific indication) and the use of the cell populations in treating particular medical conditions. The Company evaluates its indefinite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and at least on an annual basis as of October 1 of each year, by comparing the fair value of the asset with its carrying amount. When assessing the fair value of the asset, the Company considers various factors that are affected by the events or changes in circumstances. These factors include the valuation method used to determine the value of the asset and key inputs used in the method. If the carrying amount of the intangible asset exceeds its fair value, the Company would recognize an impairment loss in the amount of that excess.
	Identifiable intangible assets with finite lives consist of trademarks, technology (including patents), and customer relationships acquired in business combinations. These intangibles are amortized using the straight-line method over their estimated useful lives. The Company reviews its finite-lived intangible assets for potential impairment when circumstances indicate that the carrying amount of assets may not be recoverable by comparing the fair value of the asset with its carrying amount. When assessing the fair value of the asset, the Company considers various factors that are affected by the events or changes in circumstances. These factors include the valuation method used to determine the value of the asset and key inputs used in the method. If the carrying amount of the intangible asset exceeds its fair value, the Company would recognize an impairment loss in the amount of that excess.
	Income Taxes
	The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted.
	For the year ended December 31, 2013, the income tax provision relates exclusively to a deferred tax liability associated with the amortization of goodwill. The Company has analyzed filing positions in all of the federal and state jurisdictions where it is required to file income tax returns, as well as all open tax years in these jurisdictions. The only periods subject to examination for the Company’s federal return are the 2009 through 2013 tax years. The Company believes that its income tax filing positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded.
	The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no such items for 2013 and 2012.
	Revenue Recognition
	The Company recognizes revenue in accordance with FASB ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) consideration is fixed or determinable; and (4) collectability is reasonably assured.
	Sales of products
	The Company provides for the sale of its products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. The Company does not maintain a reserve for returned products as in the past those returns have not been material.
	Usage or leasing of blood separation equipment
	As a result of the acquisition of the Angel® business in 2010, the Company acquired various multiple element revenue arrangements that combine the (i) usage or leasing of blood separation processing equipment, (ii) maintenance of processing equipment, and (iii) purchase of disposable processing sets and supplies. Under these arrangements, the total arrangement consideration is allocated to the various elements based on their relative estimated selling prices. The usage of the blood separation processing equipment is accounted for as an operating lease; since customer payments are contingent upon the customer ordering new products, rental income is recorded following the contingent rental method when rental income is earned and collectability is reasonably assured. The sale of disposable processing sets and supplies and maintenance are deemed a combined unit of accounting; since (a) any consideration for disposable processing sets and supplies and maintenance is contingent upon the customer ordering additional disposable processing sets and supplies and (b) both the disposable products and maintenance services are provided over the same term, the Company recognizes revenue for this combined unit of accounting following the contingent revenue method at the time disposable products are delivered based on prices contained in the agreement. Rental income is currently less than 10% of total revenue and the Company therefore does not make separate disclosure in the statement of operations.
	Percentage-based fees on licensee sales of covered products are generally recorded as products are sold by licensees and are reflected as “Royalties” in the Consolidated Statements of Operations.
	Direct costs associated with product sales and royalty revenues are recorded at the time that revenue is recognized.
	Option Agreement with a global pharmaceutical company
	In October 2011, the Company entered into an option agreement with a top 20 global pharmaceutical company granting the potential partner an exclusive option period through June 30, 2012 regarding U.S. supply and distribution of the AutoloGel System. In exchange for this period of exclusivity, we have received non-refundable fees totaling $4.5 million. The revenue for these non-refundable fees is recognized, on a straight-line basis, over the exclusive option period based on the relative estimated selling price, with the remaining balance recognized at the expiration of the option period. In August 2012, the parties agreed to the early termination of the August 30, 2012 exclusivity period and ceased further negotiations concerning a distribution agreement; accordingly, all fees were recognized.
	Excise Tax
	On January 1, 2013 a medical device excise tax came into effect that required manufacturers to pay tax of 2.3% on the sale of certain medical devices. The Company has determined that the medical device excise tax will be reported on a gross basis and will be recorded as a cost of sale.
	Stock-Based Compensation
	The Company, from time to time, may issue stock options or stock awards to employees, directors, consultants, and other service providers under its 2002 Long-Term Incentive Plan (“LTIP”) or 2013 Equity Incentive Plan (“EIP”) (see Note 17). In some cases, it has issued compensatory warrants to service providers outside the LTIP or EIP (see Note 17).
	All equity-based compensation is estimated on the date of grant using the Black-Scholes-Merton option-pricing formula. The weighted-average assumptions used in the model are summarized in the following table:
			2013			2012
	Risk free rate			0.77	%		0.63	%
	Expected years until exercise			5.9			5.2
	Expected stock volatility			134	%		129	%
	Dividend yield			—			—
	For stock options, expected volatilities are based on historical volatility of the Company’s stock. Due to the Company’s short operating history, we used peer company data to estimate option exercises and employee terminations within the valuation model for the year ended December 31, 2013 and 2012. The expected years until exercise represents the period of time that options are expected to be outstanding and was estimated by using peer company information. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The Company estimated that the dividend rate on its Common stock will be zero.
	The fair value of stock options or compensatory warrants issued to service providers utilizes the same methodology with the exception of the expected term. For these awards to non-employees, the Company estimates that the options or warrants will be held for the full term.
	Stock-based compensation for awards granted to non-employees is periodically remeasured as the underlying options and warrants vest. The Company recognizes an expense for such awards throughout the performance period as the services are provided by the non-employees, based on the fair value of these options and warrants at each reporting period.
	The Company estimates the fair value of stock awards based on the closing market value of the Company’s stock on the date of grant.
	Income (Loss) Per Share
Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of Common shares outstanding during the period, excluding unvested restricted stock.
For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive Common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our dilutive potential Common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.
For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential Common shares is anti-dilutive due to the net losses.
The Common shares potentially issuable upon the exercise of these instruments were as follows at December 31:
		2013			2012
Options			8,520,816			7,866,953
Warrants			23,019,301			9,242,701
Contingent consideration			20,309,723			20,309,723
Convertible notes			9,285,117			2,078,393
			61,134,957			39,497,770
Defined Contribution Plans
The Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. Participants are always fully vested in their contributions. The Company makes employer matching contributions, which also vest immediately. This plan is designated as a “Safe Harbor” plan. During 2013 and 2012, the Company contributed approximately $164,000 and $126,000 in cash to the plan.
Fair Value of Financial Instruments
The balance sheets include various financial instruments that are carried at fair value. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:
	•	Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;
	•	Level 2, defined as observable inputs other than Level I prices such as quoted prices for similar assets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
	•	Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.
The Company accounts for derivative instruments under ASC 815, Accounting for Derivative Instruments and Hedging Activities, as amended and interpreted. ASC 815 requires that we recognize all derivatives on the balance sheet at fair value. Certain warrants issued in 2013 and prior years meet the definition of derivative liabilities. In December 2013, we issued warrants in connection with certain financing activities; the warrants are accounted for as derivative liabilities. In July and November 2011 and December 2013, we issued convertible notes that contained embedded conversion options; the embedded conversion options are accounted for as a derivative liability. We determine the fair value of these derivative liabilities using the Black-Scholes option pricing model. This model determines fair value by requiring the use of estimates that include the contractual term, expected volatility of the Company’s stock price, expected dividends and the risk-free interest rate. Changes in fair value are classified in “other income (expense)” in the consolidated statement of operations.
Additional information regarding fair value is disclosed in Note 6.
Recent Accounting Pronouncements
The Company believes the adoption of Accounting Standards Updates issued but not yet adopted will not have a material impact to our results of operations or financial position.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	Note 4 — Business Combinations
	Business Combination — Aldagen, Inc.
	On February 8, 2012, the Company acquired control of Aldagen, Inc. (“Aldagen”) by purchasing all of Aldagen’s issued and outstanding capital stock and convertible promissory notes. The acquisition of Aldagen allows the Company to expand its approach to developing regenerative biological therapies, by using Aldagen’s proprietary ALDH bright cell (“ALDHbr”) technology.
	As initial consideration, Cytomedix issued 135,398 shares of its Series E Convertible Preferred Stock (the “Series E Preferred Stock”) to Aldagen’s former investors. In May 2012, the Series E Preferred Stock automatically converted into shares of Common stock pursuant to its terms, in a 100-for-1 shares ratio, upon the Company’s filing of an amended Certificate of Incorporation to increase the number of authorized shares of Common stock. In July 2012, Aldagen’s former investors agreed to release 139,830 Common shares held in escrow to offset their liability for excess transaction expenses incurred by the Company in its acquisition of Aldagen; the Company believes that the impact of this measurement period adjustment was not material and, accordingly, recorded the adjustment in the third quarter 2012.
	In addition to the Series E Preferred Stock, Aldagen’s former investors have the right to receive up to 20,309,723 shares of the Company’s Common stock (the “Contingent Consideration”), contingent upon the achievement of certain milestones related to the current ALD-401 Phase 2 clinical trial. On February 18, 2013, the Company and Aldagen Holdings, LLC, a North Carolina limited liability company (“Aldagen Holdings”), executed an amendment to the Contingent Consideration (see Note 22). Finally, each holder of warrants to acquire shares of Aldagen capital stock agreed to exchange the Aldagen warrants for warrants to acquire an aggregate of 2,115,596 shares of the Company’s Common stock with an exercise price of $1.42 per share (the “Replacement Warrants”). Each Replacement Warrants expire December 31, 2014 and, subject to call provisions of the Replacement Warrants, are exercisable as follows: (i) commencing on the issuance date, for up to 30% of the total shares of the Company’s Common stock exercisable under the Replacement Warrants, and (ii) upon issuance of the final tranche of the Contingent Consideration, for the remaining balance of the shares under the Replacement Warrants. The Replacement Warrants contain exercise price adjustments, cashless exercise and other provisions customary to instruments of this nature. As part of the acquisition of Aldagen, the Company incurred approximately $528,000 in acquisition costs in 2012. These costs are included in operating expenses as follows:
	Consulting expenses	$	274,000
	Professional fees		225,000
	General and administrative expenses		29,000
	Total acquisition costs	$	528,000
	Simultaneous with the closing of the Acquisition, the Company executed several other transactions, which are not considered part of the purchase consideration, as follows.
	Issuance of Common Stock
	On February 8, 2012 and simultaneous with the closing of the Acquisition, the Company entered into subscription agreements (the “Subscription Agreements”) with certain accredited investors, with respect to the sale of shares of its Common stock, for gross proceeds of $5 million. See Note 17.
	Redemption of Series A and Series B Redeemable Convertible Preferred Stock
	The Company redeemed all outstanding shares of its Series A and Series B Convertible Preferred Stock, for $207,000 in cash, pursuant to their terms. See Note 17.
	Series D Convertible Preferred Stock Conversions
	All holders of the Company’s outstanding Series D Convertible Preferred Stock (the “Series D Preferred Stock”) purchased in a private placement of the Company’s securities in April 2010 converted those preferred shares into shares of the Company’s Common stock prior to the original redemption date of April 2013, under the terms of such securities at the conversion price of $0.4392 per share (or $0.558 per share in case of affiliates), for the total of 7,790,350 shares of Common stock, which included 330,000 shares of Common stock representing forgone dividend payments to such holders through April 2013. See Note 17.
	Warrant Exercises
	An offer was extended to certain holders of Company warrants (holding warrants to purchase approximately 5.7 million shares of the Company’s Common stock) acquired in previously reported transactions in 2010 and 2011 requesting them to exercise their respective warrants pursuant to the terms of individually negotiated and executed warrant exercise agreements, in exchange for additional equity considerations. In consideration for such early exercises and estimated proceeds of approximately $2.8 million, the Company agreed to issue additional warrants to purchase an aggregate of 1,180,547 shares of Common stock, at an exercise price per share of $1.42. Each warrant expires December 31, 2014 and, subject to call provisions of the warrant, is exercisable as follows: (i) commencing on the issuance date, for up to 30% of shares of the Company’s Common stock under each warrant, and (ii) upon issuance of the final tranche of the Contingent Consideration, for the remaining balance of the warrant. Each warrant also contains exercise price adjustments, cashless exercise and other provisions customary to the instruments of this nature. See Note 17.
	Post-Combination Stock-Based Compensation
	Each outstanding option to acquire shares of Aldagen capital stock was cancelled and, in satisfaction of a closing condition, the Company’s Board granted approximately 1.7 million options to acquire shares of the Company’s stock to certain newly added employees, officers, directors and advisors under the Company’s Long-Term Incentive Plan. The new options vest during a post-combination service period and will be expensed during such service period. See Note 17.
	The following table represents the allocation of the purchase consideration to the assets acquired and liabilities assumed on February 8, 2012. It has been revised to reflect an immaterial measurement period change (See Note 11):
		Estimated Fair Value
	Purchase Consideration:
	Series E Preferred Stock	$	18,760,610
	Contingent Consideration		11,109,020
	Replacement Warrants		1,883,751
	Total Consideration	$	31,753,381
	Tangible Assets Acquired:
	Cash	$	24,563
	Receivables		35,394
	Property and equipment		772,486
	Other		87,391
	Identifiable Intangible Assets Acquired:
	IPR&D Technology		29,585,000
	Trademarks and Tradename		1,990,000
	Liabilities Assumed:
	Accounts Payable and Accrued Expenses		(1,044,530	)
	Other		(118,617	)
	Goodwill		421,694
		$	31,753,381
	As the Series E Preferred Stock contains no liquidation preferences or special dividend rights, and is automatically converted into Common stock once sufficient Common stock is authorized, the Company determined that its fair value is essentially the same as the fair value of the underlying Common stock into which it is exchangeable. Accordingly, the Company valued the Series E Preferred Stock using the closing price of its Common stock on the acquisition date. The Series E Preferred Stock was converted into Common stock in May 2012.
	Aldagen’s former investors have the right to receive up to 20,309,723 shares of the Company’s Common stock contingent upon the achievement of certain milestones related to the current ALD-401 Phase 2 clinical trial. The total undiscounted value of the contingent consideration assuming the successful completion of all specified milestones and using the Company’s stock price as of the acquisition date is approximately $28.4 million. As of the acquisition date, the Company recorded $11.1 million in contingent consideration classified as a liability, subject to remeasurement (mark to market) at every balance sheet date, until sufficient Common stock is authorized. The Company determined the fair value of the contingent consideration with the assistance of a third party valuation expert; the fair value was determined using a probability weighted cash flow approach, which includes unobservable inputs such as projected achievement of certain technical milestones, the estimated dates of the achievement of the milestones, and discount rate. Upon the authorization of sufficient Common stock, the contingent consideration will be reclassified to equity, at its current fair value, and remeasurement will cease. Sufficient Common stock was authorized in May 2012. On February 18, 2013, the Company and Aldagen Holdings, executed an amendment to the Contingent Consideration (see Note 22 for additional detail).
	The Company determined the fair value of the Replacement Warrants using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends.
	Identifiable intangible assets associated with trademarks and tradenames will be amortized on a straight-line basis over their estimated useful lives of 20 years. Identifiable intangible assets associated with IPR&D are initially classified as indefinite lived; such classification will be reassessed every reporting period based on the status of the research and development projects. Goodwill, primarily related to expected clinical and commercial synergies gained from combining operations, sales growth from future product offerings and customers, together with certain intangible assets that do not qualify for separate recognition, including assembled workforce, which is not tax deductible since the transaction was structured as a tax-free exchange, is considered an indefinite lived asset.

Arthrex_Distributor_and_Licens

Arthrex Distributor and License Agreement and Related Matters	12 Months Ended
	Dec. 31, 2013
Distributors And License Agreement [Abstract]	'
Distributors And License Agreement [Text Block]	'
	Note 5 — Arthrex Distributor and License Agreement and Related Matters
	Arthrex Distributor and License Agreement
	On August 7, 2013, the Company entered into a Distributor and License Agreement (the “Arthrex Agreement”) with Arthrex, Inc., a privately held Florida based company (“Arthrex”). Under the terms of the Arthrex Agreement, Arthrex will obtain the exclusive rights to sell, distribute, and service the Company’s Angel Concentrated Platelet System and ActivAt (“Products”), throughout the world, for all uses other than chronic wound care. The Company granted Arthrex a limited license to use the Company’s intellectual property as part of enabling Arthrex to sell the Products. Arthrex will purchase Products from the Company to distribute and service at certain purchase prices, which may be changed after an initial period. Arthrex has the right, on written notice to the Company, to assume responsibility for the manufacture and supply of the Products, either by assuming the Company’s existing manufacturing and supply agreements or by entering into new manufacturing and supply agreements. Arthrex will also pay a certain royalty rate based upon volume of the Products sold. The exclusive nature of Arthrex rights to sell, distribute and service the Products is subject certain existing supply and distribution agreements such that Arthrex may instruct the Company to terminate or not renew any of such agreements. In addition, Arthrex’s rights to sell, distribute and service the Products is not exclusive in the non-surgical dermal and non-surgical aesthetics markets. In connection with the execution of the Arthrex Agreement, Arthrex agreed to pay the Company a nonrefundable upfront payment of $5 million. The term of the Arthrex Agreement is five years, automatically renewable for an additional three-year period unless Arthrex gives the Company a termination notice at least one year in advance of the end of the initial five-year period. The Arthrex Agreement contains other terms and provisions that are customary to the agreements of this nature. The foregoing description of the Arthrex Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Arthrex Agreement.
	Immediately following the execution of the Arthrex Agreement, the Company, at the request of Arthrex, agreed to temporarily provide certain services to Arthrex during a transition period (“Transition Services”). These Transition Services primarily involve customer service, sales order fulfillment, customer billing and collections, and technical support for the Products. For these services, Arthrex will pay the Company an agreed upon fee. The Transition Services period is expected to conclude in the first quarter of 2014.
	Midcap Consent and First Amendment to Security Agreement
	In connection with the Arthrex Agreement, on August 7, 2013, the Company entered into Consent and First Amendment to Security Agreement (the “Amendment to Credit Agreement”) with MidCap Funding III, LLC, as a lender and administrative agent for the lenders (“Agent”) amending that Credit and Security Agreement, dated as of February 13, 2013, by and among the Company and the Agent and the Lenders party thereto (the “Original Credit Agreement”). Under the terms of the Amendment to the Credit Agreement, the Agent consented, among other things, to the Company’s entering the Arthrex Agreement. In addition, the parties amended the Credit Agreement to terminate the Company’s ability to borrow an additional $3 million, reducing the loan amount from $7.5 million to $4.5 million, $4.5 million of which has been extended to the Company to date. The Company makes monthly principal payments under the credit facility in the amount of $150,000 plus interest.
	Finally, the Company granted to the Agent a first priority security interest in the royalty payments payable to the Company pursuant to the Arthrex Agreement. The Amendment to Credit Agreement contains other terms and provisions that are customary to the agreements of this nature. The foregoing description of the Amendment to Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment to Credit Agreement.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 6 — Fair Value Measurements
	Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value.
	Short-term Financial Instruments
	The inputs used in measuring the fair value of cash and short-term investments are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of the Company’s funds. The fair value of other short-term financial instruments (primarily accounts receivable and accounts payable and accrued expenses) approximate their carrying values because of their short-term nature.
	Other Financial Instruments
	The Company has segregated its financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. The Company has no non-financial assets and liabilities that are measured at fair value.
	The carrying amounts of the derivative liabilities are as follows:
	Description	Level 1		Level 2		Level 3		Total
	Liabilities at December 31, 2013:
	Embedded conversion options	$	—	$	—	$	1,515,540	$	1,515,540
	Stock purchase warrants		—		—		1,733,055		1,733,055
	Total measured at fair value	$	—	$	—	$	3,248,595	$	3,248,595
	Liabilities at December 31, 2012:
	Embedded conversion options	$	—	$	—	$	780,960	$	780,960
	Total measured at fair value	$	—	$	—	$	780,960	$	780,960
	The liabilities measured at fair value in the above table are classified as “derivative and other liabilities” in the accompanying consolidated balance sheets.
	The following tables set forth a summary of changes in the fair value of Level 3 liabilities for the year ended December 31, 2013 and 2012:
	Description	Balance at January 1, 2013		Established in 2013		Modification of Convertible Debt Agreement		Conversion to Common Stock			Change in Fair Value			Effect of Extinguishment of Debt			Balance at December 31, 2013
	Derivative liabilities:
	Embedded conversion options	$	780,960	$	965,484	$	250,361	$	(393,948	)	$	90,839		$	(178,156	)	$	1,515,540
	Stock purchase warrants	$	—	$	1,353,842	$	—	$	—		$	379,213		$	—		$	1,733,055
	Description	Balance at January 1, 2012		Established in 2012		Modification of Convertible Debt Agreement		Conversion to Common Stock			Change in Fair Value			Reclass to Equity			Balance at December 31, 2012
	Derivative liabilities:
	Embedded conversion options	$	1,823,207	$	—	$	—	$	(549,936	)	$	(492,311	)	$	—		$	780,960
	Contingent consideration	$	—	$	11,109,020	$	—	$	—		$	4,334,932		$	(15,443,952	)	$	—
	Gains and losses in the fair value of the contingent consideration are classified as the “change in fair value of contingent consideration” in the accompanying consolidated statements of operations. All other gains and losses in the fair value of derivative instruments are classified as the “change in the fair value of derivative instruments” in the accompanying consolidated statements of operations.
	The fair value of the contingent consideration is determined using a probability weighted cash flow approach, which includes unobservable inputs such as projected achievement of certain technical milestones and discount rate. Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the contingent consideration. Increases in projected achievement of certain technical milestones dates generally result in increases in fair value, while increases in discount rate generally result in decreases in fair value.
	The fair value of the stock purchase warrants and embedded conversion options is determined based on the Black-Scholes option pricing model, and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the stock purchase warrants. Increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value.
	In July and November 2011, we issued convertible notes that contained embedded conversion options which met the criteria for derivative liabilities. The fair value of the conversion options, at December 31, 2013, approximates $287,000.
	In December 2013, we issued convertible notes which met the criteria for derivative liabilities. The fair value of the conversion options, at December 31, 2013, approximates $2,250,000.
	In June 2013, the Company purchased a Certificate of Deposit (“CD”) from its commercial bank in the amount of $53,000. This CD bears interest at an annual rate of 0.10%, maturs on February 24, 2014, and immediately renews on the same date. The $53,000 carrying value of the CD approximates its fair value. This CD collateralizes the Letter of Credit described in Commitment and Contingencies (see Note 22).

Receivables

Receivables	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	'
	Note 7 — Receivables
	Accounts and royalties receivable, net consisted of the following:
		31-Dec-13			31-Dec-12
	Trade receivables	$	2,449,199		$	1,133,400
	Other receivables		1,493,979			643,051
			3,943,178			1,776,451
	Less allowance for doubtful accounts		(16,497	)		(42,709	)
		$	3,926,681		$	1,733,742
	Other receivables consist primarily of royalties and transition service fees due from Arthrex and the cost of raw materials needed to manufacture the Angel products that are sourced by the Company and immediately resold, at cost, to the contract manufacturer.
	The following table reflects the approximate change in allowance for doubtful accounts.
		Balance at Beginning of Period			Charged to Costs and Expenses			Balances charged-off			Balance at End of Period
	Year Ended December 31, 2013
	Allowance for doubtful accounts	$	42,709		$	75,166		$	(101,378	)	$	16,497
	Year Ended December 31, 2012
	Allowance for doubtful accounts	$	38,233		$	42,625		$	(38,149	)	$	42,709

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 8 — Inventory
	Inventory consisted of the following:
		31-Dec-13		31-Dec-12
	Raw materials	$	125,583	$	79,090
	Finished goods		985,924		1,091,007
		$	1,111,507	$	1,170,097

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2013
Prepaid Expense and Other Assets, Current [Abstract]	'
Prepaid Expenses and Other Current Assets [Text Block]	'
	Note 9 — Prepaid Expenses and Other Current Assets
	Prepaid expenses and other current assets consisted of the following:
		31-Dec-13		31-Dec-12
	Prepaid insurance	$	63,096	$	61,519
	Prepaid fees and rent		151,454		186,407
	Deposits and advances		279,870	$	409,604
	Prepaid royalties		724,999		6,250
	Other Current Assets		38,863		73,665
		$	1,258,282	$	737,445
	Prepaid fees and rent consist primarily of prepaid service contracts. Deposits and advances consist primarily of payments to the Company’s raw materials suppliers and Angel® centrifuge manufacturers. Other Current Assets is exclusively made up of parts used to refurbish the Angel® centrifuges. Prepaid royalties consist of a cash payment, common stock, and warrant issued for the release of the Worden security interest in patents (See Note 17 for more details). The royalty is amortized to cost of sales over the life of the patent. For the year ended December 31, 2013, royalty amortization expense was approximately $100,694.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 10 — Property and Equipment
	Property and equipment, net consisted of the following:
		31-Dec-13			31-Dec-12
	Medical equipment	$	1,278,681		$	3,033,792
	Office equipment		86,001			87,163
	Manufacturing equipment		307,971			303,143
	Leasehold improvements		390,911			390,911
			2,063,564			3,815,009
	Less accumulated depreciation and amortization		(1,144,095	)		(1,374,928	)
		$	919,469		$	2,440,081
	As a result of the Arthrex Agreement discussed in Note 5, Angel centrifuges are now classified as “Inventory” in the accompanying consolidated balance sheets, whereas they were previously classified as “Property and equipment”.
	For the year ended December 31, 2013 depreciation expense and amortization was approximately $726,000, of which $299,000 was reported as research, development, trials and studies, and $310,000 were reported as cost of sales.
	For the year ended December 31, 2012 depreciation expense and amortization was approximately and $823,404, of which $287,000 was reported as research, development, trials and studies, and $446,000 were reported as cost of sales.
	The net book value of property and equipment disposed was approximately $1,543,000 in 2013 (which includes approximately $1,295,000 of existing placed Angel centrifuges sold under the Arthrex Agreement) and $554,000 in 2012. The disposal of property and equipment was primarily due to the sale of centrifuges.

Goodwill_and_Identifiable_Inta

Goodwill and Identifiable Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	Note 11 — Goodwill and Identifiable Intangible Assets
	Goodwill
	Goodwill represents the purchase price of acquisitions in excess of the amounts assigned to acquired tangible or intangible assets and assumed liabilities. Amounts allocated to goodwill are tax deductible in all relevant jurisdictions.
	As a result of the Company’s acquisition of Aldagen in February 2012, the Company recorded goodwill of approximately $422,000. Prior to the acquisition of Aldagen, the Company had goodwill of approximately $707,000 as a result of the acquisition of the Angel business in April 2010.
	The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year. The Company will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the fair value of the Company below its carrying value.
	During 2013, planned enrollment in the Company’s Phase 2 clinical trial for ALDH-401 began experiencing patient enrollment delays. The delay has resulted in extended time to enroll and added costs associated with the delay. On September 17, 2013, Cytomedix announced its decision to become a more commercially focused company and reorganize its research and development activities. The plan includes a strategic reorganization of its research and development operations that involve the ALDH-401 trial and ALDH Bright Cell platform, intention to proceed with trial enrollment through the end of 2013 with an enrollment goal of 50 patients, and pursuit of strategic partnerships to continue the trial beyond 2013 (“Announcement”). This Announcement identified several indicators of a potential impairment of intangible assets acquired in the Aldagen acquisition; as such, the Company felt it necessary to perform an impairment analysis on its goodwill as of September 30, 2013.
	U.S. GAAP provides for a two-step process for measuring for impairment of goodwill. Step 1 of the impairment process is to determine if the fair value of the reporting unit exceeds its carrying value. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, thus the second step of the impairment test is unnecessary.
	The Company’s goodwill is contained in its sole operating segment and reporting unit. Based on its assessment, the fair value of the reporting unit (determined with reference to its quoted market cap) exceeded its carrying value at September 30, 2013 and the Company determined that goodwill was not impaired. Accordingly, the Step Two analysis is not applicable.
	The Company also conducted an impairment test of goodwill as of October 1, 2013 and determined that goodwill was not impaired. In addition, other than the events identified above, no other triggering events were identified during the year ended December 31, 2013.
	The table below sets forth the changes in the carrying amount of goodwill for the period indicated:
	Balance at January 1, 2012	$	706,823
	Goodwill related to Aldagen acquisition		616,826
	Adjustment as a result of measurement period change		(195,132	)
	Balance at December 31, 2012	$	1,128,517
	Change in 2013		—
	Balance at December 31, 2013	$	1,128,517
	Identifiable Intangible Assets
	Cytomedix’s identifiable intangible assets consist of trademarks, technology (including patents), customer relationships, and in-process research and development. These assets are a result of the Angel Business and Aldagen acquisitions. The carrying value of those intangible assets, and the associated amortization, were as follows:
		31-Dec-13			December 31,
					2012
	Trademarks	$	2,310,000		$	2,310,000
	Technology		2,355,000			2,355,000
	Customer relationships		708,000			708,000
	In-process research and development		29,585,000			29,585,000
	Total	$	34,958,000		$	34,958,000
	Less accumulated amortization		(1,189,046	)		(822,713	)
		$	33,768,954		$	34,135,287
	Definite-lived intangible assets
	The Company's intangible assets that have definite lives are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i. e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. The Company periodically reevaluates the useful lives for these intangible assets to determine whether events and circumstances warrant a revision in their remaining useful lives.
	As a result of the September 17, 2013 announcement discussed above, the Company believed an impairment assessment of the Aldagen-related Trademarks and Trademark, as of September 30, 2013, was warranted. The Company performed a qualitative assessment and identified driving factors used in the original valuation of the Trademarks and Tradename, including the projected revenue stream and discount factor that may have changed. The Company considered the impact of such changes to the undiscounted future cash flows used to value the Trademarks and Tradename, and concluded that the changes to the driving factors that management was able to quantify did not have a significant impact to the undiscounted future cash flows. The Company realizes that, in addition to the projected revenue stream and discount factor, other additional factors may have changed whose financial impacts are currently unknown, but may become more clear as strategic discussions proceed over the next few months. The Company expects that before the end of the second quarter of 2014, when the Company expects to announce top line efficacy, there will be additional clarity regarding the process and its impacts to the recoverability of the Trademarks and Tradename asset.
	As a result, management concludes that the fair value of the Trademarks and Tradename definite-lived intangible asset is not less than its carrying value of approximately $1.7 million and therefore it is not impaired as of September 30, 2013. Other than the events identified above, no other triggering events were identified during the year ended December 31, 2013.
	Indefinite-lived intangible assets
	The Company evaluates its indefinite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and at least on an annual basis on October 1 of each year, by comparing the fair value of the asset with its carrying amount. If the carrying amount of the intangible asset exceeds its fair value, the Company would recognize an impairment loss in the amount of that excess. The Company's sole indefinite-lived intangible asset is its in-process research and development (“IPR&D”) acquired in connection with its acquisition of Aldagen in 2012. The IPR&D asset consists of its ALDH bright cell platform. The Company is currently conducting (i) a Phase 2 clinical trial for this technology in ischemic stroke, (ii) a Phase 1/2 clinical trial in critical limb ischemia that is being funded by the National Institutes of Health, and (iii) a Phase 1 clinical trial in grade IV malignant glioma following surgery that is funded by Duke University.
	As a result of the September 17, 2013 announcement discussed above, the Company believed an impairment assessment of the IPR&D, as of September 30, 2013, was warranted. The Company performed a qualitative assessment and identified driving factors used in the original valuation of the IPR&D, including the projected non-diagnostic revenues and expenses, clinical trial expenses, commercial revenue stream and discount factor, that may have changed. The changes to driving factors that management was able to identify (including delayed revenue stream generation and increased clinical trial costs) were offset by the impacts on the model of the passage of time (i.e., the clinical trial delay approximates the passage of time). The Company realizes that, in addition to the delayed revenue stream generation and increased clinical trial costs, other additional factors may have changed whose financial impacts are currently unknown, but may become more clear as strategic discussions proceed over the next few months. The Company expects that before the end of the second quarter of 2014, when the Company expects to announce top line efficacy, there will be additional clarity regarding the process and its impacts to the recoverability of the IPR&D asset. Negative results from this data or other factors that negatively impact the fair value of such assets could result in impairment and a resulting non-cash write-off of a significant portion of our goodwill and intangible assets, which would have an adverse effect on our financial condition and operating results.
	As a result, management concludes that the fair value of the IPR&D indefinite-lived intangible asset approximates its carrying value (is not less than its carrying value) and therefore it is not impaired as of September 30, 2013.
	The Company also conducted a quantitative impairment test of the IPR&D as of October 1, 2013 and determined that the IPR&D was not impaired. In addition, other than the events identified above, no other triggering events were identified during the year ended December 31, 2013. The impairment valuation process included updating the valuation model that was initially used to establish the expected fair value of the IPR&D in February 2012. This included adjusting the timing and amounts of expected cash flows resulting from the change from an operational model to a royalty model and other factors such as discount rates. The resulting valuation resulted in a fair value that exceeded the carrying value by approximately $1.5 million as of October 1, 2013.
	Amortization expense of approximately $88,000 was recorded to cost of sales, $69,000 to cost of royalties, and approximately $209,000 was recorded to general and administrative expense in the year ended December 31, 2013. Annual amortization expense based on our existing intangible assets and their estimated useful lives is expected to be approximately:
	2014		366,333
	2015		366,333
	2016		366,333
	2017		366,333
	2018		299,985
	Thereafter		2,418,637

Accounts_payable_and_accrued_e

Accounts payable and accrued expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Note 12 — Accounts payable and accrued expenses
	Accounts payable and accrued expenses consisted of the following:
		31-Dec-13		31-Dec-12
	Trade payables	$	3,351,844	$	1,434,166
	Accrued compensation and benefits		795,584		833,141
	Accrued professional fees		199,634		156,205
	Accrued interest		2,250		750
	Customer deposits		1,795,803		—
	Other payables		1,873,557		388,109
		$	8,018,672	$	2,812,371
	Other payables include approximately $1,631,000 due to Arthrex for payments collected on Angel sales made by Cytomedix, on behalf of Arthrex, during the transition services period (see Note 5 for additional details).

Deferred_Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2013
Deferred Revenue [Abstract]	'
Deferred Revenue Disclosure [Text Block]	'
	Note 13 — Deferred Revenue
	Deferred revenue consists of prepaid licensing revenue of $1,844,229 and deferred sales of $338,613 from the prepayment of Angel centrifuges, as a result of the Arthrex Agreement. Revenue related to the purchase of Angel centrifuges is recognized upon delivery to the point of sale. Revenue related to prepaid licensing is recognized on a straight-line basis over 5 years, the term of the Arthrex Agreement. Revenue of $167,657 related to the prepaid license was recognized in the year ended December 31, 2013.

Derivatives_and_other_liabilit

Derivatives and other liabilities	12 Months Ended
	Dec. 31, 2013
Derivative and Other Liabilities [Abstract]	'
Derivative And Other Liabilities Disclosure [Text Block]	'
	Note 14 — Derivatives and other liabilities
	Derivative and other liabilities consisted of the following:
		31-Dec-13		31-Dec-12
	Derivative liability, long-term portion		3,248,595	$	780,960
	Deferred rent		185,405		58,005
	Deferred tax liability		68,589		50,000
	Interest payable		44,194		33,379
	Conditional grant payable		30,000		30,000
	Accrued term loan fee		38,738		—
		$	3,615,521	$	952,344
	In September 2012, the Company received $30,000 in proceeds for an Economic Development Fund Agreement with Montgomery County Maryland as a “conditional grant” to be funded by the County’s Department of Economic Development. This conditional grant is to be repaid with interest unless certain performance conditions are achieved through 2017. If the performance conditions are met then repayment of principal and interest is forgiven.

Debt

Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 15 — Debt
	4% Convertible Notes
	On July 15, 2011, Cytomedix issued $1.3 million of its 4% Convertible Notes (the “July 4% Convertible Notes”) to an unaffiliated third party. The July 4% Convertible Notes mature on May 23, 2016 and bear a one-time interest charge of 4% due on maturity. The July 4% Convertible Notes (plus accrued interest) convert at the option of the unaffiliated third party, in whole or in part and from time to time, into shares of the Company’s Common stock at a conversion rate equal to (i) the lesser of $0.80 per share or (ii) 80% of the average of the three lowest closing prices of the Company’s Common stock for the previous 20 trading days prior to conversion (subject to a “floor” price of $0.25 per share). At December 31, 2013, approximately $287,000 face amount of the July 4% Convertible Notes remained and were convertible into approximately 0.8 million shares of Common stock at a conversion price of $0.34 per share.
	On November 18, 2011, Cytomedix issued $0.5 million of its 4% Convertible Notes (the “November 4% Convertible Notes”) to an unaffiliated third party. The November 4% Convertible Notes mature on May 23, 2016 and bear a one-time interest charge of 4% due on maturity. The November 4% Convertible Notes (plus accrued interest) convert at the option of the holder, in whole or in part and from time to time, into shares of the Company’s Common stock at a conversion rate equal to 80% of the average of the three lowest closing prices of the Company’s Common stock for the previous 20 trading days prior to conversion (subject to a “floor” price of $0.25 per share). At December 31, 2013, no unpaid balance remained of the November 4% Convertible Notes.
	The unaffiliated third party has the option to provide additional funding of up to $1.0 million on substantially the same terms; however, the Company may elect to cancel such notes, in its sole discretion, with no penalty.
	The conversion option embedded in the July and November 4% Convertible Notes is accounted for as a derivative liability, and resulted in the creation at issuance of a discount to the carrying amount of the debt, totaling $1.8 million, which is being amortized as additional interest expense using the straight-line method over the term of the July and November 4% Convertible Notes (the Company determined that using the straight-line method of amortization did not yield a materially different amortization schedule than the effective interest method). The embedded conversion option is recorded at fair value and is marked to market at each period, with the resulting change in fair value being reflected as “change in fair value of derivative liabilities” in the accompanying condensed consolidated statements of operations.
	On February 19, 2013, the Company and the holder of these notes, agreed, in consideration of the subordination of the rights and remedies under these notes to that of another party, to amend the notes to extend the maturity date to May 23, 2016. Also, as part of the consideration, the Company repaid approximately $0.3 million of the principal of the note. The amendments were accounted for as a partial “extinguishment” and a partial “modification” of the notes. The partial extinguishment resulted in the immediate expensing of approximately $54,000 of new fees and expenses and $54,000 of the increase in the fair value of the embedded conversion option. The partial modification resulted in the deferral of approximately $46,000 of new fees and expenses and $197,000 of the increase in the fair value of the embedded conversion option (as additional debt discount).
	12% Interest Only Note
	On April 28, 2011, the Company borrowed $2.1 million pursuant to a secured promissory note that matures May 20, 2016. The note accrues interest at a rate of 12% per annum, and requires interest-only payments each quarter commencing September 30, 2011, with the then outstanding principal due on the maturity date. The note may be accelerated by the lender if Cytomedix defaults in the performance of the terms of the promissory note, if the representations and warranties made by us in the note are materially incorrect, or if we undergo a bankruptcy event. The note is secured by our Angel assets.
	In connection with the issuance of the secured promissory note, the Company issued the lender a warrant to purchase up to 1,000,000 shares at an exercise price of $0.50 per share vesting as follows: (a) 666,667 shares upon issuance of the note, (b) 83,333 shares if the note has not been prepaid by the first anniversary of its issuance, (c) 116,667 shares if the note has not been prepaid by the second anniversary of its issuance, and (d) 133,333 shares if the note has not been prepaid by the third anniversary of its issuance.
	Of the $2,100,000 due under the note, our payment obligations with respect to $1,400,000 under the note were guaranteed by certain insiders, affiliates, and shareholders of the Company, including Mr. David Jorden, one of the Company’s directors. In connection with this guarantee, the Company issued the guarantors warrants to purchase an aggregate of up to 1,500,000 shares, on a pro rata basis based on the amount of the guarantee, at an exercise price of $0.50 per share vesting as follows: (a) 833,333 shares upon issuance of the note, (b) 166,667 shares if the note has not been prepaid by the first anniversary of its issuance, (c) 233,333 shares if the note has not been prepaid by the second anniversary of its issuance, and (d) 266,667 shares if the note has not been prepaid by the third anniversary of its issuance.
	The warrants issued to the lender and the guarantors were valued at approximately $546,000, were recorded as deferred debt issuance costs, and are being amortized to interest expense on a straight-line basis over the guarantee period. The Company determined that the straight-line method of amortization did not yield a materially different amortization schedule from the effective interest method.
	On February 19, 2013, The Company and the holder of the note, in consideration for subordination of its security interest under the note to that of another party, agreed to amend the note. In the amendment, the Company agreed to extend the maturity date of the note to November 19, 2016. In addition, the parties agreed to amend the vesting schedule on the warrants issued by the Company in April 2011 such that the remaining 250,000 warrant shares are exercisable immediately and to issue the holder a new warrant to purchase up to 266,666 shares at an exercise price of $0.70 per share vesting as follows: (i) 133,333 shares may be exercised only if the note has not been paid by the fourth anniversary of its issuance, and (ii) the remaining 133,333 shares may be exercised only if the note has not been paid by the fifth anniversary of its issuance.
	The Company also: (i) amended the warrant vesting schedule on the guarantors’ warrants issued by the Company in April 2011 such that the remaining 500,000 warrant shares are exercisable immediately and (ii) granted new warrants to the guarantors to acquire up to 533,334 shares of the Company’s Common stock pursuant to warrants at the exercise price of $0.70 per share, vesting as follows: (i) 266,667 warrant shares may be exercised only if the JP Trust Note has not been prepaid by the fourth anniversary of its issuance, and (ii) the remaining 266,667 shares may be exercised only if the note has not been paid by the fifth anniversary of its issuance.
	The amendment was accounted for as a “modification.” Accordingly, the warrants issued to the lender as a result of the amendment (valued at approximately $152,000) were recorded as deferred debt issuance costs, and are being amortized to interest expense on a straight-line basis over the guarantee period. The Company determined that the straight-line method of amortization did not yield a materially different amortization schedule from the effective interest method. The warrants issued to the guarantors as a result of the amendment were valued at approximately $304,000 and were recorded as interest expense in the first quarter of 2013.
	Term Loan
	On February 19, 2013, the Company entered into a Credit and Security Agreement (the “Credit Agreement”) with an unaffiliated third party (“MidCap”) that provides for an aggregate term loan commitments of $7.5 million, subsequently modified to $4.5 million. The Company received the first tranche of $4.5 million on February 27, 2013.
	The term loan will mature on February 19, 2016, and will be repaid on a straight-line amortization basis, with the first twelve months being an interest only period and commencing on the thirteenth month. The principal will be amortized in equal monthly amounts through the maturity date.
	In connection with the foregoing loan facility, the Company issued the lender a seven-year warrant to purchase 1,079,137 shares of the Company’s Common stock at the warrant exercise price of $0.70 per share. The exercise price and the number of shares issuable upon exercise of the warrant is subject to standard anti-dilution adjustments and contains a cashless exercise provision.
	Interest on the outstanding balance of the term loan is payable monthly in arrears at an annual rate of the one-month London Interbank Offered Rate (LIBOR), plus 8.0%, subject to a LIBOR floor of 3%, and is calculated on the basis of the actual number of days elapsed in a 360 day year. In the event the term loan is prepaid by the Company prior to the end of its term, the Company will be required to pay to the lender a fee equal to an amount determined by multiplying the outstanding amount on the loan by 5% in the first year, 3% in the second year and 1% after that.
	Amounts borrowed under the Credit Agreement are secured by a first priority security interest on all existing and after-acquired assets of the Company, including the intellectual property of the Company and its subsidiaries.
	The Credit Agreement contains events of default and remedies customary for loan transactions of this sort including, among others, those related to a default in the payment of principal or interest, a material inaccuracy of a representation or warranty, a default with regard to performance of certain covenants, a material adverse change (as defined in the Credit Agreement) occurs, and certain change of control events. In addition, the failure to consummate the Capital Raise Event constitutes an event of default under the Credit Agreement. The Company would also be in default under the Credit Agreement in the event of certain withdrawals, recalls, adverse test results or enforcement actions with respect to the Company’s products. Upon the occurrence of a default, in some cases following a notice and cure period, lender may accelerate the maturity of the loans and require the full and immediate repayment of all borrowings under the Credit Agreement. The Credit Agreement also contains financial and customary negative covenants, including with respect to the Company’s ability to sell, lease, transfer, assign, grant a security interest in or otherwise dispose of its assets except in the ordinary course of business, or incur additional indebtedness.
	The warrants issued to the lender were valued at approximately $568,000, were recorded as a debt discount, and are being amortized to interest expense over the term of the loan. The Company determined that the straight-line method of amortization did not yield a materially different amortization schedule from the effective interest method. The warrants are classified in equity.
	On August 7, 2013, the Company and MidCap amended the terms of the Credit Agreement. Under the terms of the amendment to the Credit Agreement, the Agent consented, among other things, to the Company’s entering the Arthrex Agreement. In addition, the parties amended the Credit Agreement to terminate the Company’s ability to borrow an additional $3 million, reducing the loan amount from $7.5 million to $4.5 million, $4.5 of which has been extended to the Company to date. The Company and MidCap also agreed to a revised monthly payment amortization schedule such that in the event that the Company has raised cash proceeds of at least $500,000 before September 1, 2013 in a public or private offering of its equity securities, then, commencing on September 1, 2013, and continuing thereafter, the Company would have made monthly payments under the credit facility of $125,000, provided, however, if no such subsequent equity event takes place by September 1, 2013, the monthly payments under the credit facility will be $150,000. No such subsequent equity event took place by September 1, 2013, and the Company is required to make monthly principal payments under the credit facility in the amount of $150,000 plus interest.
	Finally, the Company granted to the Agent a first priority security interest in the royalty payments payable to the Company pursuant to the Arthrex Agreement. The Amendment to Credit Agreement contains other terms and provisions that are customary to the agreements of this nature. The foregoing description of the Amendment to Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment to Credit Agreement.
	On December 10, 2013, the Company and MidCap revised the exercise price of the warrants to $0.46 per share (“Amendment to the MidCap Warrant”). As a result of the Amendment to the MidCap Warrant, the fair value of the warrants were modified and the change was recognized as an increase to debt discount and amortized over the remaining life of the loan. The change in the fair value of the warrants was approximately $12,000.
	10% Subordinated Convertible Notes
	On November 21, 2013, we executed agreements with certain investors for the subsequent issuance of 10% subordinated convertible notes (“10% Subordinated Convertible Notes”) and stock purchase warrants, for expected gross proceeds of up to $3 million. The eventual closing was contingent upon several factors. The Company received $2.25 million of the expected gross proceeds at the first closing, which occurred on December 10, 2013 after the Company received an acceptable CMS reimbursement determination for Autologel. The remaining $0.75 million of the expected gross proceeds is contingent upon the effectiveness of a registration statement covering the resale of Common shares underlying the 10% Subordinated Convertible Notes and related stock purchase warrants. The 10% Subordinated Convertible Notes mature on May 20, 2016 and accrue interest at 10% per annum and is paid quarterly in arrears in cash or in shares of Company stock (valued at market price on the day before interest is due), at the Company’s option. The 10% Subordinated Convertible Notes are convertible, in whole or in part and from time to time, by investors into shares of the Company’s Common stock at the initial conversion price of $0.46 (“Initial Conversion Price”). The conversion option contains standard anti-dilution protection (i.e., is adjustable for stock dividends, stock splits, and other similar distributions) that resets the Initial Conversion Price. At December 31, 2013, the face amount of the 10% Subordinated Convertible Notes was approximately $2.25 million.
	In connection with the issuance of the Notes, the Company also agreed to issue to the investors in the Offering five-year warrants (the “Warrants”) to purchase shares of the Company’s Common stock in the amount equal to 75% of the number of the Company’s shares into which the Notes may be converted at the Closing, at an exercise price equal to 125% of the Market Price [defined as the average closing price for the previous last five trading days]. The Warrants also contain exercise price anti-dilution adjustments, cashless exercise and other similar provisions.
	The Company agreed, pursuant to the terms of the Registration Rights Agreement entered into with the investors in the Offering, to file, within thirty days of the Closing, a registration statement with the Securities and Exchange Commission for the purposes of registering the resale the shares of the Company’s Common stock underlying the Notes, the Warrants and the placement agent warrants to be issued in the Offering, and in the event of late filing of such registration statement, to pay certain late registration statement filing penalties as set forth in the Registration Rights Agreement. The registration statement covering the resale of Common shares underlying the 10% Subordinated Convertible Notes and related stock purchase warrants was filed January 9, 2014.
	The conversion option embedded in the 10% Subordinated Convertible Notes and related warrants issued to the investors are accounted for as a derivative liability and were recorded at full fair value relative to the total gross proceeds which totaled $2.25 million at December 10, 2013. The warrants issued to the lender and the guarantors were valued at approximately $1.7 million. A debt discount of $2.25 million was also recorded arising from the allocation of fair value to the embedded conversion option and the Warrants. The debt discount is being amortized as additional interest expense using the interest rate method through the maturity date. The embedded conversion option is recorded at fair value and is marked to market at each period, with the resulting change in fair value being reflected as “change in fair value of derivative liabilities” in the accompanying condensed consolidated statements of operations.
	Finally, the warrants issued to the placement agent were value at approximately $69,000, were recorded as deferred debt issuance costs, and are being amortized to interest expense on a straight-line basis through the maturity date. The Company determined that the straight-line method of amortization did not yield a materially different amortization schedule from the effective interest method.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 16 — Income Taxes
	Income tax (expense) benefit for the years ended December 31, 2013 and 2012 consisted of the following:
		2013			2012
	Current:
	Federal	$	—		$	—
	State		—			—
	Deferred:
	Federal		(212,022	)		1,267,000
	State		(401,215	)		(653,000	)
	Net operating loss carryforward		4,243,885			4,635,000
	Valuation Allowance		(3,649,237	)		(5,267,000	)
	Total income tax (expense) benefit	$	(18,589	)	$	(18,000	)
	Significant components of Cytomedix’s deferred tax assets and liabilities consisted of the following at December 31:
		2013			2012
	Deferred tax assets:
	Stock-based compensation	$	5,371,000		$	5,087,000
	Tax credits		2,895,000			2,512,000
	Deferred financing costs		(3,000	)		714,000
	Start-up and organizational costs		272,000			272,000
	Tax deductible Goodwill		112,000			136,000
	Property and equipment		240,000			244,000
	Derivative liabilities		(2,000	)		522,000
	Other		1,019,000			109,000
	Total deferred tax assets		9,904,000			9,596,000
	Deferred tax liabilities:
	Intangible Assets		(12,219,000	)		(12,353,000	)
	Discount on Note Payable		(1,088,000	)		(377,000	)
	Other		(69,000	)		(50,000	)
	Total deferred tax liabilities		(13,376,000	)		(12,780,000	)
	Net deferred tax assets, excluding net operating loss		(3,472,000	)		(3,184,000	)
	carryforwards
	Net operating loss carryforwards		45,458,000			41,540,000
			41,986,000			38,356,000
	Less valuation allowance		(42,055,000	)		(38,406,000	)
	Total deferred tax assets (liabilities)	$	(69,000	)	$	(50,000	)
	The following table reflects the change in the valuation allowance for deferred tax assets at December 31:
	Valuation allowance – January 1, 2012	$	19,700,000
	Purchase Accounting changes		13,439,000
	2012 provision		5,267,000
	Valuation allowance – December 31, 2012		38,406,000
	2013 provision		3,649,000
	Valuation allowance – December 31, 2013	$	42,055,000
	The following table presents a reconciliation between the U.S. federal statutory income tax rate and the Company’s effective tax rate:
		2013			2012
	U.S. Federal statutory income tax		35	%		35	%
	State and local income tax, net of benefits		4.4	%		4.2	%
	Fair value of Derivatives		(2.9	)%		(6.8	)%
	Nondeductible guarantee fees		(0.9	)%		(3.7	)%
	Impact of changes in rates		(12.2	)%		(0.2	)%
	Other		(5.5	)%		(1.9	)%
	Valuation allowance for deferred income tax assets		(18.0	)%		(26.5	)%
	Effective income tax rate		(0.1	)%		0.1	%
	The Company had loss carry-forwards of approximately $122,389,000 as of December 31, 2013 that may be offset against future taxable income. The carry-forwards will expire between 2021 and 2034. Use of these carry-forwards may be subject to annual limitations based upon previous significant changes in stock ownership. Management has determined that realization of the net deferred tax assets is not assured and accordingly has established a valuation allowance of $42,055,000 and $38,406,000 at December 31, 2013 and 2012, respectively.
	In 2013, the Company recorded an income tax provision of approximately $19,000 related to a deferred tax liability resulting from the amortization of Goodwill for tax purposes.
	The Company’s source of income (loss) before income tax provision (benefit) is primarily domestic.
	The Company does not believe it has any uncertain income tax positions as described in its discussion of Income Tax accounting policy in Note 3.

Capital_Stock

Capital Stock	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 17 — Capital Stock
	The Company has several classes of stock as described below.
	Common Stock
	Common stock has a par value of $.0001 per share and is limited to a maximum of 200,000,000 shares. It is subordinate to Series A, B, C, and D Convertible Preferred stock and to all other classes and series of equity securities of the Company which by their terms rank senior to it, in the event of a liquidation, dissolution, or winding up of the Company or with regard to any other rights, privileges or preferences. Each share of Common stock represents the right to one vote. Holders of Common stock are entitled to receive dividends as may be declared by the Board of Directors, subject to the limitations in the terms of the Series A, B, C, and D Convertible Preferred stock described below.
	Series A Convertible Preferred Stock
	The Series A Convertible Preferred stock (the “Series A”) was redeemed in February 2012.
	Series A stock has a par value of $.0001 per share and is limited to a maximum of 5,000,000 shares. It has a stated liquidation preference of $1.00 per share and preference over and rank senior to (i) Series B Convertible Preferred stock, (ii) Common stock, and (iii) all other classes and series of equity securities of the Company which by its terms do not rank senior to the Series A stock. The Series A stock contains a negative covenant prohibiting the Company from granting any security interest in the Company’s patents and/or future royalty streams (“Intellectual Property”). The holders of record of shares are entitled to receive cumulative dividends at the rate of 8% of the stated liquidation preference amount per share per annum, payable quarterly in arrears. These dividends are prior and in preference to any declaration or payment of any distribution on any outstanding shares of Common stock or any other equity securities of the Company ranking junior as to the payment of dividends. Dividends are to be paid in shares of Series A stock or, in the sole discretion of the Board of Directors, in cash. Each share of Series A stock shall entitle the holder thereof to vote on all matters voted on by holders of Common stock of the Company voting together as a single class with the other shares entitled to vote.
	Each share of Series A stock may be converted into Common stock at a conversion rate equal to 90% of the twenty-day average closing price of the Company’s Common stock, but in no case shall this price be less than $3.00 per share. The Company may redeem Series A stock for cash at a price per share equal to 104% of the liquidation preference amount plus all accrued but unpaid dividends, by providing proper notice of not less than 10 days nor more than 60 days prior to a redemption date set by the Company.
	Series B Convertible Preferred Stock
	The Series B Convertible Preferred stock (the “Series B”) was redeemed in February 2012.
	Series B stock has a par value of $.0001 per share and is limited to a maximum of 5,000,000 shares. It has a stated liquidation preference of $1.00 per share, is subordinate to the Series A stock, and has preference over and ranks senior to (i) Common stock, and (ii) all other classes and series of equity securities of the Company which by its terms do not rank senior to the Series B stock. The Series B stock contains a negative covenant prohibiting the Company from granting any security interest in the Company’s Intellectual Property. The holders of record of shares are entitled to receive cumulative dividends at the rate of 8% of the stated liquidation preference amount per share per annum, payable quarterly in arrears. These dividends are prior and in preference to any declaration or payment of any distribution on any outstanding shares of Common stock or any other equity securities of the Company ranking junior as to the payment of dividends. Dividends are to be paid in shares of Series B stock or, in the sole discretion of the Board of Directors, in cash. Each share of Series B stock shall entitle the holder thereof to vote on all matters voted on by holders of Common stock of the Company voting together as a single class with the other shares entitled to vote.
	Each share of Series B stock may be converted into Common stock at a conversion rate equal to 90% of the twenty-day average closing price of the Company’s Common stock, but in no case shall this price be less than $3.00 per share. The Company may redeem Series B stock for cash at a price per share equal to 103% of the liquidation preference amount plus all accrued but unpaid dividends, by providing proper notice of not less than 10 days nor more than 60 days prior to a redemption date set by the Company.
	Series D Convertible Preferred Stock
	The 10% Series D Convertible Preferred stock (the “Series D”) was converted into Common stock in February 2012.
	The Company’s Board designated 2,000,000 shares of the preferred stock as the Series D stock with a stated value of $1,000 per share. The Series D stock earned cumulative dividends at the rate of 10% per annum, payable quarterly in cash in arrears on January 15, April 15, July 15 and October 15, beginning on July 15, 2010, or, in the Company’s sole discretion, in shares of Common stock valued at the 5-day volume weighted average price ending 3 days immediately preceding the dividend due date, but in no case at a price less than $0.40 per share. The Series D stock was convertible, at the holder’s option, into shares of Common stock at a conversion price equal to $0.4392. Upon any liquidation, dissolution or winding-up of our company, whether voluntary or involuntary, the holders were entitled to receive out of the Company’s assets an amount equal to the stated value, plus any accrued and unpaid dividends thereon and any other fees then due and owing thereon, for each share of Series D stock before any distribution or payment is made to the holders of any junior securities. The holders of the Series D stock could vote their shares on a “one share one vote” basis. At any time after the third anniversary of the issuance date, the Company could redeem some or all of the then outstanding Series D stock, for cash equal to 100% of the aggregate stated value and accrued but unpaid dividends. The Series D stock also provided that with limited exceptions as discussed below, in no event would the Company effect any conversion of the Series D stock and the holder of the Series D stock would not have the right to convert the Series D stock, to the extent that such conversion would result in beneficial ownership by the holder of the Series D stock and its affiliates in excess of 9.99% of the then outstanding shares of Common stock (after taking into account the shares to be issued to the holder upon such conversion). The Series D stock holder could decrease the foregoing threshold upon 61 days’ notice of such decrease to us. The Series D stock was not listed on any securities exchange or automated quotation system.
	Warrants and Options
	The Company had the following outstanding warrants and options at December 31:
			# Outstanding
	Equity Instrument		31-Dec-13		31-Dec-12
	Fitch/Coleman Warrants(1)			975,000		975,000
	August 2009 Warrants(2)			1,070,916		1,070,916
	April 2010 Warrants(3)			1,295,138		1,295,138
	October 2010 Warrants(4)			1,488,839		1,488,839
	Guarantor 2011 Warrants(5)			916,665		916,665
	February 2012 Inducement Warrants(6)			1,180,547		1,180,547
	February 2012 Aldagen Warrants(7)			2,115,596		2,115,596
	February 2013 MidCap Warrants(8)			1,079,137		—
	February 2013 Subordination Warrants(9)			800,000		—
	February 2013 Worden Warrants(10)			250,000		—
	February 2013 RDO Warrants(11)			6,363,638		—
	February 2013 PA Warrants(12)			136,364		—
	December 2013 Note Warrants(13)			5,047,461		—
	Other warrants(14)			300,000		200,000
	Options issued under the 2002 Long-Term Incentive Plan(15)			8,510,816		7,866,953
	Options issued under the 2013 Equity Incentive Plan(16)			10,000		—
		-1	These warrants were issued in connection with the August 2, 2007 Term Sheet Agreement and Shareholders’ Agreement with the Company’s outside patent counsel, Fitch Even Tabin & Flannery and The Coleman Law Firm, and have a 7.5 year term. The strike prices on the warrants are: 325,000 at $1.25 (Group A); 325,000 at $1.50 (Group B); and 325,000 at $1.75 (Group C). The Company may call up to 100% of these warrants, provided that the closing stock price is at or above the following call prices for ten consecutive trading days: Group A — $4/share; Group B — $5/share; Group C — $6/share. If the Company exercises its right to call, it shall provide at least 45 days notice for one-half of the warrants subject to the call and at least 90 days notice for the remainder of the warrants subject to the call.
		-2	These warrants were issued in connection with the August 2009 financing, are voluntarily exercisable at $0.51 per share and expire in February 2014. These amounts reflect adjustments for an additional 420,896 warrants due to anti-dilutive provisions. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.
		-3	These warrants were issued in connection with the April 2010 Series D preferred stock offering, are voluntarily exercisable at $0.54 per share and expire on April 9, 2015.
		-4	These warrants were issued in connection with the October 2010 financing. They have an exercise price of $0.60 and expire on April 7, 2016. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.
		-5	These warrants were issued pursuant to the Guaranty Agreements executed in connection with the Promissory Note issued in April 2011. These warrants have an exercise price of $0.50 per share and expire on April 28, 2016.
		-6	These warrants were issued in connection with the February 2012 warrant exercise agreements executed with certain existing Cytomedix warrant holders. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.
		-7	These warrants were issued in February 2012 in connection with the warrant exchange agreements between Cytomedix and various warrant holders of Aldagen. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.
		-8	These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share and expire on February 19, 2020.
		-9	These warrants were issued in connection with the February 2013 financing, have an exercise price of $0.70 per share, and expire on February 19, 2018. They are only exercisable if the JPNT Note remains outstanding on or after 04-28-2015 (50% of total) and 04-15-2016 (remainder).
		-10	These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share, and expire on February 19, 2020.
		-11	These warrants were issued in connection with the February 2013 registered direct offering. They are voluntarily exercisable, have an exercise price of $0.75 per share, and expire on February 22, 2018.
		-12	These warrants were issued to the placement agent in connection with the February 2013 registered direct offering. They are exercisable on or after August 21, 2013, have an exercise price of $0.66 per share, and expire on February 22, 2018.
		-13	These warrants were issued in connection with the December 2013 debt financing. They are voluntarily exercisable, have an exercise price of $0.68 per share, and expire on December 8, 2018.
		-14	These warrants were issued to consultants and other professional service providers in exchange for services provided. A warrant for 200,000 Common shares has an exercise price of $1.50, expires on February 24, 2014, and is vested and voluntarily exercisable. A warrant for 100,000 Common shares has an exercise price of $0.37, expires on October 15, 2015, and is voluntarily exercisable upon vesting (50% vested as of December 31, 2013 and 100% vested by February 15, 2014). There is no call provision associated with either of these warrants.
		-15	These options were issued under the Company’s 2002 Long-Term Incentive Plan approved by shareholders. See Note 17 for a full discussion regarding these options.
		-16	These options were issued under the Company’s 2013 Equity Incentive Plan approved by shareholders. See Note 17 for a full discussion regarding these options.
	Activity
	The Company issued 13,356,469 shares of Common stock during 2013. The following table lists the sources of and the net proceeds from those issuances:
	Source		# of Shares		Net Proceeds
	Sale of shares pursuant to registered direct offering			9,090,911	$	4,557,188
	Sale of shares pursuant to October 2010 equity purchase			450,000	$	303,000
	agreement
	Sale of shares pursuant to February 2013 equity purchase agreement			1,500,000	$	601,944
	Issuance of shares in lieu of cash for fees incurred pursuant to February 2013 equity purchase agreement			390,261	$	—
	Issuance of shares for conversion of 4% Convertible Notes			1,600,219	$	—
	Issuance of shares for release of security interest in patents			250,000	$	—
	Issuance of shares to Class 4A Equity shareholder pursuant to June 2002 Reorganization Plan			27,000	$	—
	Issuance of shares in lieu of cash for consultants			37,500	$	—
Other			10,578	$	—
Totals			13,356,469	$	5,462,132
The Company issued 38,272,094 shares of Common stock during 2012. The following table lists the sources of and the proceeds from those issuances:
Source		# of Shares		Total Proceeds
Conversion of Series D Convertible Preferred shares			7,460,350	$	—
Inducement to remaining shareholders of Series D Convertible Preferred stock to convert all outstanding shares			330,000	$	—
Conversion of Series E Convertible Preferred shares			13,399,986	$	—
Exercise of August 2008 warrants			584,672	$	584,672
Exercise of August 2009 warrants			418,968	$	213,674
Exercise of April 2010 warrants			2,833,493	$	1,521,028
Exercise of Guarantor 2010 warrants			1,333,334	$	715,734
Exercise of October 2010 warrants			375,000	$	225,000
Exercise of Guarantor 2011 warrants			1,583,335	$	791,667
Exercise of options issued under the Long-Term Incentive Plan			35,602	$	15,185
Common stock issued in lieu of cash for dividend payable on Series D Convertible Preferred shares			76,461	$	—
Partial conversion of 4% Convertible Notes			1,062,500	$	—
Sale of shares pursuant to private offering			4,231,192	$	5,000,000
Sale of shares pursuant to October 2010 equity purchase			4,350,000	$	4,493,902
agreement
Common stock issued in lieu of cash for fees incurred pursuant to October 2010 equity purchase agreement			179,701	$	—
Common stock issued in lieu of cash for consultant			17,500	$	—
Totals			38,272,094	$	13,560,862
The Company has used the cash proceeds from these 2013 and 2012 issuances for general corporate and research and development purposes. The issuance of shares of the Company’s securities were either registered under the Securities Act or made in reliance on the private offering exemptions contained in Section 4(2) of the Securities Act and regulations promulgated thereunder, and in reliance on similar exemptions under applicable state laws as a transaction not involving a public offering. None of these transactions involved any underwriters, underwriting discounts or commissions.
Lincoln Park Transaction
On February 18, 2013, Cytomedix entered into a purchase agreement (the “Purchase Agreement”), together with a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right to sell to and Lincoln Park is obligated to purchase up to $15 million in shares of the Company’s Common stock (“Common Stock”), subject to certain limitations, from time to time, over the 30-month period commencing on the date that a registration statement, which the Company agreed to file with the Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed. The Company may direct Lincoln Park every other business day, at its sole discretion and subject to certain conditions, to purchase up to 150,000 shares of Common Stock in regular purchases, increasing to amounts of up to 200,000 shares depending upon the closing sale price of the Common Stock. In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases if on the date of a regular purchase the closing sale price of the Common Stock is not below $1.00 per share. The purchase price of shares of Common Stock related to the future funding will be based on the prevailing market prices of such shares at the time of sales (or over a period of up to 12 business days leading up to such time), but in no event will shares be sold to Lincoln Park on a day the Common Stock closing price is less than the floor price of $0.45 per share, subject to adjustment. The Company’s sales of shares of Common Stock to Lincoln Park under the Purchase Agreement are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 9.99% of the then outstanding shares of the Common Stock.
In connection with the Purchase Agreement, the Company issued to Lincoln Park 375,000 shares of Common Stock and is required to issue up to 375,000 additional shares of Common Stock pro rata as the Company requires Lincoln Park to purchase the Company’s shares under the Purchase Agreement over the term of the agreement. Lincoln Park represented to the Company, among other things, that it was an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”), and the Company sold the securities in reliance upon an exemption from registration contained in Section 4(2) under the Securities Act. The securities sold may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. Actual sales of shares of Common Stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. There are no trading volume requirements or restrictions under the Purchase Agreement. Lincoln Park has no right to require any sales by the Company, but is obligated to make purchases from the Company as it directs in accordance with the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our shares.
Common Stock and Warrant Registered Offering
On February 19, 2013, the Company entered into securities purchase agreements with certain institutional accredited investors, including certain current shareholders of the Company, to raise gross proceeds of $5,000,000, before placement agent’s fees and other offering expenses, in a registered offering. The Company will issue to the investors units of the Company’s securities consisting, in the aggregate, of 9,090,911 shares of the Company’s Common stock and five-year warrants to purchase 6,363,638 shares of Common stock. The purchase price paid by investors was $0.55 for each unit. Each warrant is immediately exercisable at $0.75 per share on or after February 22, 2013 and is subject to transfer restrictions, including among others, compliance with the state securities laws. The closing of the offering took place on February 22, 2013. Proceeds from the transaction will be used for general corporate and working capital purposes. The warrants are classified in equity.
Pursuant to the terms of the Placement Agent Agreement, the Company has agreed to pay an aggregate cash fee in the amount of $350,000 (the “Placement Fee”). The Company has also agreed to reimburse up to $52,000 for expenses incurred by the placement agent in connection with the offering. In addition, the Company granted to the placement agent warrants to purchase 136,364 shares of our Common stock. The warrants will have the same terms as the investor warrants in this offering, except that the exercise price will be 120% of the exercise price of the investor warrants and may also be exercised on a cashless basis.
The offering was made pursuant to a shelf registration statement on Form S-3 (SEC File No. 333-183704, the base prospectus originally filed with the SEC on August 31, 2012, as subsequently amended and as supplemented by a prospectus supplement filed with the Securities and Exchange Commission on February 20, 2013).
The securities purchase agreements contain representations, covenants and other provisions customary for the agreements of this nature. In addition, such agreements provide for certain “piggy-back” registrations rights with respect to the Company’s securities (including shares to be issued upon warrant exercises) purchased in the offering by investors that are affiliates of the Company, such that the Company agreed, to the extent such affiliate investors are not able to resell such securities without restriction, to include such securities in its future registration statements, subject to applicable limitations. Also, to the extent that such securities have been not registered at the time the Company is required to file a registration statement in connection with the final milestone event relating to the February 2012 Aldagen acquisition, the affiliate investors will have the right to include such securities in such registration statement.
In connection with this offering, the Company and the Maryland Venture Fund (Maryland Department of Business and Economic Development), an investor in the above referenced offering (“MVF”), in compliance with MVF’s investment policies, agreed to execute a certain Stock Repurchase Agreement which requires the Company to repurchase the MVF’s investment, at MVF’s option, upon certain events outside of the Company’s control; provided, however, that in the event that, at the time of either such event the Company’s securities are listed on a national securities exchange, the foregoing repurchase will not be triggered. The Common shares issued to MVF are classified as “contingently redeemable Common shares” in the accompanying condensed consolidated balance sheet. The value of the warrants and offering expenses allocable to the contingently redeemable Common shares was not material.
Release of the Worden Security Interest in the Licensed Patents
On February 19, 2013, the Company and Charles E. Worden Sr., an individual holder of security interest in patents pursuant to the Substitute Royalty Agreement, dated November 4, 2001 (the “SRA”), executed an Amendment to the SRA (the “SRA Amendment”) for the purposes of terminating and releasing the security interest and the reversionary interest under the terms of the SRA in exchange for the following consideration: (i) a one-time cash payment of $500,000 (to replace all future minimum monthly royalty payments), (ii) issuance of 250,000 shares of the Company’s Common stock (the “Worden Shares”), and (iii) grant of the right to acquire up to 250,000 shares of the Company’s Common stock pursuant to a seven-year warrant with the exercise price of $0.70 per share (the “Worden Warrant”). In addition, under the terms of the Amendment, Mr. Worden’s future annual royalty stream limitation was increased from $600,000 to $625,000. The exercise price and the number of shares issuable upon exercise of the Worden Warrant is subject to standard anti-dilution provisions. The Worden Warrants contain provisions that are customary for the instruments of this nature, including, among others, a cashless exercise provision. The warrants are classified as equity.
Mr. Worden is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act), and the Company therefore sold the Worden Shares and the Worden Warrant in reliance upon an exemption from registration contained in Section 4(2) under the Securities Act. The securities sold may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
JP Nevada Trust Note Amendment
On February 19, 2013, the Company and its wholly-owned subsidiary, Cytomedix Acquisition Company, LLC, the holder of the April 28, 2011 $2.1 million secured promissory note (the “JP Trust Note”), JP’s Nevada Trust (the “Lender”), agreed, in consideration for subordination of its security interest under the JP Trust Note to that of MidCap pursuant to the terms of the Subordination Agreement, to amend the JP Trust Note to (i) extend the maturity date of such note to November 19, 2016 and (ii) expand the Lender’s second lien security interest under the Note to include the assets of the Company and Aldagen, Inc., the Company’s wholly-owned subsidiary, in addition to the previously secured assets of Cytomedix Acquisition Company, LLC. The parties also agreed to amend the vesting schedule on the Lender’s warrants issued by the Company in April 2011 such that the remaining 250,000 warrant shares are exercisable immediately. Finally, the Company agreed to issue the Lender a new warrant to purchase up to 266,666 shares at an exercise price of $0.70 per share vesting as follows: (i) 133,333 shares may be exercised only if the JP Trust Note has not been paid by the fourth anniversary of its issuance, and (ii) the remaining 133,333 shares may be exercised only if the JP Trust Note has not been paid by the fifth anniversary of its issuance.
As disclosed in the Company’s Current Report on Form 8-K relating to the original issuance of the JP Trust Note, the Company’s payment obligations with respect to $1.4 million under the JP Trust Note were guaranteed by certain insiders, affiliates, and shareholders of the Company, including David E. Jorden, Chairman of the Board of the Company (the “Guarantors”). In light of the foregoing changes to the Lender’s warrant vesting schedule and issuance of new warrants the Lender, as described above, the disinterested members of the Board also: (i) reviewed and approved amendments to the warrant vesting schedule on the Guarantors’ warrants (including those held by Mr. Jorden) issued by the Company in April 2011 such that the remaining 500,000 warrant shares are exercisable immediately and (ii) granted the right to the Guarantors to acquire up to 533,334 shares of the Company’s Common stock pursuant to warrants at the exercise price of $0.70 per share, vesting as follows: (i) 266,667 warrant shares may be exercised only if the JP Trust Note has not been prepaid by the fourth anniversary of its issuance, and (ii) the remaining 266,667 shares may be exercised only if the JP Trust Note has not been paid by the fifth anniversary of its issuance (including 107,143 of the previously issued warrants held by Mr. Jorden, which will now vest immediately, and (i) 57,143 of his warrant shares may be exercised only if the JP Trust Note has not been paid by the fourth anniversary of its issuance, and (ii) the remaining 57,143 shares may be exercised only if the JP Trust Note has not been paid by the fifth anniversary of its issuance).
The warrant was sold in a transaction exempt from registration under the Securities Act of 1933, in reliance on Section 4(2) thereof. The Lender and each of the Guarantors are “accredited investors” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act), and the Company sold the securities in reliance upon an exemption from registration contained in Section 4(2) and Rule 506 under the Securities Act. The securities sold may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
JMJ Financial Note Amendment and Subordination
On February 19, 2013, the Company and JMJ Financial (“JMJ”), the holder of certain convertible promissory notes issued by the Company (together, the “JMJ Notes”), agreed, in consideration of the subordination of JMJ’s rights and remedies under the JMJ Note to that of MidCap pursuant to the terms of the certain Subordination Agreement (the “JMJ Subordination Agreement”), to amend the JMJ Notes to extend the maturity date of the JMJ Notes to the later of (i) three years from the effective date of such notes or (ii) the date that is one business day following the date the MidCap loan is paid in full. In addition, JMJ converted $100,000 of the outstanding balance on one of the JMJ Notes into shares of the Company’s Common stock and the Company remitted a payment in the amount of $370,000 to partially satisfy one of the JMJ Notes.
Other
In 2013, the Company granted 1,038,000 options to purchase the Company’s Common stock with exercise prices ranging from $0.45 to $0.53 under the 2002 LTIP and 2013 EIP (see Note 18).
During the year ended December 31, 2013, 384,137 stock options expired or were forfeited by contract due to the termination of the underlying service arrangement.
In 2012, the Company granted 2,271,500 options to purchase the Company’s Common stock with exercise prices ranging from $0.72 to $2.28 under the LTIP (see Note 18).
During the year ended December 31, 2012, 804,649 stock options and compensatory warrants expired or were forfeited by contract due to the termination of the underlying service arrangement.
On January 17, 2012, pursuant to the terms of the Certificate of Designation, the Company paid a dividend on its Series D Preferred stock in the form of shares of its Common stock. The total dividend paid to all Series D Preferred stock holders was 76,461 Common shares.
On February 8, 2012, in connection with the acquisition of Aldagen, the Company sold 4,231,192 shares of Common stock at a purchase price of $1.18 per share for an aggregate amount of $5 million to certain owners of Aldagen. The shares were sold in transactions exempt from registration under the Securities Act of 1933, in reliance on Section 4(2) thereof and Rule 506 of Regulation D thereunder. Each purchaser represented that it was an “accredited investor” as defined in Regulation D.
On February 8, 2012, in connection with the acquisition of Aldagen, Series D convertible preferred stockholders converted their preferred stock into 7,460,350 shares of Common stock. In order to induce such conversion the Company issued an aggregate of 330,000 additional shares of Common stock to these shareholders.
On February 8, 2012, in connection with the acquisition of Aldagen, the Company issued 135,398 shares of its newly designated Series E convertible preferred stock. These shares automatically converted into 13,539,816 shares of Common stock upon shareholder approval of an increase in the Company’s authorized Common stock at a special shareholders’ meeting held on May 18, 2012. In July 2012, Aldagen’s former investors agreed to release 139,830 Common shares held in escrow to offset their liability for excess transaction expenses incurred by the Company in its acquisition of Aldagen.
On February 8, 2012, in connection with the acquisition of Aldagen, the Company executed warrant exercise agreements with various existing Cytomedix warrant holders. These agreements obligated the warrant holders to exercise approximately $2.8 million worth of warrants, representing 5,288,256 shares, no later than June 30, 2012. As of June 30, 2012, these warrant exercise agreements had been fulfilled. The Company issued 1,180,547 of new warrants to the shareholders as an inducement for their commitment. The new warrants have an exercise price of $1.42 per share and expire December 31, 2014. Of these warrants, 30% vested upon issuance and 70% will vest only upon the achievement of certain clinical milestones defined in the exchange and purchase agreement related to the Aldagen acquisition.
On February 8, 2012, in connection with the acquisition of Aldagen, the Company issued 2,115,596 warrants to existing Aldagen warrant holders in exchange for then existing Aldagen warrants. The new warrants have an exercise price of $1.42 per share and expire December 31, 2014. Of these warrants, 30% vested upon issuance and 70% will vest only upon the achievement of certain clinical milestones defined in the exchange and purchase agreement related to the Aldagen acquisition.
On February 13, 2012, the Company redeemed all of the then outstanding Series A and B convertible preferred stock for an aggregate amount of approximately $170,000 and satisfied all accrued, but unpaid, dividends on said stock in the aggregate amount of approximately $37,000.
No dividends were declared or paid on the Company’s Common stock in 2013 and 2012.
At December 31, 2013 and 2012, there were no amounts accrued for dividends payable.

LongTerm_Incentive_Plan_Equity

Long-Term Incentive Plan, Equity Incentive Plan and Other Compensatory Awards	12 Months Ended
	Dec. 31, 2013
Long Term Incentive Plans And Other Compensatory Awards Disclosure [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 18 — Long-Term Incentive Plan, Equity Incentive Plan and Other Compensatory Awards
	Cytomedix has a shareholder-approved 2002 LTIP and 2013 EIP that permits awards of stock options, stock appreciation rights, restricted stock, phantom stock, performance units, dividend equivalents and other stock-based awards. Cytomedix may issue up to 10,500,000 and 3,000,000 shares of stock under the LTIP and EIP, respectively. As of July 2013, incentive stock options may no longer be granted under the LTIP. At December 31, 2013, 1,457,382 and 2,990,000 shares were available under the LTIP and EIP, respectively, for future grants. Of all stock options granted through December 31, 2013, 531,802 had been exercised and 8,520,816 remained outstanding. Option terms are set by the Board of Directors for each option grant, and generally vest immediately upon grant or over a period of time ranging up to three years, are exercisable in whole or installments, and expire ten years from the date of grant. Outstanding options expire at various dates through December 17, 2023.
	A summary of option activity under the LTIP and EIP as of December 31, 2013, and changes during the year then ended is presented below:
	Stock Options	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
	Outstanding at January 1, 2013		7,866,953		$	1.28
	Granted		1,038,000		$	0.5
	Exercised		0			—
	Forfeited or expired		(384,137	)	$	1.19
	Outstanding at December 31, 2013		8,520,816		$	1.19		5	$	61,018
	Exercisable at December 31, 2013		7,258,925		$	1.26		4.3	$	58,163
	The weighted-average grant-date fair value of stock options granted under these plans during the years 2013 and 2012 was $0.45 and $1.19, respectively. Stock options granted and exercised under the LTIP were 2,271,500 and 35,602, respectively, during the fiscal years ended December 31, 2013 and 2012.
	The following table summarizes information about stock options outstanding as of December 31, 2013:
		Options Outstanding							Options Exercisable
	Range of Exercise Prices	Number of Outstanding Shares			Weighted Average Remaining Contract Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
	$0.30 – $1.50		6,859,483			5.6	$	0.92		5,644,594	$	0.95
	$1.51 – $3.00		1,591,333			2.5	$	2.19		1,544,331	$	2.18
	$3.01 – $4.50		0			—		—		0		—
	$4.51 – $6.00		70,000			2	$	5.2		70,000	$	5.2
	As of December 31, 2013, there was approximately $675,000 of total unrecognized compensation cost related to non-vested stock options granted under the LTIP and EIP. That cost is expected to be recognized over a weighted-average period of 0.9 years. The total fair value of stock options granted under the LTIP and EIP that vested during the fiscal years ended December 31, 2013 and 2012 was approximately $712,000 and $1,828,000, respectively.
	Additionally, the Company has issued certain compensatory warrants outside of the LTIP and EIP, in exchange for the performance of services. A summary of service provider warrant activity as of December 31, 2013, and changes during the year then ended is presented below:
	Warrants to Service Providers	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
	Outstanding at January 1, 2013		1,175,000		$	1.5
	Granted		486,364		$	0.62
	Exercised		0			—
	Forfeited or expired		0			—
	Outstanding at December 31, 2013		1,661,364		$	1.24		2	$	10,400
	Exercisable at December 31, 2013		1,611,364		$	1.27		2	$	5,200
	There were no compensatory warrants granted or exercised during the fiscal year ended December 31, 2012.
	The following table summarizes information about compensatory warrants outstanding as of December 31, 2013:
		Warrants Outstanding							Warrants Exercisable
	Range of Exercise Prices	Number of Outstanding Shares			Weighted Average Remaining Contract Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
	$0.37 – $1.50		1,336,364			2.3	$	1.12		1,286,364	$	1.15
	$1.75		325,000			1.1	$	1.75		325,000	$	1.75
	As of December 31, 2013, there was approximately $6,000 of total unrecognized compensation cost related to these warrants. That cost is expected to be recognized over a weighted-average period of 0.1 years.
	The Company has recorded stock-based compensation expense as follows:
		Year Ended December 31
	Stock-Based Expense	2013			2012
	Awards under the 2002 LTIP	$	679,433		$	2,027,031
	Awards under the 2013 EIP		117			—
	Awards outside the equity-based plans		38,313			20,700
		$	717,863		$	2,047,731
	Included in Statements of Operations caption as follows:
	Salaries and wages	$	564,737		$	1,389,001
	Consulting expense		16,278			275,924
	General and administrative		136,848			382,806
		$	717,863		$	2,047,731

Supplemental_Cash_Flow_Disclos

Supplemental Cash Flow Disclosures - Non-Cash Transactions	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Elements [Abstract]	'
Cash Flow, Supplemental Disclosures [Text Block]	'
	Note 19 — Supplemental Cash Flow Disclosures — Non-Cash Transactions
	Non-cash Investing and Financing transactions for years ended December 31 include:
		2013		2012
	Conversion of convertible debt to common stock	$	523,927	$	924,904
	Preferred dividends paid by issuance of stock		—		82,500
	Business combination:
	Issuance of Series E liability		—		18,955,742
	Issuance of contingent consideration		—		11,109,020
	Issuance of replacement warrants		—		1,883,751
	Common stock issued in satisfaction of subscription receivable		—		2,790,107
	Effect of cancellation of escrowed shares		—		195,132
	Obligation to issue shares for professional services		—		30,000
	Effect of modification of convertible debt		151,032		—
	Common Stock issued for committed equity financing facility		204,015		—
	Warrants issued for term loan modification		151,758		—
	Warrants issued for term loan		568,324		—
	Common stock and warrants issued for release of security interest in patents		325,693		—
	Warrants issued in connection with convertible debt		1,353,842		—
	Derivative liability for embedded conversion option		965,484		—
	Common stock issued for professional services		17,850		—
	Common stock issued for settlement of contingency		39,150		—
	Cash paid for interest was $564,000 and $342,000 in 2013 and 2012, respectively. There were no income taxes paid in 2013 and 2012.

Operating_Leases

Operating Leases	12 Months Ended
	Dec. 31, 2013
Leases, Operating [Abstract]	'
Leases of Lessee Disclosure [Text Block]	'
	Note 20 — Operating Leases
	The Company leases its office spaces under operating leases with approximate future minimum lease payments as indicated in the table below:
	Years ending December 31:
	2014	$	360,000
	2015		360,000
	2016		360,000
	2017		340,000
	2018		—
	Thereafter		—
	Total future minimum lease payments	$	1,420,000
	The Company’s primary office and warehouse facilities are located in Gaithersburg, Maryland, and comprise approximately 7,200 square feet. This facility falls under one lease with monthly rent, including our share of certain annual operating costs and taxes, at approximately $10,000 per month with the lease expiring October 2017. The Company also leases a 16,300 square foot facility located in Durham, North Carolina. This facility falls under one lease with monthly rent, including our share of certain annual operating costs and taxes, at approximately $20,000 per month with the lease expiring December 31, 2018.
	For the years ended December 31, 2013 and 2012, the Company incurred rent expense of approximately $324,000 and $289,000, respectively.

Geographic_and_Customer_Concen

Geographic and Customer Concentration information	12 Months Ended
	Dec. 31, 2013
Geographic Areas, Revenues from External Customers [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 21 — Geographic and Customer Concentration information
	Product sales consist of the following:
		Year Ended December 31,
		2013		2012
	Revenue from U.S. product sales	$	9,549,015	$	6,179,050
	Revenue from non-U.S. product sales		949,711		1,062,363
	Total revenue from product sales	$	10,498,726	$	7,241,413
	In 2013, Arthrex accounted for $4,972,306, or 47%, of total product sales. No other single customer accounted for more than 5% of total product sales.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 22 — Commitments and Contingencies
	Under the Company’s plan of reorganization upon emergence from bankruptcy in July 2002, the Series A Preferred stock and the dividends accrued thereon that existed prior to emergence from bankruptcy were to be exchanged into one share of new Common stock for every five shares of Series A Preferred stock held as of the date of emergence from bankruptcy. This exchange was contingent on the Company’s attaining aggregate gross revenues for four consecutive quarters of at least $10,000,000 and if met would result in the issuance of 325,000 shares of the Company’s Common stock. The Company reached such aggregate revenue levels as of the end of the quarter ended June 30, 2012 and, as a result, expensed approximately $471,000 related to the resolution of the contingency. The expense amount, classified as other expenses in the accompanying condensed consolidated statement of operations, represents the fair value of 325,000 shares of the Company’s Common stock to be issued to former Series A Preferred Stock holders. The Common stock issuable is classified as equity.
	Aldagen’s former investors have the right to receive up to 20,309,723 shares of the Company’s Common stock, contingent upon the achievement of certain milestones related to the current ALD-401 Phase 2 clinical trial. In February 2013, the Company and former Aldagen shareholders modified the terms of the contingent consideration. As a result of the amendment, approximately $1,006,000 was recognized as operating expense with the offset to equity.
	In conjunction with its FDA clearance, the Company agreed to conduct a post-market surveillance study to further analyze the safety profile of bovine thrombin as used in the AutoloGel TM System. This study was estimated to cost between $500,000 and $700,000 over a period of several years, which began in the third quarter of 2008. As of December 31, 2013, approximately $368,000 had been incurred. Since the inception of this study, the Company has enrolled 120 patients, noting no adverse events. Based on the additional positive safety data, the Company has suspended further enrollment in this study pending further discussion with the FDA.
	In July 2009, in satisfaction of a new Maryland law pertaining to Wholesale Distributor Permits, the Company established a Letter of Credit, in the amount of $50,000, naming the Maryland Board of Pharmacy as the beneficiary. This Letter of Credit serves as security for the performance by the Company of its obligations under applicable Maryland law regarding this permit and is collateralized by a Certificate of Deposit (“CD”) purchased from the Company’s commercial bank. The CD bears interest at an annual rate of 0.10%, matures on February 24, 2014, and is immediately renewed on the same date.
	In connection with the securities purchase agreements executed on February 19, 2013, the Company and the MVF, in compliance with MVF’s investment policies, agreed to execute a certain Stock Repurchase Agreement which requires the Company to repurchase the MVF’s investment, at MVF’s option, upon certain events outside of the Company’s control; provided, however, that in the event that, at the time of either such event the Company’s securities are listed on a national securities exchange, the foregoing repurchase will not be triggered. The Common shares issued to MVF are classified as “contingently redeemable Common shares” in the accompanying condensed consolidated balance sheet. The value of the warrants and offering expenses allocable to the contingently redeemable Common shares was not material. Upon the termination of the stock repurchase agreement or the sale of the stock by MVF, the temporary equity will be re-classed to permanent equity.
	The Company’s primary office and warehouse facilities are located in Gaithersburg, Maryland, and comprise approximately 7,200 square feet. This facility falls under one lease with monthly rent, including our share of certain annual operating costs and taxes, at approximately $10,000 per month with the lease expiring October 2017. The Company also leases a 16,300 square foot facility located in Durham, North Carolina. This facility falls under one lease with monthly rent, including our share of certain annual operating costs and taxes, at approximately $20,000 per month with the lease expiring December 31, 2018.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 23 — Subsequent Events
	Completion of the December 2013 Private Offering
	On November 21, 2013, we entered into subscription agreements (the “Subscription Agreements”) with certain institutional and individual “accredited investors”, with respect to the sale of 10% subordinated convertible notes (the “Notes”) and warrants to purchase shares of our Common stock for gross proceeds of $3 million (the “Offering”). At closing of the Offering which took place on December 10, 2013, 75% of the net proceeds were disbursed to the Company, with the balance to be disbursed ten days after the Company’s registration statement in connection with the resale of the securities sold in the Offering is declared effective. Subsequently, the remaining proceeds were delivered to the Company.
	The principal amount of the Notes will be due May 1, 2016 (or 91 days following payment in full of our senior debt facility currently in place with Midcap Financial LLC (“Midcap”)). The Notes will accrue interest at a rate of 10% per annum, payable quarterly in cash or shares of our Common stock, and may be converted into the shares of our Common stock at any time following the closing at the conversion price of $0.46 per share. We may, upon advance notice, at any time prior to 120 days after the closing, repurchase the Notes from the investors at a price equal to 110% of the principal amount of the Notes outstanding plus any accrued and unpaid interest. The Notes also contain conversion price anti-dilution adjustments and other similar provisions. In connection with the issuance of the Notes, we also agreed to issue to the investors in the Offering five-year warrants (the “Warrants”) to purchase shares of our Common stock in the amount equal to 75% of the number of our Common stock shares into which the Notes may be converted at the closing, at an exercise price of $0.68 per share. The Warrants also contain exercise price anti-dilution adjustments, cashless exercise and other similar provisions.
	As agreed with the investors in the Offering, we filed a registration statement to register the resale the shares of our Common stock underlying the Notes, the Warrants and the placement agent warrants to be issued in the Offering. The registration statement was declared effective by the SEC.
	In connection with the Offering, we paid to BTIG, LLC, the placement agent in connection with this Offering, $240,000 cash commission on the gross proceeds of the Offering, and issued the placement agent warrant to acquire 194,133 shares of our Common stock on the terms and provisions substantially similar to the investor warrants, including the same registration rights, as well as reimbursed the placement agent for certain out of pocket and legal expenses. Also, in connection with the foregoing Offering, we entered into a certain warrant modification agreement with our senior secured lender, Midcap, also an investor in this Offering, to reduce the exercise price of the February 2013 warrant issued by the Company to Midcap to $0.46 per share, subject to future reduction upon completion of a future financing. In addition, we granted to the investors in the offering, as a group, a right of participation in the amount of up to 35% of the gross amount to be raised in a subsequent offering with respect to future sales of our equity securities to third party investors for a period of nine months following the closing of the December 2013 private offering. We intend to use the net proceeds of the Offering for the general corporate and working capital purposes.
	Deerfield Facility Agreement
	On March 31, 2014, Cytomedix, Inc., a Delaware corporation (the “Company”), and Deerfield Management Company, L.P. (“Deerfield”) entered into a certain Facility Agreement, dated as of March 31, 2014 (the “Facility Agreement”). Under the terms of this agreement, Deerfield agreed to provide to the Company with a convertible credit facility (the “Facility”) in an amount up to $35 million to be disbursed as follows: (i) the initial draw of $9 million of the Facility to be disbursed on the closing date of this transaction, which took place on March 31, 2014 (the “Closing”) (the “Initial Draw”), and (ii) following the authorization by the Company’s shareholders to increase the Company’s authorized capital stock of the Company at a special meeting of the Company’s shareholders (the “Share Authorization Event”), the Company will be required to draw and Deerfield will be required to fund, the remaining $26 million of the Facility (the “Second Draw”). Certain existing stockholders of the Company, representing approximately 30% of the common shares outstanding of the Company entitled to vote at the special meeting of the Company’s shareholders, entered into voting agreements pursuant to which they agreed to vote their shares of the Company’s stock in favor of, among other things, the Share Authorization Event. Such shareholders, however, retained the right to terminate the voting agreements upon the occurrence of certain events generally referred to as the Stroke Trial Price Event. The Stroke Trial Price Event (as fully defined in the Facility Agreement) would occur if (i) the primary efficacy endpoint of the RECOVER Stroke Phase 2 trial is met in the modified intent to treat population, (ii) failure of the Company’s shareholders to approve the Share Authorization Event, (iii) the average VWAP of the Company’s stock price for the five days immediately after the public announcement of the results of the stroke trial is at least 50% greater than the average VWAP for the five day period immediately preceding the announcement of the results of the stroke trial, and (iv) the average VWAP for the five day period preceding the announcement of the results of the special meeting of the Company’s shareholders is at least 200% of the Conversion Price of $0.52 or $1.04.
	The Facility will be due in full on the fifth anniversary of the Closing. The Facility is structured as a purchase of senior secured convertible notes (the “Notes”), which bear interest at a rate of 5.75% per annum, payable quarterly in arrears in cash or, at the Company’s election after the Second Draw, registered shares of the Company’s common stock; provided, that during the first five quarters following the Closing, the Company has the option of having all or any portion of accrued interest added to the principal balance of the Facility. However, in the event (of the earlier one to occur) that the Second Draw has not occurred within 120 days following the Closing or the Company’s shareholders do not approve the Share Authorization Event, Deerfield will be entitled, at its election after such event, to a cash payment equal to the greater of: (i) the outstanding principal amount plus all interest accrued and unpaid under the Note plus the Yield Enhancement Payment (as defined below), or (ii) an amount equal to the outstanding principal amount plus all interests accrued and unpaid under the Notes and the Yield Enhancement Payment, multiplied by the ratio of (a) the average of the daily volume weighted average sale price of the Company’s common stock (the “Average VWAP”) for each of the five trading days prior to the Share Authorization Event divided by (b) the Conversion Price (as defined below). However, in the event of a Stroke Trial Price Event (as defined in the Facility Agreement), the Company would have 100 days to cure such non-occurrence of the Share Authorization Event so that a sufficient number of the shares of the Company’s common stock is authorized to allow the conversion of the Notes issued in the Initial Draw and associated Deerfield Warrants into shares of the Company’s common stock. The term “Yield Enhancement Payment” refers to a payment of 3% of the principal amount of the Facility drawn, payable in shares of the Company’s common stock at the Conversion Price immediately after the Second Draw unless there has been the non-occurrence of the Share Authorization Event, or, in cash, if such shares of the Company’s common stock are otherwise not available for issuance.
	At any time after the Share Authorization Event, Deerfield will have the right, subject to 9.98% beneficial ownership limitation, to convert the principal amount of the Facility into shares of common stock of the Company (“Conversion Shares”) at a per share price equal to $0.52. In addition, the Company granted to Deerfield the option to require the Company to redeem up to 33.33% of the total amount drawn under the Facility together with any accrued and unpaid interest thereon, on each of the 2nd, 3rd and 4th anniversaries of the Closing with the option right triggered upon the Company’s net revenues failing to be equal or exceed the quarterly milestone amounts set forth in the Facility Agreement. The Company also granted Deerfield the option to require the Company to apply 35% of the proceeds received by the Company in equity-raising transaction(s) to redeem outstanding principal and interest of the Notes, provided that the first $10 million so raised by the Company will be exempt from this put option.
	The Facility Agreement includes customary representations and warranties and covenants by the Company, including restrictions on the incurrence of additional indebtedness. Events of default under the Facility Agreement include, among others, failure by the Company to timely make payments due under the Facility; failure by the Company to comply with its covenants under the Facility Agreement, subject to a cure period with respect to most covenants; inaccuracies in representations and warranties of the Company; insolvency or bankruptcy-related events with respect to the Company; or the Company’s cash and cash equivalents and short-term and long-term marketable securities, as set forth on the Company’s balance sheet, being less than $5 million following the Second Draw.
	In addition, also on the Closing date, the Company entered into a Security Agreement (the “Security Agreement”), which provides, among other things, that the Company’s obligations under the Notes will be secured by a first priority security interest, subject to customary permitted liens, on all assets of the Company. The Security Agreement also includes customary covenants by the Company, remedies of Deerfield and representations and warranties by the Company.
	In connection with the Facility and at the time of the Initial Draw, the Company agreed to issue to Deerfield 25,115,384 warrants to purchase shares of the Company’s common stock at the exercise price of $0.52 per share (the “Deerfield Warrants”), subject to adjustments. However, no such adjustment will take place in the event a Stroke Trial Price Event takes place. At the time of the Second Draw, if any, the Company will issue to Deerfield additional 67,500,001 warrants to purchase shares of the Company’s common stock at the exercise price of $0.52. The seven-year Deerfield Warrants also contain certain limitations that prevent the holder of any Warrants from acquiring shares upon exercise of a warrant that would result in the number of shares beneficially owned by it and its affiliates to exceed 9.98% of the total number of shares of our common stock then issued and outstanding. The number of shares for which the Warrants are exercisable and the associated exercise prices are subject to certain adjustments as set forth in the Warrants. The holder has the right to net exercise any outstanding Warrants for shares of the Company’s common stock. In addition, upon certain changes in control of the Company, to the extent the Warrants are not assumed by the acquiring entity, the holder can elect to receive, subject to certain limitations and assumptions, a number of shares of our common stock or, in certain circumstances, cash equal to the Black-Scholes value of the outstanding Warrants. The maximum number of shares of our common stock that can be issued pursuant to the terms of the Warrants, assuming we issue the additional warrants, is 92,615,385 million shares. The Company relied on the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), for the issuance of the Deerfield Warrants and expects to rely on such exemption for any issuance of its shares issuable upon exercise of the Deerfield Warrants (the “Deerfield Warrant Shares”). The Deerfield Warrants and the Deerfield Warrant Shares have not been registered under the Securities Act or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements.
	The Company and Deerfield also entered into a Registration Rights Agreement dated as of the same date (the “Deerfield Registration Rights Agreement”) pursuant to which the Company agreed to file a registration statement to register the resale of the Conversion Shares and the Deerfield Warrant Shares of the Company’s common stock following the Share Authorization Event.
	The Company agreed to pay BTIG, LLC, the placement agent in connection with this transaction (the “Placement Agent”), the following compensation if the full $35 million Facility is funded: (i) $2,450,000 cash commission (of which $720,000 will be paid upon closing of the Initial Draw), (ii) a warrant to acquire 4,797,692 shares of the Company’s common stock on the terms and provisions substantially similar to the Deerfield Warrants, (the “Deerfield Placement Agent Warrants”) (of which 1,272,692 warrants will be issued upon closing of the Initial Draw and (iii) out of pocket and legal expenses of the placement agent.
	Upon the closing of the Initial Draw and following the prepayment and retirement of (i) the MidCap Note, interest and fees in the amount of approximately $3.8 million, and (ii) one of the December 2013 Convertible Notes in the amount of approximately $339,000, net proceeds to the Company in the amount of approximately $4.1 million will be utilized for general corporate and working capital purposes.
	JP Nevada Trust Subordination
	In connection with the foregoing, the Company (and its subsidiaries, Cytomedix Acquisition Company, a Delaware limited liability company, and Aldagen, Inc., a Delaware corporation) and the holder of the April 2011 $2.1 million secured promissory note, JP’s Nevada Trust (“JPT”), agreed to subordinate its security interest in the Company under the note to that of Deerfield, in consideration for the Company’s issuing JPT a 5-year warrant to purchase 750,000 shares of the Company’s common stock at an exercise price of $0.52 (the “JPT Warrants”). The JPT Warrants also contain price adjustments and other provisions customary to instruments of this nature. The JPT Warrants were issued in a transaction exempt from registration under the Securities Act, in reliance on Section 4(2) thereof. JPJ is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and the Company issued the securities in reliance upon an exemption from registration contained in Section 4(2) and Rule 506 under the Securities Act. These securities qualify for exemption since the issuance of the securities by us did not involve a public offering as defined in Section 4(2) due to our existing relationship with the note holder, the insubstantial number of persons involved in the sale, size of the offering, manner of the offering and number of securities offered. Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act and Regulation D for this transaction. The JPT Warrants and the shares of the Company’s common stock underlying such warrants may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
	Payoff and Discharge of the MidCap Note
	On March 31, 2014, the Company paid approximately $3.8 million to extinguish the secured debt, (interest accrued to date and applicable fees) (evidenced by a senior secured promissory note) owed to MidCap under such note, dated February 19, 2013, thereby discharging the Note and the debt thereunder. The Company has no further obligations or liability under the Note. The financial impact of the foregoing payoff will be reflected in the Company's quarterly period ended March 31, 2014.
	December 2013 Convertible Note Conversions
	All (except one) holders of the Company’s outstanding 10% subordinated convertible notes (the “Notes”) purchased in the December 2013 private placement converted their Notes and accrued interest into shares of the Company’s common stock, under the terms of such Notes at the conversion price of $0.4636 per share, and at a conversion price of $0.5295 for the accrued interest for the total of 5,981,859 shares of the Company’s common stock. All such holders of the Notes were “accredited investors” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act), and the Company issued such securities in reliance upon an exemption from registration requirements under the Securities Act. These securities qualify for exemption since the issuance of the securities by us did not involve a public offering as defined in Section 4(2) due to our existing relationship with the note holder, the insubstantial number of persons involved in the sale, size of the offering, manner of the offering and number of securities offered. Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act and Regulation D for this transaction.
	Private Placement of Common Stock and Warrants
	On March 31, 2014, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with an institutional accredited investor (the “Purchaser”), with respect to the sale of 3,846,154 shares of the Company’s common stock and warrants to purchase shares of common stock of the Company (the “Warrants”) (together, the “Securities”), for gross proceeds of $2 million (the “Offering”). The Purchaser will be issued 5-year Warrants to purchase 2,884,615 shares of common stock at an exercise price per share (the “Exercise Price”) of $0.52. The Warrants are exercisable immediately on the date of issuance and will expire on March 31, 2019. In addition, the Purchaser agreed to execute a lockup agreement relating to the securities acquired by the Purchaser in the Offering pursuant to which the Purchaser agreed, among other things, to not to sell or otherwise dispose of such securities until the earlier of: (i) ten trading days following the Share Authorization Event or (ii) June 30, 2014. The Company agreed, pursuant to the terms of the Registration Rights Agreement entered into with the Purchaser (the “Equity Registration Right Agreement”), to register, subject to certain limitations, the securities sold in connection with the Offering (as well as warrants to purchase shares of the Company’s common stock in connection with the Offering, as well as the Deerfield Placement Agent Warrants, also issued in connection with this Offering and the Deerfield financing) for resale alongside with the Company’s securities registrable under the terms of the Deerfield Registration Rights Agreement. The Company agreed to pay the Placement Agent in connection with this Offering $160,000 cash commission on the gross proceeds of the Offering and 201,923 warrants to purchase shares of the Company’s common stock on the terms and provisions substantially similar to the Warrants, including the same registration rights, as well as out of pocket and legal expenses of the Placement Agent. The Warrants in the Offering and the placement agent warrants were sold in a transaction exempt from registration under the Securities Act, in reliance on Section 4(2) thereof. The Purchaser is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and the Company sold the securities in reliance upon an exemption from registration contained in Section 4(2) and Rule 506 under the Securities Act. These securities qualify for exemption since the issuance of the securities by us did not involve a public offering as defined in Section 4(2) due to our existing relationship with the note holder, the insubstantial number of persons involved in the sale, size of the offering, manner of the offering and number of securities offered. Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act and Regulation D for this transaction. The Warrants and the shares of the Company’s common stock underlying such warrants may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The net proceeds of the Offering will be used for general corporate and working capital purposes.
	The foregoing description of the Facility Agreement, the Notes, the Security Agreement, the Registration Rights Agreement, the Voting Agreements, the Deerfield Warrants, the Subscription Agreement, the Anson Registration Rights Agreement, the Warrants, JPT Warrants and other agreements and instruments in connection therewith does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such agreements and instruments, which are filed as Exhibits to this filing and are incorporated herein by reference. These various agreements contain representations and warranties by each of the parties thereto. The representations, warranties and covenants contained in such documents and agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements, and (i) should not be treated as statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) may have been qualified in the agreements by disclosures that were made to the other party in connection with the negotiation of the agreements; (iii) may apply contract standards of “materiality” that are different from “materiality” under the applicable securities laws; and (iv) were made only as of the date of such agreements or such other date or dates as may be specified in the agreements.
	Appointment Dean Tozer as the Company’s Chief Commercial Officer
	On March 30, 2014, the Board appointed Dean Tozer as the Company’s Chief Commercial Officer, effective immediately. From 2006 to 2011, he was Senior Vice President at Advanced BioHealing Inc. where he was responsible for the acquisition and reintroduction of Dermagraft® into the U.S. market. Subsequently, Mr. Tozer was Vice President of Corporate Development at Shire Regenerative Medicine following the acquisition of Advanced BioHealing, where he led the business development efforts for that division including the 2012 acquisition of Pervasis Therapeutics, Inc. Mr. Tozer holds a Bachelor of Commerce degree from St. Mary’s University in Halifax, Canada and is a Certified Management Accountant.
	There is no arrangement or understanding between Mr. Tozer and any other persons pursuant to which he was appointed as discussed above. Nor are there any family relationships between him and any executive officers and directors. Further, there are no transactions involving the Company which transaction would be reportable pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Act.
	In addition, the Board also approved the terms and provisions of Mr. Tozer’s employment with the Company as set forth in an employment letter dated March 30, 2014, to include, among others: (i) base salary of $300,000 per annum, subject to review by the Board for subsequent increases on an annual basis; (ii) an opportunity to earn an annual bonus, subject to the Board’s review and approval, and (iii) provisions relating to termination of his employment with or without cause as well as terminations for change in control of the Company. In addition, Mr. Tozer’s will be entitled to receive, at the Board’s review and discretion, a grant of stock options under the Company’s Equity Incentive Plan to acquire up to 1.27% of the Company’s common stock outstanding, vesting in equal installments over three years after the issuance date, 40% of which options vesting on the first anniversary of the issuance, and the remaining 60% — in equal monthly installments over the 24 month period following such first anniversary. The letter agreement also contains non-solicitation, non-disparagement, non-competition and other covenants and provisions customary for agreements of this nature.
	Promotion of Peter Clausen to the Company’s Chief Science Officer
	On March 30, 2014, the Board appointed Peter Clausen, the Company’s Senior VP of Technology and Business Development, to the offices of the Company’s Chief Science Officer. Pursuant to the terms of the letter agreement, (i) beginning on April 1, 2014, Mr. Clausen’s annual base salary was set to $290,000, subject to annual review by the Compensation Committee and (ii) he will be eligible to earn up to 40% of his annual salary as an annual bonus. In addition, Mr. Clausen will be entitled to receive, at the Board’s review and discretion, a grant of stock options under the Company’s Equity Incentive Plan to acquire up to 1.06% of the Company’s common stock outstanding, vesting in equal installments over three years after the issuance date, 25% of which options vesting on the first anniversary of the issuance, and the remaining 75% — in equal monthly installments over the 36 month period following such first anniversary. The letter agreement also contains non-solicitation, non-disparagement, non-competition and other covenants and provisions customary for agreements of this nature.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation and Consolidation
	The Company’s financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. They include the accounts of the company and our subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation with no impact to net loss.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.
Business Combinations Policy [Policy Text Block]	'
	Business Combinations
	The Company accounts for business combinations using the acquisition method. Under this method the Company allocates the purchase price to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition, including intangible assets that arise from contractual or other legal rights or are separable (i.e. capable of being sold, transferred, licensed, rented, or exchanged separately from the entity). Determination of fair value is based on certain estimates and assumptions regarding such things as forecasted future revenues and expenses, customer attrition, prevailing royalty rates, required rates of return, etc. The purchase price in excess of the fair value of the net assets and liabilities is recorded as goodwill.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Risk
	Approximately $613,000 and $40,000 held in financial institutions was in excess of FDIC insurance at December 31, 2013 and 2012, respectively. Approximately $2,667,000 and $1,754,000 held in money market accounts at brokerage firms was in excess of Securities Investor Protection Corporation (“SIPC”) at December 31, 2013 and 2012, respectively. The amount not covered by SIPC is insured by the Company’s brokerage firm through additional “excess of SIPC” coverage from third party insurers. These third party insurers would cover losses in the event of the financial failure and liquidation of the financial institution that holds the Company’s institutional money market investments, however they do not insure against losses due to market fluctuations.
	The Company currently has two commercially marketed products, both using PRP technology, that are presently marketed. Significant changes in technology could lead to new products or services that compete with the product offered by the Company. These changes could materially affect the price of the Company’s product or render it obsolete. The Company outsources manufacturing for all the components of its offerings.
	Company utilizes single suppliers for several components of the Angel and AutoloGel product lines. We outsource the manufacturing of various products, including component parts, composing the Angel line to contract manufacturers. While we believe these manufacturers to be of sufficient competency, quality, reliability, and stability, there is no assurance that one or more of them will not experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of AutoloGel are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom the Company has an established vendor relationship.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash Equivalents
	The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.
Accounts Receivable Policy [Policy Text Block]	'
	Accounts Receivable
	Cytomedix generates accounts receivable from the sale of its products. Cytomedix provides for a reserve against receivables for estimated losses that may result from a customer’s inability or unwillingness to pay. The allowance for doubtful accounts is estimated primarily based upon historical write-off percentages, known problem accounts, and current economic conditions. Accounts are written off against the allowance for doubtful accounts when the Company determines that amounts are not collectable. Recoveries of previously written-off accounts are recorded when collected. At December 31, 2013 and 2012 the Company maintained an allowance for doubtful accounts of $16,000 and $43,000, respectively.
Inventory, Policy [Policy Text Block]	'
	Inventory
	The Company’s inventory is produced by third party manufacturers and consists primarily of finished goods. Inventory cost is determined on a first-in, first-out basis and is stated at the lower of cost or net realizable value. The Company’s primary product is the Angel Processing set which has a shelf life of three years. The Company also maintains an inventory of kits, reagents, and other disposables that have shelf lives that generally range from ten months to five years. Expired products are segregated and used for demonstration purposes only; the Company writes off expired inventory through cost of sales.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over its estimated useful life ranging from three to five years for all assets except for furniture, lab, and manufacturing equipment which is depreciated over seven and ten years, respectively. Leasehold improvements are stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over the lesser of the expected lease term or its estimated useful life ranging from three to six years. Amortization of leasehold improvements is included in depreciation expense. Maintenance and repairs are charged to operations as incurred. When assets are disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income (expense).
	Centrifuges may be sold, leased, or placed at no charge with customers. Depreciation expense for centrifuges that are available for sale, leased, or placed at no charge with customers are charged to cost of sales. Depreciation expense for centrifuges used for sales and marketing and other internal purposes are charged to operations. When the centrifuges are sold the net book value is charged to cost of sales.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	'
	Goodwill
	The Company is required to perform a review for impairment of goodwill in accordance with FASB ASC 350, Intangibles — Goodwill and Other. Goodwill is considered to be impaired if it is determined that the carrying value of the Company exceeds its fair value. The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year. In addition to the annual review, an interim review is required if an event occurs or circumstances change that would more likely than not reduce the fair value of the Company below its carrying amount. Examples of such events or circumstances include:
		•	a significant adverse change in legal factors or in the business climate;
		•	a significant decline in Cytomedix’s stock price or the stock price of comparable companies;
		•	a significant decline in the Company’s projected revenue or cash flows;
		•	an adverse action or assessment by a regulator;
		•	unanticipated competition;
		•	a loss of key personnel;
		•	a more-likely-than-not expectation that the Company will be sold or otherwise disposed of;
		•	a substantial doubt about the Company’s ability to continue as a going concern.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	'
	Intangible Assets
	The Company capitalizes the costs of purchased patents, trademarks, customer, and technology related intangibles.
	Indefinite lived intangible assets consist of in-process research and development (IPR&D) acquired in the acquisition of Aldagen. The acquired IPR&D consists of specific cell populations (that are related to a specific indication) and the use of the cell populations in treating particular medical conditions. The Company evaluates its indefinite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and at least on an annual basis as of October 1 of each year, by comparing the fair value of the asset with its carrying amount. When assessing the fair value of the asset, the Company considers various factors that are affected by the events or changes in circumstances. These factors include the valuation method used to determine the value of the asset and key inputs used in the method. If the carrying amount of the intangible asset exceeds its fair value, the Company would recognize an impairment loss in the amount of that excess.
	Identifiable intangible assets with finite lives consist of trademarks, technology (including patents), and customer relationships acquired in business combinations. These intangibles are amortized using the straight-line method over their estimated useful lives. The Company reviews its finite-lived intangible assets for potential impairment when circumstances indicate that the carrying amount of assets may not be recoverable by comparing the fair value of the asset with its carrying amount. When assessing the fair value of the asset, the Company considers various factors that are affected by the events or changes in circumstances. These factors include the valuation method used to determine the value of the asset and key inputs used in the method. If the carrying amount of the intangible asset exceeds its fair value, the Company would recognize an impairment loss in the amount of that excess.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted.
	For the year ended December 31, 2013, the income tax provision relates exclusively to a deferred tax liability associated with the amortization of goodwill. The Company has analyzed filing positions in all of the federal and state jurisdictions where it is required to file income tax returns, as well as all open tax years in these jurisdictions. The only periods subject to examination for the Company’s federal return are the 2009 through 2013 tax years. The Company believes that its income tax filing positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded.
	The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no such items for 2013 and 2012.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenue in accordance with FASB ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) consideration is fixed or determinable; and (4) collectability is reasonably assured.
	Sales of products
	The Company provides for the sale of its products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. The Company does not maintain a reserve for returned products as in the past those returns have not been material.
	Usage or leasing of blood separation equipment
	As a result of the acquisition of the Angel® business in 2010, the Company acquired various multiple element revenue arrangements that combine the (i) usage or leasing of blood separation processing equipment, (ii) maintenance of processing equipment, and (iii) purchase of disposable processing sets and supplies. Under these arrangements, the total arrangement consideration is allocated to the various elements based on their relative estimated selling prices. The usage of the blood separation processing equipment is accounted for as an operating lease; since customer payments are contingent upon the customer ordering new products, rental income is recorded following the contingent rental method when rental income is earned and collectability is reasonably assured. The sale of disposable processing sets and supplies and maintenance are deemed a combined unit of accounting; since (a) any consideration for disposable processing sets and supplies and maintenance is contingent upon the customer ordering additional disposable processing sets and supplies and (b) both the disposable products and maintenance services are provided over the same term, the Company recognizes revenue for this combined unit of accounting following the contingent revenue method at the time disposable products are delivered based on prices contained in the agreement. Rental income is currently less than 10% of total revenue and the Company therefore does not make separate disclosure in the statement of operations.
	Percentage-based fees on licensee sales of covered products are generally recorded as products are sold by licensees and are reflected as “Royalties” in the Consolidated Statements of Operations.
	Direct costs associated with product sales and royalty revenues are recorded at the time that revenue is recognized.
	Option Agreement with a global pharmaceutical company
	In October 2011, the Company entered into an option agreement with a top 20 global pharmaceutical company granting the potential partner an exclusive option period through June 30, 2012 regarding U.S. supply and distribution of the AutoloGel System. In exchange for this period of exclusivity, we have received non-refundable fees totaling $4.5 million. The revenue for these non-refundable fees is recognized, on a straight-line basis, over the exclusive option period based on the relative estimated selling price, with the remaining balance recognized at the expiration of the option period. In August 2012, the parties agreed to the early termination of the August 30, 2012 exclusivity period and ceased further negotiations concerning a distribution agreement; accordingly, all fees were recognized.
Excise Tax [Policy Text Block]	'
	Excise Tax
	On January 1, 2013 a medical device excise tax came into effect that required manufacturers to pay tax of 2.3% on the sale of certain medical devices. The Company has determined that the medical device excise tax will be reported on a gross basis and will be recorded as a cost of sale.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	The Company, from time to time, may issue stock options or stock awards to employees, directors, consultants, and other service providers under its 2002 Long-Term Incentive Plan (“LTIP”) or 2013 Equity Incentive Plan (“EIP”) (see Note 17). In some cases, it has issued compensatory warrants to service providers outside the LTIP or EIP (see Note 17).
	All equity-based compensation is estimated on the date of grant using the Black-Scholes-Merton option-pricing formula. The weighted-average assumptions used in the model are summarized in the following table:
			2013			2012
	Risk free rate			0.77	%		0.63	%
	Expected years until exercise			5.9			5.2
	Expected stock volatility			134	%		129	%
	Dividend yield			—			—
	For stock options, expected volatilities are based on historical volatility of the Company’s stock. Due to the Company’s short operating history, we used peer company data to estimate option exercises and employee terminations within the valuation model for the year ended December 31, 2013 and 2012. The expected years until exercise represents the period of time that options are expected to be outstanding and was estimated by using peer company information. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The Company estimated that the dividend rate on its Common stock will be zero.
	The fair value of stock options or compensatory warrants issued to service providers utilizes the same methodology with the exception of the expected term. For these awards to non-employees, the Company estimates that the options or warrants will be held for the full term.
	Stock-based compensation for awards granted to non-employees is periodically remeasured as the underlying options and warrants vest. The Company recognizes an expense for such awards throughout the performance period as the services are provided by the non-employees, based on the fair value of these options and warrants at each reporting period.
	The Company estimates the fair value of stock awards based on the closing market value of the Company’s stock on the date of grant.
Earnings Per Share, Policy [Policy Text Block]	'
	Income (Loss) Per Share
	Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of Common shares outstanding during the period, excluding unvested restricted stock.
	For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive Common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our dilutive potential Common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.
	For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential Common shares is anti-dilutive due to the net losses.
	The Common shares potentially issuable upon the exercise of these instruments were as follows at December 31:
			2013			2012
	Options			8,520,816			7,866,953
	Warrants			23,019,301			9,242,701
	Contingent consideration			20,309,723			20,309,723
	Convertible notes			9,285,117			2,078,393
				61,134,957			39,497,770
Defined Contribution Plan [Policy Text Block]	'
	Defined Contribution Plans
	The Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. Participants are always fully vested in their contributions. The Company makes employer matching contributions, which also vest immediately. This plan is designated as a “Safe Harbor” plan. During 2013 and 2012, the Company contributed approximately $164,000 and $126,000 in cash to the plan.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The balance sheets include various financial instruments that are carried at fair value. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:
		•	Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;
		•	Level 2, defined as observable inputs other than Level I prices such as quoted prices for similar assets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
		•	Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
	An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.
	The Company accounts for derivative instruments under ASC 815, Accounting for Derivative Instruments and Hedging Activities, as amended and interpreted. ASC 815 requires that we recognize all derivatives on the balance sheet at fair value. Certain warrants issued in 2013 and prior years meet the definition of derivative liabilities. In December 2013, we issued warrants in connection with certain financing activities; the warrants are accounted for as derivative liabilities. In July and November 2011 and December 2013, we issued convertible notes that contained embedded conversion options; the embedded conversion options are accounted for as a derivative liability. We determine the fair value of these derivative liabilities using the Black-Scholes option pricing model. This model determines fair value by requiring the use of estimates that include the contractual term, expected volatility of the Company’s stock price, expected dividends and the risk-free interest rate. Changes in fair value are classified in “other income (expense)” in the consolidated statement of operations.
	Additional information regarding fair value is disclosed in Note 6.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	The Company believes the adoption of Accounting Standards Updates issued but not yet adopted will not have a material impact to our results of operations or financial position.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The weighted-average assumptions used in the model are summarized in the following table:
		2013			2012
	Risk free rate		0.77	%		0.63	%
	Expected years until exercise		5.9			5.2
	Expected stock volatility		134	%		129	%
	Dividend yield		—			—
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The Common shares potentially issuable upon the exercise of these instruments were as follows at December 31:
		2013			2012
	Options		8,520,816			7,866,953
	Warrants		23,019,301			9,242,701
	Contingent consideration		20,309,723			20,309,723
	Convertible notes		9,285,117			2,078,393
			61,134,957			39,497,770

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Schedule Of Acquisition Costs [Table Text Block]	'
	These costs are included in operating expenses as follows:
	Consulting expenses	$	274,000
	Professional fees		225,000
	General and administrative expenses		29,000
	Total acquisition costs	$	528,000
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	'
	The following table represents the allocation of the purchase consideration to the assets acquired and liabilities assumed on February 8, 2012. It has been revised to reflect an immaterial measurement period change (See Note 11):
		Estimated Fair Value
	Purchase Consideration:
	Series E Preferred Stock	$	18,760,610
	Contingent Consideration		11,109,020
	Replacement Warrants		1,883,751
	Total Consideration	$	31,753,381
	Tangible Assets Acquired:
	Cash	$	24,563
	Receivables		35,394
	Property and equipment		772,486
	Other		87,391
	Identifiable Intangible Assets Acquired:
	IPR&D Technology		29,585,000
	Trademarks and Tradename		1,990,000
	Liabilities Assumed:
	Accounts Payable and Accrued Expenses		(1,044,530	)
	Other		(118,617	)
	Goodwill		421,694
		$	31,753,381

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Inputs Liability Quantitative Information [Table Text Block]	'
	The carrying amounts of the derivative liabilities are as follows:
	Description	Level 1		Level 2		Level 3		Total
	Liabilities at December 31, 2013:
	Embedded conversion options	$	—	$	—	$	1,515,540	$	1,515,540
	Stock purchase warrants		—		—		1,733,055		1,733,055
	Total measured at fair value	$	—	$	—	$	3,248,595	$	3,248,595
	Liabilities at December 31, 2012:
	Embedded conversion options	$	—	$	—	$	780,960	$	780,960
	Total measured at fair value	$	—	$	—	$	780,960	$	780,960
Fair Value, Measurement Inputs, Disclosure [Table Text Block]	'
	The following tables set forth a summary of changes in the fair value of Level 3 liabilities for the year ended December 31, 2013 and 2012:
	Description	Balance at January 1, 2013		Established in 2013		Modification of Convertible Debt Agreement		Conversion to Common Stock			Change in Fair Value			Effect of Extinguishment of Debt			Balance at December 31, 2013
	Derivative liabilities:
	Embedded conversion options	$	780,960	$	965,484	$	250,361	$	(393,948	)	$	90,839		$	(178,156	)	$	1,515,540
	Stock purchase warrants	$	—	$	1,353,842	$	—	$	—		$	379,213		$	—		$	1,733,055
	Description	Balance at January 1, 2012		Established in 2012		Modification of Convertible Debt Agreement		Conversion to Common Stock			Change in Fair Value			Reclass to Equity			Balance at December 31, 2012
	Derivative liabilities:
	Embedded conversion options	$	1,823,207	$	—	$	—	$	(549,936	)	$	(492,311	)	$	—		$	780,960
	Contingent consideration	$	—	$	11,109,020	$	—	$	—		$	4,334,932		$	(15,443,952	)	$	—

Receivables_Tables

Receivables (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	'
	Accounts and royalties receivable, net consisted of the following:
		31-Dec-13			31-Dec-12
	Trade receivables	$	2,449,199		$	1,133,400
	Other receivables		1,493,979			643,051
			3,943,178			1,776,451
	Less allowance for doubtful accounts		(16,497	)		(42,709	)
		$	3,926,681		$	1,733,742
Schedule Of Change In Allowance For Doubtfull Accounts [Table Text Block]	'
	The following table reflects the approximate change in allowance for doubtful accounts.
		Balance at Beginning of Period			Charged to Costs and Expenses			Balances charged-off			Balance at End of Period
	Year Ended December 31, 2013
	Allowance for doubtful accounts	$	42,709		$	75,166		$	(101,378	)	$	16,497
	Year Ended December 31, 2012
	Allowance for doubtful accounts	$	38,233		$	42,625		$	(38,149	)	$	42,709

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventory consisted of the following:
		31-Dec-13		31-Dec-12
	Raw materials	$	125,583	$	79,090
	Finished goods		985,924		1,091,007
		$	1,111,507	$	1,170,097

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Prepaid Expense and Other Assets, Current [Abstract]	'
Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block]	'
	Prepaid expenses and other current assets consisted of the following:
		31-Dec-13		31-Dec-12
	Prepaid insurance	$	63,096	$	61,519
	Prepaid fees and rent		151,454		186,407
	Deposits and advances		279,870	$	409,604
	Prepaid royalties		724,999		6,250
	Other Current Assets		38,863		73,665
		$	1,258,282	$	737,445

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment, net consisted of the following:
		31-Dec-13			31-Dec-12
	Medical equipment	$	1,278,681		$	3,033,792
	Office equipment		86,001			87,163
	Manufacturing equipment		307,971			303,143
	Leasehold improvements		390,911			390,911
			2,063,564			3,815,009
	Less accumulated depreciation and amortization		(1,144,095	)		(1,374,928	)
		$	919,469		$	2,440,081

Goodwill_and_Identifiable_Inta1

Goodwill and Identifiable Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
	The table below sets forth the changes in the carrying amount of goodwill for the period indicated:
	Balance at January 1, 2012	$	706,823
	Goodwill related to Aldagen acquisition		616,826
	Adjustment as a result of measurement period change		(195,132	)
	Balance at December 31, 2012	$	1,128,517
	Change in 2013		—
	Balance at December 31, 2013	$	1,128,517
Schedule of Intangible Assets and Goodwill [Table Text Block]	'
	The carrying value of those intangible assets, and the associated amortization, were as follows:
		31-Dec-13			December 31,
					2012
	Trademarks	$	2,310,000		$	2,310,000
	Technology		2,355,000			2,355,000
	Customer relationships		708,000			708,000
	In-process research and development		29,585,000			29,585,000
	Total	$	34,958,000		$	34,958,000
	Less accumulated amortization		(1,189,046	)		(822,713	)
		$	33,768,954		$	34,135,287
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Annual amortization expense based on our existing intangible assets and their estimated useful lives is expected to be approximately:
	2014		366,333
	2015		366,333
	2016		366,333
	2017		366,333
	2018		299,985
	Thereafter		2,418,637

Accounts_payable_and_accrued_e1

Accounts payable and accrued expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
	Accounts payable and accrued expenses consisted of the following:
		31-Dec-13		31-Dec-12
	Trade payables	$	3,351,844	$	1,434,166
	Accrued compensation and benefits		795,584		833,141
	Accrued professional fees		199,634		156,205
	Accrued interest		2,250		750
	Customer deposits		1,795,803		—
	Other payables		1,873,557		388,109
		$	8,018,672	$	2,812,371

Derivatives_and_other_liabilit1

Derivatives and other liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Derivative and Other Liabilities [Abstract]	'
Schedule Of Derivative And Other Long Term Liabilities At Fair Value [Table Text Block]	'
	Derivative and other liabilities consisted of the following:
		31-Dec-13		31-Dec-12
	Derivative liability, long-term portion		3,248,595	$	780,960
	Deferred rent		185,405		58,005
	Deferred tax liability		68,589		50,000
	Interest payable		44,194		33,379
	Conditional grant payable		30,000		30,000
	Accrued term loan fee		38,738		—
		$	3,615,521	$	952,344

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	Income tax (expense) benefit for the years ended December 31, 2013 and 2012 consisted of the following:
		2013			2012
	Current:
	Federal	$	—		$	—
	State		—			—
	Deferred:
	Federal		(212,022	)		1,267,000
	State		(401,215	)		(653,000	)
	Net operating loss carryforward		4,243,885			4,635,000
	Valuation Allowance		(3,649,237	)		(5,267,000	)
	Total income tax (expense) benefit	$	(18,589	)	$	(18,000	)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Significant components of Cytomedix’s deferred tax assets and liabilities consisted of the following at December 31:
		2013			2012
	Deferred tax assets:
	Stock-based compensation	$	5,371,000		$	5,087,000
	Tax credits		2,895,000			2,512,000
	Deferred financing costs		(3,000	)		714,000
	Start-up and organizational costs		272,000			272,000
	Tax deductible Goodwill		112,000			136,000
	Property and equipment		240,000			244,000
	Derivative liabilities		(2,000	)		522,000
	Other		1,019,000			109,000
	Total deferred tax assets		9,904,000			9,596,000
	Deferred tax liabilities:
	Intangible Assets		(12,219,000	)		(12,353,000	)
	Discount on Note Payable		(1,088,000	)		(377,000	)
	Other		(69,000	)		(50,000	)
	Total deferred tax liabilities		(13,376,000	)		(12,780,000	)
	Net deferred tax assets, excluding net operating loss		(3,472,000	)		(3,184,000	)
	carryforwards
	Net operating loss carryforwards		45,458,000			41,540,000
			41,986,000			38,356,000
	Less valuation allowance		(42,055,000	)		(38,406,000	)
	Total deferred tax assets (liabilities)	$	(69,000	)	$	(50,000	)
Schedule Of Change In Valuation Allowance For Deferred Tax Assets [Table Text Block]	'
	The following table reflects the change in the valuation allowance for deferred tax assets at December 31:
	Valuation allowance – January 1, 2012	$	19,700,000
	Purchase Accounting changes		13,439,000
	2012 provision		5,267,000
	Valuation allowance – December 31, 2012		38,406,000
	2013 provision		3,649,000
	Valuation allowance – December 31, 2013	$	42,055,000
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The following table presents a reconciliation between the U.S. federal statutory income tax rate and the Company’s effective tax rate:
		2013			2012
	U.S. Federal statutory income tax		35	%		35	%
	State and local income tax, net of benefits		4.4	%		4.2	%
	Fair value of Derivatives		(2.9	)%		(6.8	)%
	Nondeductible guarantee fees		(0.9	)%		(3.7	)%
	Impact of changes in rates		(12.2	)%		(0.2	)%
	Other		(5.5	)%		(1.9	)%
	Valuation allowance for deferred income tax assets		(18.0	)%		(26.5	)%
	Effective income tax rate		(0.1	)%		0.1	%

Capital_Stock_Tables

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	The Company had the following outstanding warrants and options at December 31:
			# Outstanding
	Equity Instrument		31-Dec-13		31-Dec-12
	Fitch/Coleman Warrants(1)			975,000		975,000
	August 2009 Warrants(2)			1,070,916		1,070,916
	April 2010 Warrants(3)			1,295,138		1,295,138
	October 2010 Warrants(4)			1,488,839		1,488,839
	Guarantor 2011 Warrants(5)			916,665		916,665
	February 2012 Inducement Warrants(6)			1,180,547		1,180,547
	February 2012 Aldagen Warrants(7)			2,115,596		2,115,596
	February 2013 MidCap Warrants(8)			1,079,137		—
	February 2013 Subordination Warrants(9)			800,000		—
	February 2013 Worden Warrants(10)			250,000		—
	February 2013 RDO Warrants(11)			6,363,638		—
	February 2013 PA Warrants(12)			136,364		—
	December 2013 Note Warrants(13)			5,047,461		—
	Other warrants(14)			300,000		200,000
	Options issued under the 2002 Long-Term Incentive Plan(15)			8,510,816		7,866,953
	Options issued under the 2013 Equity Incentive Plan(16)			10,000		—
		-1	These warrants were issued in connection with the August 2, 2007 Term Sheet Agreement and Shareholders’ Agreement with the Company’s outside patent counsel, Fitch Even Tabin & Flannery and The Coleman Law Firm, and have a 7.5 year term. The strike prices on the warrants are: 325,000 at $1.25 (Group A); 325,000 at $1.50 (Group B); and 325,000 at $1.75 (Group C). The Company may call up to 100% of these warrants, provided that the closing stock price is at or above the following call prices for ten consecutive trading days: Group A — $4/share; Group B — $5/share; Group C — $6/share. If the Company exercises its right to call, it shall provide at least 45 days notice for one-half of the warrants subject to the call and at least 90 days notice for the remainder of the warrants subject to the call.
		-2	These warrants were issued in connection with the August 2009 financing, are voluntarily exercisable at $0.51 per share and expire in February 2014. These amounts reflect adjustments for an additional 420,896 warrants due to anti-dilutive provisions. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.
		-3	These warrants were issued in connection with the April 2010 Series D preferred stock offering, are voluntarily exercisable at $0.54 per share and expire on April 9, 2015.
		-4	These warrants were issued in connection with the October 2010 financing. They have an exercise price of $0.60 and expire on April 7, 2016. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.
		-5	These warrants were issued pursuant to the Guaranty Agreements executed in connection with the Promissory Note issued in April 2011. These warrants have an exercise price of $0.50 per share and expire on April 28, 2016.
		-6	These warrants were issued in connection with the February 2012 warrant exercise agreements executed with certain existing Cytomedix warrant holders. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.
		-7	These warrants were issued in February 2012 in connection with the warrant exchange agreements between Cytomedix and various warrant holders of Aldagen. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.
		-8	These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share and expire on February 19, 2020.
		-9	These warrants were issued in connection with the February 2013 financing, have an exercise price of $0.70 per share, and expire on February 19, 2018. They are only exercisable if the JPNT Note remains outstanding on or after 04-28-2015 (50% of total) and 04-15-2016 (remainder).
		-10	These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share, and expire on February 19, 2020.
		-11	These warrants were issued in connection with the February 2013 registered direct offering. They are voluntarily exercisable, have an exercise price of $0.75 per share, and expire on February 22, 2018.
		-12	These warrants were issued to the placement agent in connection with the February 2013 registered direct offering. They are exercisable on or after August 21, 2013, have an exercise price of $0.66 per share, and expire on February 22, 2018.
		-13	These warrants were issued in connection with the December 2013 debt financing. They are voluntarily exercisable, have an exercise price of $0.68 per share, and expire on December 8, 2018.
		-14	These warrants were issued to consultants and other professional service providers in exchange for services provided. A warrant for 200,000 Common shares has an exercise price of $1.50, expires on February 24, 2014, and is vested and voluntarily exercisable. A warrant for 100,000 Common shares has an exercise price of $0.37, expires on October 15, 2015, and is voluntarily exercisable upon vesting (50% vested as of December 31, 2013 and 100% vested by February 15, 2014). There is no call provision associated with either of these warrants.
		-15	These options were issued under the Company’s 2002 Long-Term Incentive Plan approved by shareholders. See Note 17 for a full discussion regarding these options.
		-16	These options were issued under the Company’s 2013 Equity Incentive Plan approved by shareholders. See Note 17 for a full discussion regarding these options.
Schedule Of Proceeds From Stock Issuances [Table Text Block]	'
	The following table lists the sources of and the net proceeds from those issuances:
	Source		# of Shares		Net Proceeds
	Sale of shares pursuant to registered direct offering			9,090,911	$	4,557,188
	Sale of shares pursuant to October 2010 equity purchase			450,000	$	303,000
	agreement
	Sale of shares pursuant to February 2013 equity purchase agreement			1,500,000	$	601,944
	Issuance of shares in lieu of cash for fees incurred pursuant to February 2013 equity purchase agreement			390,261	$	—
	Issuance of shares for conversion of 4% Convertible Notes			1,600,219	$	—
	Issuance of shares for release of security interest in patents			250,000	$	—
	Issuance of shares to Class 4A Equity shareholder pursuant to June 2002 Reorganization Plan			27,000	$	—
	Issuance of shares in lieu of cash for consultants			37,500	$	—
	Other			10,578	$	—
	Totals			13,356,469	$	5,462,132
	The following table lists the sources of and the proceeds from those issuances:
	Source		# of Shares		Total Proceeds
	Conversion of Series D Convertible Preferred shares			7,460,350	$	—
	Inducement to remaining shareholders of Series D Convertible Preferred stock to convert all outstanding shares			330,000	$	—
	Conversion of Series E Convertible Preferred shares			13,399,986	$	—
	Exercise of August 2008 warrants			584,672	$	584,672
	Exercise of August 2009 warrants			418,968	$	213,674
	Exercise of April 2010 warrants			2,833,493	$	1,521,028
	Exercise of Guarantor 2010 warrants			1,333,334	$	715,734
	Exercise of October 2010 warrants			375,000	$	225,000
	Exercise of Guarantor 2011 warrants			1,583,335	$	791,667
	Exercise of options issued under the Long-Term Incentive Plan			35,602	$	15,185
	Common stock issued in lieu of cash for dividend payable on Series D Convertible Preferred shares			76,461	$	—
	Partial conversion of 4% Convertible Notes			1,062,500	$	—
	Sale of shares pursuant to private offering			4,231,192	$	5,000,000
	Sale of shares pursuant to October 2010 equity purchase			4,350,000	$	4,493,902
	agreement
	Common stock issued in lieu of cash for fees incurred pursuant to October 2010 equity purchase agreement			179,701	$	—
	Common stock issued in lieu of cash for consultant			17,500	$	—
	Totals			38,272,094	$	13,560,862

LongTerm_Incentive_Plan_Equity1

Long-Term Incentive Plan, Equity Incentive Plan and Other Compensatory Awards (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes information about stock options outstanding as of December 31, 2013:
		Options Outstanding									Options Exercisable
	Range of Exercise Prices	Number of Outstanding Shares				Weighted Average Remaining Contract Life			Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
	$0.30 – $1.50		6,859,483				5.6		$	0.92		5,644,594	$	0.95
	$1.51 – $3.00		1,591,333				2.5		$	2.19		1,544,331	$	2.18
	$3.01 – $4.50		0				—			—		0		—
	$4.51 – $6.00		70,000				2		$	5.2		70,000	$	5.2
Schedule Of ShareBased Compensation Stock Warrants Activity [Table Text Block]	'
	A summary of service provider warrant activity as of December 31, 2013, and changes during the year then ended is presented below:
							Weighted-
				Weighted-			Average
				Average			Remaining	Aggregate
				Exercise			Contractual	Intrinsic
	Warrants to Service Providers	Shares		Price			Term	Value
	Outstanding at January 1, 2013	1,175,000		$	1.5
	Granted	486,364		$	0.62
	Exercised	0			—
	Forfeited or expired	0			—
	Outstanding at December 31, 2013	1,661,364		$	1.24		2	$	10,400
	Exercisable at December 31, 2013	1,611,364		$	1.27		2	$	5,200
Schedule Of Warrants Outstanding [Table Text Block]	'
	The following table summarizes information about compensatory warrants outstanding as of December 31, 2013:
		Warrants Outstanding									Warrants Exercisable
	Range of Exercise Prices	Number of Outstanding Shares				Weighted Average Remaining Contract Life			Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
	$0.37 – $1.50		1,336,364				2.3		$	1.12		1,286,364	$	1.15
	$1.75		325,000				1.1		$	1.75		325,000	$	1.75
Schedule Of ShareBased Compensation Expense [Table Text Block]	'
	The Company has recorded stock-based compensation expense as follows:
		Year Ended December 31
	Stock-Based Expense	2013				2012
	Awards under the 2002 LTIP	$	679,433			$	2,027,031
	Awards under the 2013 EIP		117				—
	Awards outside the equity-based plans		38,313				20,700
		$	717,863			$	2,047,731
	Included in Statements of Operations caption as follows:
	Salaries and wages	$	564,737			$	1,389,001
	Consulting expense		16,278				275,924
	General and administrative		136,848				382,806
		$	717,863			$	2,047,731
Long Term Incentive Plan [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of option activity under the LTIP and EIP as of December 31, 2013, and changes during the year then ended is presented below:
	Stock Options	Shares				Weighted-Average Exercise Price			Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
	Outstanding at January 1, 2013		7,866,953			$	1.28
	Granted		1,038,000			$	0.5
	Exercised		0				—
	Forfeited or expired		(384,137	)		$	1.19
	Outstanding at December 31, 2013		8,520,816			$	1.19			5	$	61,018
	Exercisable at December 31, 2013		7,258,925			$	1.26			4.3	$	58,163

Supplemental_Cash_Flow_Disclos1

Supplemental Cash Flow Disclosures - Non-Cash Transactions (Tables)	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Elements [Abstract]	'
Details of Nonmonetary Transactions [Table Text Block]	'
	Non-cash Investing and Financing transactions for years ended December 31 include:
		2013		2012
	Conversion of convertible debt to common stock	$	523,927	$	924,904
	Preferred dividends paid by issuance of stock		—		82,500
	Business combination:
	Issuance of Series E liability		—		18,955,742
	Issuance of contingent consideration		—		11,109,020
	Issuance of replacement warrants		—		1,883,751
	Common stock issued in satisfaction of subscription receivable		—		2,790,107
	Effect of cancellation of escrowed shares		—		195,132
	Obligation to issue shares for professional services		—		30,000
	Effect of modification of convertible debt		151,032		—
	Common Stock issued for committed equity financing facility		204,015		—
	Warrants issued for term loan modification		151,758		—
	Warrants issued for term loan		568,324		—
	Common stock and warrants issued for release of security interest in patents		325,693		—
	Warrants issued in connection with convertible debt		1,353,842		—
	Derivative liability for embedded conversion option		965,484		—
	Common stock issued for professional services		17,850		—
	Common stock issued for settlement of contingency		39,150		—

Operating_Leases_Tables

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2013
Leases, Operating [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	The Company leases its office spaces under operating leases with approximate future minimum lease payments as indicated in the table below:
	Years ending December 31:
	2014	$	360,000
	2015		360,000
	2016		360,000
	2017		340,000
	2018		—
	Thereafter		—
	Total future minimum lease payments	$	1,420,000

Geographic_and_Customer_Concen1

Geographic and Customer Concentration information (Tables)	12 Months Ended
	Dec. 31, 2013
Geographic Areas, Revenues from External Customers [Abstract]	'
Schedule Of Geographic Information On Revenues [Table Text Block]	'
	Product sales consist of the following:
		Year Ended December 31,
		2013		2012
	Revenue from U.S. product sales	$	9,549,015	$	6,179,050
	Revenue from non-U.S. product sales		949,711		1,062,363
	Total revenue from product sales	$	10,498,726	$	7,241,413

Description_of_the_Business_De

Description of the Business (Details Textual)	12 Months Ended
	Dec. 31, 2013
Business Combination Segment Allocation [Line Items]	'
Entity Wide Disclosure On Geographic Areas Revenue From External Customers Attributed To Foreign Countries Percentage	91.00%
Arthrex [Member]	'
Business Combination Segment Allocation [Line Items]	'
Percentage of accounts receivable	92.00%
Concentration Risk, Percentage	48.00%
Arthrex [Member] | Angel [Member]	'
Business Combination Segment Allocation [Line Items]	'
Concentration Risk, Percentage	100.00%

Liquidity_Risks_and_Management1

Liquidity Risks and Management's Plans (Details Textual) (USD $)	Dec. 31, 2013	Feb. 19, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 31, 2014
					Subsequent Event [Member]
					Deerfield Facility Agreement [Member]
Risks Inherent in Servicing Assets and Servicing Liabilities [Line Items]	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	$7,500,000	'	'	$35,000,000
Initial Draw Disbursement Amount	'	'	'	'	9,000,000
Second Draw Disbursement Amount	'	'	'	'	26,000,000
Cash	$3,286,713	'	$2,615,805	$2,246,050	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies [Line Items]	'	'
Risk free rate	0.77%	0.63%
Expected years until exercise	'5 years 10 months 24 days	'5 years 2 months 12 days
Expected stock volatility	134.00%	129.00%
Dividend yield	0.00%	0.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount	61,134,957	39,497,770
Convertible Notes Payable [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount	9,285,117	2,078,393
Contingent consideration [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount	20,309,723	20,309,723
Warrants (Member)	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount	23,019,301	9,242,701
Options [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount	8,520,816	7,866,953

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Allowance for Doubtful Accounts Receivable	$16,497	$42,709	$38,233
Non Refundable Fees	'	4,500,000	'
Medical Device Excise Tax Percentage	2.30%	'	'
Maximum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'5 years	'	'
Minimum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'
Safe Harbor Plan [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Defined Contribution Plan, Employer Discretionary Contribution Amount	164,000	126,000	'
Federal Deposit Insurance Corporation [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Cash, Uninsured Amount	613,000	40,000	'
Securities Investor Protection Corporation [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Concentration Risk Excess Deposit In Brokerage Firm	$2,667,000	$1,754,000	'
Centrifuges [Member] | Maximum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'6 years	'	'
Centrifuges [Member] | Minimum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'
Furniture Lab and Manufacturing Equipment [Member] | Maximum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'10 years	'	'
Furniture Lab and Manufacturing Equipment [Member] | Minimum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'7 years	'	'

Business_Combinations_Details

Business Combinations (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Business Combination Segment Allocation [Line Items]	'
Total acquisition costs	$528,000
Consultancy Expenses [Member]	'
Business Combination Segment Allocation [Line Items]	'
Total acquisition costs	274,000
Professional Fees [Member]	'
Business Combination Segment Allocation [Line Items]	'
Total acquisition costs	225,000
General and Administrative Expense [Member]	'
Business Combination Segment Allocation [Line Items]	'
Total acquisition costs	$29,000

Business_Combinations_Details_

Business Combinations (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013
Purchase Consideration:	'
Series E Preferred Stock	$18,760,610
Contingent Consideration	11,109,020
Replacement Warrants	1,883,751
Total Consideration	31,753,381
Tangible Assets Acquired:	'
Cash	24,563
Receivables	35,394
Property and equipment	772,486
Other	87,391
Liabilities Assumed:	'
Accounts Payable and Accrued Expenses	-1,044,530
Other	-118,617
Goodwill	421,694
Total Consideration	31,753,381
Ipr And D Technology [Member]	'
Identifiable Intangible Assets Acquired:	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	29,585,000
Trademarks and Trade Names [Member]	'
Identifiable Intangible Assets Acquired:	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$1,990,000

Business_Combinations_Details_1

Business Combinations (Details Textual) (USD $)

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 10, 2013

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jul. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Trademarks [Member]

Long Term Incentive Plan [Member]

Long Term Incentive Plan [Member]

Long Term Incentive Plan [Member]

Aldagen [Member]

Equity Sweetner [Member]

February 2012 Aldagen Warrants [Member]

February 2012 Aldagen Warrants [Member]

Aldagen S Former Investors [Member]

Aldagen S Former Investors [Member]

Series E Preferred Stock [Member]

Series A and Series B Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Employees, Officers, Directors and Advisors [Member]

Affiliated Entity [Member]

Business Combination Segment Allocation [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135,398

207,000

'

'

'

Conversion of Stock, Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'the Series E Preferred Stock automatically converted into shares of Common stock pursuant to its terms, in a 100-for-1 shares ratio, upon the Company’s filing of an amended Certificate of Incorporation to increase the number of authorized shares of Common stock.

'

'

'

'

Release Of Stock Held In Escrow Account

'

'

'

'

'

'

'

'

'

'

'

'

'

139,830

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

'

5,288,256

'

'

'

'

'

'

2,115,596

[1]

2,115,596

[1]

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

0.46

1.42

'

'

'

'

'

1.42

1.42

1.42

'

'

'

'

'

'

'

Class Of Warrant Or Right Exercise Description

'

'

'

'

'

'

'

'

'

'

'

'(i) commencing on the issuance date, for up to 30% of the total shares of the Company’s Common stock exercisable under the Replacement Warrants, and (ii) upon issuance of the final tranche of the Contingent Consideration, for the remaining balance of the shares under the Replacement Warrants. The Replacement Warrants contain exercise price adjustments, cashless exercise and other provisions customary to instruments of this nature.

'

'

'

'

'

'

'

'

Convertible Preferred Stock Conversion Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.44

'

$0.56

Convertible Preferred Stock Shares Issuable Upon Conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,790,350

Stock Issued During Period On Inducement To Remaining Shareholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

330,000

330,000

Class Of Warrant Or Right Additional Number Of Securities Called By Warrants Or Rights

'

'

'

'

'

'

'

'

'

'

5,700,000

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises

'

'

'

'

'

'

'

'

'

'

$2,800,000

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

6,363,638

'

'

'

'

'

'

'

'

'

1,180,547

'

'

'

'

'

'

'

'

'

Business Combination Contingent Consideration Shares Issuable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,309,723

'

'

'

'

'

Business Combination Contingent Consideration Undiscounted Value

'

'

'

'

'

'

28,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

'

1,038,000

2,271,500

'

'

'

2,271,500

35,602

1,700,000

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Asset, Useful Life

'

'

'

'

'

'20 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination Contingent Consideration

'

'

'

'

'

'

11,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition Contingent Consideration Share Issuable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,309,723

'

'

'

'

'

Class Of Warrants Or Rights Expiry Date

'

'

'

'

'

'

'

'

'

'

'

31-Dec-14

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement

$5,000,000

'

'

'

'

'

'

'

'

$5

'

'

'

'

'

'

'

'

'

'

[1]

These warrants were issued in February 2012 in connection with the warrant exchange agreements between Cytomedix and various warrant holders of Aldagen. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.

Arthrex_Distributor_and_Licens1

Arthrex Distributor and License Agreement and Related Matters (Details Textual) (USD $)	1 Months Ended
	Aug. 30, 2013	Feb. 27, 2013	Feb. 19, 2013	Dec. 31, 2013	Dec. 31, 2013	Feb. 19, 2013
				Arthrex [Member]	Term Loan [Member]	Term Loan [Member]
Arthrex Distributor And License Agreement [Line Items]	'	'	'	'	'	'
Retainage Deposit	'	'	'	$5,000,000	'	'
Reduction In Borrowing Facility	'	'	'	'	3,000,000	300,000
Line of Credit Facility, Maximum Borrowing Capacity	'	'	7,500,000	'	7,500,000	'
Line of Credit Facility, Current Borrowing Capacity	'	4,500,000	'	'	4,500,000	'
Line of Credit Facility, Periodic Payment	$150,000	'	'	'	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Embedded conversion options	$1,515,540	$780,960
Stock purchase warrants	1,733,055	'
Total measured at fair value	3,248,595	780,960
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Embedded conversion options	0	0
Stock purchase warrants	0	'
Total measured at fair value	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Embedded conversion options	0	0
Stock purchase warrants	0	'
Total measured at fair value	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Embedded conversion options	1,515,540	780,960
Stock purchase warrants	1,733,055	'
Total measured at fair value	$3,248,595	$780,960

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Change in fair value	$0	($4,334,932)
Balance, Ending	1,733,055	'
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Balance, Ending	1,733,055	'
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Balance, Opening	0	'
Established	1,353,842	'
Modification of Convertible Debt Agreement	0	'
Conversion to Common Stock	0	'
Change in fair value	379,213	'
Reclass to Equity	0	'
Balance, Ending	1,733,055	'
Fair Value, Inputs, Level 3 [Member] | Embedded conversion options [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Balance, Opening	780,960	1,823,207
Established	965,484	0
Modification of Convertible Debt Agreement	250,361	0
Conversion to Common Stock	-393,948	-549,936
Change in fair value	90,839	-492,311
Reclass to Equity	-178,156	0
Balance, Ending	1,515,540	780,960
Fair Value, Inputs, Level 3 [Member] | Contingent consideration [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Balance, Opening	'	0
Established	'	11,109,020
Modification of Convertible Debt Agreement	'	0
Conversion to Common Stock	'	0
Change in fair value	'	4,334,932
Reclass to Equity	'	-15,443,952
Balance, Ending	'	$0

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details Textual) (USD $)	1 Months Ended
	Jun. 30, 2013	Dec. 31, 2013	Nov. 30, 2011	Jul. 31, 2011
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Convertible Debt, Fair Value Disclosures	'	$2,250,000	$287,000	$287,000
Time Deposits, at Carrying Value	$53,000	'	'	'
Time Deposits Annual Interest Rate	0.10%	'	'	'
Time Deposits Maturity Date	24-Feb-14	'	'	'

Receivables_Details

Receivables (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Trade receivables	$2,449,199	$1,133,400
Other receivables	1,493,979	643,051
Accounts and Other Receivables Gross Current	3,943,178	1,776,451
Less allowance for doubtful accounts	-16,497	-42,709
Accounts and Other Receivables	$3,926,681	$1,733,742

Receivables_Details_1

Receivables (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Balance at Beginning of Period	$42,709	$38,233
Charged to Costs and Expenses	75,166	42,625
Balances charged-off	-101,378	-38,149
Balance at End of Period	$16,497	$42,709

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
Raw materials	$125,583	$79,090
Finished goods	985,924	1,091,007
Total	$1,111,507	$1,170,097

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Prepaid Expenses And Other Current Assets [Line Items]	'	'
Prepaid insurance	$63,096	$61,519
Prepaid fees and rent	151,454	186,407
Deposits and advances	279,870	409,604
Prepaid royalties	724,999	6,250
Other Current Assets	38,863	73,665
Prepaid Expense and Other Assets, Current	$1,258,282	$737,445

Prepaid_Expenses_and_Other_Cur3

Prepaid Expenses and Other Current Assets (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013
Prepaid Expenses And Other Current Assets [Line Items]	'
Amortization of Advance Royalty	$100,694

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$2,063,564	$3,815,009
Less accumulated depreciation and amortization	-1,144,095	-1,374,928
Property and Equipment Net	919,469	2,440,081
Medical equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	1,278,681	3,033,792
Office equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	86,001	87,163
Manufacturing equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	307,971	303,143
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$390,911	$390,911

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Cost of Goods Sold, Depreciation	$310,000	$446,000
Research Development Trials Studies Expenses	299,000	287,000
Costs Of Depreciation And Amortization	726,000	823,404
Centrifuges [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Disposals	1,295,000	'
Property And Equipments Net Book Value	$1,543,000	$554,000

Goodwill_and_Identifiable_Inta2

Goodwill and Identifiable Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Balance, Beginning	$1,128,517	$706,823
Goodwill related to Aldagen acquisition	'	616,826
Adjustment as a result of measurement period change	'	-195,132
Change in 2013	0	'
Balance, Ending	$1,128,517	$1,128,517

Goodwill_and_Identifiable_Inta3

Goodwill and Identifiable Intangible Assets (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Total	$34,958,000	$34,958,000
Less accumulated amortization	-1,189,046	-822,713
Intangible assets, net	33,768,954	34,135,287
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total	2,310,000	2,310,000
Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total	2,355,000	2,355,000
Customer relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total	708,000	708,000
In-process research and development [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total	$29,585,000	$29,585,000

Goodwill_and_Identifiable_Inta4

Goodwill and Identifiable Intangible Assets (Details 2) (USD $)	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'
2014	$366,333
2015	366,333
2016	366,333
2017	366,333
2018	299,985
Thereafter	$2,418,637

Goodwill_and_Identifiable_Inta5

Goodwill and Identifiable Intangible Assets (Details Textual) (USD $)	9 Months Ended				12 Months Ended
	Sep. 30, 2013	Oct. 01, 2013	Feb. 29, 2012	Apr. 30, 2010	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Aldagen [Member]	Angel [Member]	Cost Of Sales [Member]	General and Administrative Expense [Member]	Cost Of Royalties [Member]
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'
Goodwill related to Aldagen acquisition	'	'	$422,000	$707,000	'	'	'
Amortization	'	'	'	'	88,000	209,000	69,000
Intangible Asset Carrying Value	1,700,000	'	'	'	'	'	'
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure	'	$1,500,000	'	'	'	'	'

Accounts_payable_and_accrued_e2

Accounts payable and accrued expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts Payable And Accrued Expenses [Line Items]	'	'
Trade payables	$3,351,844	$1,434,166
Accrued compensation and benefits	795,584	833,141
Accrued professional fees	199,634	156,205
Accrued interest	2,250	750
Customer deposits	1,795,803	0
Other payables	1,873,557	388,109
Total	$8,018,672	$2,812,371

Accounts_payable_and_accrued_e3

Accounts payable and accrued expenses (Detail Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts Payable And Accrued Expenses [Line Items]	'	'
Other Accrued Liabilities, Current	$1,873,557	$388,109
Arthrex [Member]	'	'
Accounts Payable And Accrued Expenses [Line Items]	'	'
Other Accrued Liabilities, Current	$1,631,000	'

Deferred_Revenue_Details_Textu

Deferred Revenue (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Deferred Revenue Arrangement [Line Items]	'	'
Deferred Licensing Revenue	$1,844,229	'
Deferred Revenue	338,613	'
Deferred Licensing Revenue, Recognized Period	'5 years	'
Licenses Revenue	$167,657	$3,154,722

Derivatives_and_other_liabilit2

Derivatives and other liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Derivative and Other Liabilities [Line Items]	'	'
Derivative liability, long-term portion	$3,248,595	$780,960
Deferred rent	185,405	58,005
Deferred tax liability	68,589	50,000
Interest payable	44,194	33,379
Conditional grant payable	30,000	30,000
Accrued term loan fee	38,738	0
Derivative and other liabilities	$3,615,521	$952,344

Derivatives_and_other_liabilit3

Derivatives and other liabilities (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2012
Derivative and Other Liabilities [Line Items]	'
Proceeds From Conditional Grants	$30,000

Debt_Details_Textual

Debt (Details Textual) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Dec. 10, 2013

Nov. 21, 2013

Aug. 30, 2013

Dec. 31, 2013

Feb. 28, 2013

Feb. 27, 2013

Feb. 19, 2013

Jun. 30, 2012

Dec. 10, 2013

Nov. 21, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 28, 2013

Feb. 28, 2013

Apr. 30, 2011

Dec. 31, 2013

Apr. 30, 2011

Dec. 31, 2013

Apr. 30, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 19, 2013

Convertible Subordinated Debt [Member]

Convertible Subordinated Debt [Member]

Convertible Subordinated Debt [Member]

Ten Percent Subordinated Convertible Notes [Member]

Embedded Conversion Options Partial Extinguishment [Member]

Embedded Conversion Options Partial Modification [Member]

Debt Issuance Costs [Member]

Debt Discount [Member]

Promissory Note [Member]

Related Party Guarantor [Member]

Worden [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Midcap Financial Llc [Member]

July Four Percent Convertible Notes [Member]

November Four Percent Convertible Notes [Member]

Term Loan [Member]

Term Loan [Member]

Criteria One [Member]

Criteria One [Member]

Criteria Two [Member]

Criteria Two [Member]

Debt Conversion [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Issued

'

'

'

$500,000

'

'

'

'

'

'

'

'

'

'

'

'

$2,100,000

$2,100,000

'

'

'

'

'

'

'

'

'

$1,300,000

'

'

'

Debt Instrument, Convertible, Terms of Conversion Feature

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The July 4% Convertible Notes (plus accrued interest) convert at the option of the unaffiliated third party, in whole or in part and from time to time, into shares of the Companys Common stock at a conversion rate equal to (i) the lesser of $0.80 per share or (ii) 80% of the average of the three lowest closing prices of the Companys Common stock for the previous 20 trading days prior to conversion (subject to a floor price of $0.25 per share).

'The November 4% Convertible Notes mature on May 23, 2016 and bear a one-time interest charge of 4% due on maturity. The November 4% Convertible Notes (plus accrued interest) convert at the option of the holder, in whole or in part and from time to time, into shares of the Companys Common stock at a conversion rate equal to 80% of the average of the three lowest closing prices of the Companys Common stock for the previous 20 trading days prior to conversion (subject to a floor price of $0.25 per share).

'

'

Debt Instrument Issuance Date1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28-Apr-11

'

'

'

'

'

'

'

'

'

'

15-Jul-11

18-Nov-11

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

10.00%

'

75.00%

'

'

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

4.00%

4.00%

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

20-May-16

'

'

'

'

'

'

'

20-May-16

'

'

'

'

'

'

'

'

'

'

23-May-16

23-May-16

'

'

Long-term Debt, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

287,000

'

'

'

Secured Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

$0.46

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.34

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

Debt Instrument Date Of First Required Payment1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30-Sep-11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

6,363,638

'

'

'

'

'

'

'

'

'

'

'

1,000,000

1,500,000

250,000

266,666

533,334

266,666

'

'

'

'

1,079,137

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.46

'

'

'

'

'

'

1.42

'

'

'

'

'

'

'

'

0.5

0.5

0.7

0.7

0.7

0.7

'

'

'

'

0.7

'

'

'

'

Shares To Be Vested In Period One

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

666,667

833,333

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares To Be Vested In Period Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

83,333

166,667

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares To Be Vested In Period Three

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

116,667

233,333

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares To Be Vested In Period Four

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

133,333

266,667

'

'

'

'

'

'

'

'

'

'

'

'

'

Guarantor Obligations, Current Carrying Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

Debt Instrument, Description of Variable Rate Basis

'

'

'

'(LIBOR), plus 8.0%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Description Of Floor Price

'

'

'

'LIBOR floor of 3%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term Loan Fee Payable Percentage Year One

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term Loan Fee Payable Percentage Year Two

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term Loan Fee Payable Percentage Thereafter

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term Loan Commitments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

568,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Rights Issued To Lender

'

'

'

152,000

'

'

'

'

'

'

'

'

'

'

546,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Rights Issued To Guarantors

'

'

'

304,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercisable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

500,000

250,000

'

'

'

'

'

'

'

'

'

Warrants Exercised Upon Default In Payment Of Note On Fourth Anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

133,333

'

'

266,667

133,333

266,667

133,333

'

'

'

'

'

Embedded Derivative Expenses

'

'

'

'

'

'

'

'

'

'

'

'

54,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Embedded Derivative, Gain on Embedded Derivative

'

'

'

'

'

'

'

'

'

'

'

'

54,000

197,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Gain Loss On Embedded Derivative

'

'

'

'

'

'

'

'

'

'

'

'

'

46,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction In Borrowing Facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

300,000

Line Of Credit Facility Periodic Payment If Condition Satisfied

'

'

125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500,000

'

Line of Credit Facility, Current Borrowing Capacity

'

'

'

'

'

4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,500,000

'

Line of Credit Facility, Periodic Payment

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Condition For Credit Facility

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Changes In Fair Value Warrants

12,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Convertible Debt

2,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Proceeds from Convertible Notes and Stock Warrants

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected Gross Proceeds From Subordinated Convertible Notes

'

'

'

'

'

'

'

'

'

750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

2,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercise Price Percentage

'

'

'

'

'

'

'

'

'

'

'

125.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants

'

'

'

'

'

'

'

'

'

'

'

2,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued During Period Value To The Lender And The Guarantors

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Discount Conversion of Options And Warrants

'

'

'

2,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued During Period Value To Placement Agent

'

'

'

$69,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current:	'	'
Federal	$0	$0
State	0	0
Deferred:	'	'
Federal	-212,022	1,267,000
State	-401,215	-653,000
Net operating loss carryforward	4,243,885	4,635,000
Valuation Allowance	-3,649,237	-5,267,000
Total income tax (expense) benefit	($18,589)	($18,000)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets:	'	'	'
Stock-based compensation	$5,371,000	$5,087,000	'
Tax credits	2,895,000	2,512,000	'
Deferred financing costs	-3,000	714,000	'
Start-up and organizational costs	272,000	272,000	'
Tax deductible Goodwill	112,000	136,000	'
Property and equipment	240,000	244,000	'
Derivative liabilities	-2,000	522,000	'
Other	1,019,000	109,000	'
Total deferred tax assets	9,904,000	9,596,000	'
Deferred tax liabilities:	'	'	'
Intangible Assets	-12,219,000	-12,353,000	'
Discount on Note Payable	-1,088,000	-377,000	'
Other	-69,000	-50,000	'
Total deferred tax liabilities	-68,589	-50,000	'
Net deferred tax assets, excluding net operating loss carryforwards	-3,472,000	-3,184,000	'
Net operating loss carryforwards	45,458,000	41,540,000	'
Deferred Tax Assets, Gross, Noncurrent	41,986,000	38,356,000	'
Less valuation allowance	-42,055,000	-38,406,000	-19,700,000
Total deferred tax assets (liabilities)	($69,000)	($50,000)	'

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
Valuation allowance	$38,406,000	$19,700,000
Purchase Accounting changes	'	13,439,000
Change in valuation	3,649,000	5,267,000
Valuation allowance	$42,055,000	$38,406,000

Income_Taxes_Details_3

Income Taxes (Details 3)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
U.S. Federal statutory income tax	35.00%	35.00%
State and local income tax, net of benefits	4.40%	4.20%
Fair value of Derivatives	-2.90%	-6.80%
Nondeductible guarantee fees	-0.90%	-3.70%
Impact of changes in rates	-12.20%	-0.20%
Other	-5.50%	-1.90%
Valuation allowance for deferred income tax assets	-18.00%	-26.50%
Effective income tax rate	-0.10%	0.10%

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	Dec. 31, 2013
Income Tax Disclosure [Line Items]	'
Deferred Tax Liability Provision For Income Tax	$19,000
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	$122,389,000

Capital_Stock_Details

Capital Stock (Details)

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Fitch/Coleman Warrants [Member]

Fitch/Coleman Warrants [Member]

August 2009 Warrants [Member]

August 2009 Warrants [Member]

April 2010 Warrants [Member]

April 2010 Warrants [Member]

October 2010 Warrants [Member]

October 2010 Warrants [Member]

Guarantor 2011 Warrants [Member]

Guarantor 2011 Warrants [Member]

February 2012 Inducement Warrants [Member]

February 2012 Inducement Warrants [Member]

February 2012 Aldagen Warrants [Member]

February 2012 Aldagen Warrants [Member]

February 2013 MidCap Warrants (Member)

February 2013 MidCap Warrants (Member)

February 2013 Subordination Warrants (Member)

February 2013 Subordination Warrants (Member)

February 2013 Worden Warrants [Member]

February 2013 Worden Warrants [Member]

February 2013 RDO Warrants [Member]

February 2013 RDO Warrants [Member]

February 2013 PA Warrants [Member]

February 2013 PA Warrants [Member]

December 2013 Note Warrants [Member]

December 2013 Note Warrants [Member]

Other Warrants [Member]

Other Warrants [Member]

Options Issued Under The 2002 Long Term Incentive Plan [Member]

Options Issued Under The 2002 Long Term Incentive Plan [Member]

Options Issued Under The 2013 Equity Incentive Plan [Member]

Options Issued Under The 2013 Equity Incentive Plan [Member]

Schedule of Equity Method Investments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Right Outstanding

5,288,256

975,000

[1]

975,000

[1]

1,070,916

[2]

1,070,916

[2]

1,295,138

[3]

1,295,138

[3]

1,488,839

[4]

1,488,839

[4]

916,665

[5]

916,665

[5]

1,180,547

[6]

1,180,547

[6]

2,115,596

[7]

2,115,596

[7]

1,079,137

[8]

0

[8]

800,000

[9]

0

[9]

250,000

[10]

0

[10]

6,363,638

[11]

0

[11]

136,364

[12]

0

[12]

5,047,461

[13]

0

[13]

300,000

[14]

200,000

[14]

8,510,816

[15]

7,866,953

[15]

10,000

[16]

0

[16]

[1]

These warrants were issued in connection with the August 2, 2007 Term Sheet Agreement and Shareholdersb Agreement with the Companybs outside patent counsel, Fitch Even Tabin & Flannery and The Coleman Law Firm, and have a 7.5 year term. The strike prices on the warrants are: 325,000 at $1.25 (Group A); 325,000 at $1.50 (Group B); and 325,000 at $1.75 (Group C). The Company may call up to 100% of these warrants, provided that the closing stock price is at or above the following call prices for ten consecutive trading days: Group AB $4/share; Group B B $5/share; Group C B $6/share. If the Company exercises its right to call, it shall provide at least 45 days notice for one-half of the warrants subject to the call and at least 90 days notice for the remainder of the warrants subject to the call.

[2]

These warrants were issued in connection with the August 2009 financing, are voluntarily exercisable at $0.51 per share and expire in February 2014. These amounts reflect adjustments for an additional 420,896 warrants due to anti-dilutive provisions. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.

[3]

These warrants were issued in connection with the April 2010 Series D preferred stock offering, are voluntarily exercisable at $0.54 per share and expire on April 9, 2015.

[4]

These warrants were issued in connection with the October 2010 financing. They have an exercise price of $0.60 and expire on April 7, 2016. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.

[5]

These warrants were issued pursuant to the Guaranty Agreements executed in connection with the Promissory Note issued in April 2011. These warrants have an exercise price of $0.50 per share and expire on April 28, 2016.

[6]

These warrants were issued in connection with the February 2012 warrant exercise agreements executed with certain existing Cytomedix warrant holders. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.

[7]

These warrants were issued in February 2012 in connection with the warrant exchange agreements between Cytomedix and various warrant holders of Aldagen. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.

[8]

These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share and expire on February 19, 2020.

[9]

These warrants were issued in connection with the February 2013 financing, have an exercise price of $0.70 per share, and expire on February 19, 2018. They are only exercisable if the JPNT Note remains outstanding on or after 04-28-2015 (50% of total) and 04-15-2016 (remainder).

[10]

These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share, and expire on February 19, 2020.

[11]

These warrants were issued in connection with the February 2013 registered direct offering. They are voluntarily exercisable, have an exercise price of $0.75 per share, and expire on February 22, 2018.

[12]

These warrants were issued to the placement agent in connection with the February 2013 registered direct offering. They are exercisable on or after August 21, 2013, have an exercise price of $0.66 per share, and expire on February 22, 2018.

[13]

These warrants were issued in connection with the December 2013 debt financing. They are voluntarily exercisable, have an exercise price of $0.68 per share, and expire on December 8, 2018.

[14]

These warrants were issued to consultants and other professional service providers in exchange for services provided. A warrant for 200,000 Common shares has an exercise price of $1.50, expires on February 24, 2014, and is vested and voluntarily exercisable. A warrant for 100,000 Common shares has an exercise price of $0.37, expires on October 15, 2015, and is voluntarily exercisable upon vesting (50% vested as of December 31, 2013 and 100% vested by February 15, 2014). There is no call provision associated with either of these warrants.

[15]

These options were issued under the Companybs 2002 Long-Term Incentive Plan approved by shareholders. See Note 17 for a full discussion regarding these options.

[16]

These options were issued under the Companybs 2013 Equity Incentive Plan approved by shareholders. See Note 17 for a full discussion regarding these options.

Capital_Stock_Details_1

Capital Stock (Details 1) (USD $)	1 Months Ended	12 Months Ended
	Feb. 28, 2013	Dec. 31, 2013	Dec. 31, 2012
Schedule of Equity Method Investments [Line Items]	'	'	'
Sale of shares pursuant to registered direct offering (in shares)	'	9,090,911	'
Sale of shares pursuant to October 2010 equity purchase agreement (in shares)	'	450,000	4,350,000
Sale of shares pursuant to February 2013 equity purchase agreement (in shares)	'	1,500,000	'
Issuance of shares in lieu of cash for fees incurred pursuant to equity purchase agreement (in shares)	'	390,261	'
Issuance of shares for conversion of 4% Convertible Notes (in shares)	'	1,600,219	'
Issuance of shares for release of security interest in patents (in shares)	'	250,000	'
Issuance of shares to Class 4A Equity shareholder pursuant to June 2002 Reorganization Plan (in shares)	'	27,000	'
Issuance of shares in lieu of cash for consultants	'	37,500	17,500
Other	'	10,578	'
Totals	'	13,356,469	38,272,094
Sale of shares pursuant to registered direct offering	'	$4,557,188	'
Sale of shares pursuant to October 2010 equity purchase agreement	'	303,000	4,493,902
Sale of shares pursuant to February 2013 equity purchase agreement	'	601,944	'
Totals	'	5,462,132	13,560,862
Proceeds from Issuance of Private Placement	5,000,000	'	'
Exercise of options issued under the Long-Term Incentive Plan	'	'	35,602
Exercise of options issued under the Long-Term Incentive Plan	'	'	15,185
Common stock issued in lieu of cash for dividend payable on Series D Convertible Preferred shares	'	'	76,461
Partial conversion of 4% Convertible Notes	'	1,600,219	'
Sale of shares pursuant to private offering	'	'	4,231,192
Acquisition Of Aldagen [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Proceeds from Issuance of Private Placement	'	'	5,000,000
Convertible Notes Payable [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Issuance of shares for conversion of 4% Convertible Notes (in shares)	'	'	1,062,500
Partial conversion of 4% Convertible Notes	'	'	1,062,500
August Two Thousand and Eight Warrant [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Proceeds from Warrant Exercises	'	'	584,672
Class Of Warrant Or Right Excercised During Period	'	'	584,672
August Two Thousand and Nine Warrant [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Proceeds from Warrant Exercises	'	'	213,674
Class Of Warrant Or Right Excercised During Period	'	'	418,968
April Two Thousand and Ten Warrant [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Proceeds from Warrant Exercises	'	'	1,521,028
Class Of Warrant Or Right Excercised During Period	'	'	2,833,493
Guarantor Two Thousand and Ten Warrant [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Proceeds from Warrant Exercises	'	'	715,734
Class Of Warrant Or Right Excercised During Period	'	'	1,333,334
October Two Thousand and Ten Warrant [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Common stock issued in lieu of cash for fees incurred pursuant to October 2010 equity purchase agreement	'	'	179,701
Proceeds from Warrant Exercises	'	'	225,000
Class Of Warrant Or Right Excercised During Period	'	'	375,000
Guarantor Two Thousand and Eleven Warrant [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Proceeds from Warrant Exercises	'	'	$791,667
Class Of Warrant Or Right Excercised During Period	'	'	1,583,335
Series D Preferred Stock [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Conversion of Convertible Preferred shares	'	'	7,460,350
Inducement to remaining shareholders of Series D Convertible Preferred stock to convert all outstanding shares	'	'	330,000
Series E Preferred Stock [Member]	'	'	'
Schedule of Equity Method Investments [Line Items]	'	'	'
Conversion of Convertible Preferred shares	'	'	13,399,986

Capital_Stock_Details_Textual

Capital Stock (Details Textual) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Feb. 29, 2012

Feb. 28, 2013

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 10, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 15, 2014

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2013

Feb. 28, 2013

Apr. 30, 2011

Dec. 31, 2013

Apr. 30, 2011

Dec. 31, 2013

Apr. 30, 2011

Dec. 31, 2013

Apr. 30, 2011

Apr. 30, 2011

Feb. 28, 2013

Feb. 28, 2013

Feb. 28, 2013

Feb. 19, 2013

Dec. 31, 2013

Dec. 31, 2012

Jul. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Feb. 29, 2012

Feb. 29, 2012

Feb. 29, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Issue One [Member]

Issue Two [Member]

Subsequent Event [Member]

Long Term Incentive Plan [Member]

Long Term Incentive Plan [Member]

Lincoln Park [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jorden [Member]

Jorden [Member]

Burrill Securities Llc [Member]

Worden [Member]

JMJ Note [Member]

JMJ Note [Member]

Midcap Financial Llc [Member]

Acquisition Of Aldagen [Member]

Aldagen S Former Investors [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series A and Series B Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series A And Series B Convertible Preferred Stock [Member]

Series E Convertible Preferred Stock [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Fitch Coleman Warrants [Member]

Fitch Coleman Warrants [Member]

Fitch Coleman Warrants [Member]

August 2009 Warrants [Member]

August 2009 Warrants [Member]

April 2010 Warrant [Member]

October 2010 Warrants [Member]

October 2010 Warrants [Member]

Guarantor 2011 Warrants [Member]

Guarantor 2011 Warrants [Member]

February 2012 Inducement Warrants [Member]

February 2012 Inducement Warrants [Member]

Other Warrants [Member]

Other Warrants [Member]

February 2012 Aldagen Warrants [Member]

February 2012 Aldagen Warrants [Member]

February 2013 MidCap Warrants (Member)

February 2013 MidCap Warrants (Member)

February 2013 Subordination Warrants (Member)

February 2013 Subordination Warrants (Member)

February 2013 Worden Warrants [Member]

February 2013 Worden Warrants [Member]

February 2013 RDO Warrants [Member]

February 2013 RDO Warrants [Member]

February 2013 PA Warrants [Member]

February 2013 PA Warrants [Member]

February 2013 Warrants [Member]

February 2013 Warrants [Member]

February 2013 Warrants [Member]

February 2013 Warrants [Member]

February 2013 Warrants [Member]

February 2013 Warrants [Member]

February 2012 Warrant [Member]

February 2012 Warrant [Member]

December 2013 Warrant [Member]

Criteria One [Member]

Criteria One [Member]

Criteria Two [Member]

Criteria Two [Member]

Criteria One [Member]

Criteria Two [Member]

Long Term Incentive Plan [Member]

Long Term Incentive Plan [Member]

Worden [Member]

Long Term Incentive Plan [Member]

Long Term Incentive Plan [Member]

Worden [Member]

Group A Category [Member]

Group B Category [Member]

Group C Category [Member]

Issue One [Member]

Issue Two [Member]

Issue Three [Member]

Issue Four [Member]

Issue Five [Member]

Issue One [Member]

Issue Two [Member]

Schedule of Equity Method Investments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Right Outstanding

'

'

5,288,256

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

325,000

325,000

325,000

1,070,916

[1]

1,070,916

[1]

'

1,488,839

[2]

1,488,839

[2]

916,665

[3]

916,665

[3]

1,180,547

[4]

1,180,547

[4]

300,000

[5]

200,000

[5]

2,115,596

[6]

2,115,596

[6]

1,079,137

[7]

0

[7]

800,000

[8]

0

[8]

250,000

[9]

0

[9]

6,363,638

[10]

0

[10]

136,364

[11]

0

[11]

'

'

'

'

'

'

'

'

'

Entire Outstanding Warrants Callup Condition Based On Minimum Trading Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4

$5

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

1,038,000

2,271,500

'

'

'

'

2,271,500

35,602

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Stock Options and Compensatory Warrants Forfeited In Period

'

'

'

'

'

'

'

'

'

384,137

804,649

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional Warrants Adjustments Due To Antidilutive Provisions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

420,896

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Capital Shares Reserved For Future Issuance Value

'

'

'

'

'

'

'

'

'

'

'

$15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issuable Under Purchase Agreements

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase In Shares Issuable Under Purchase Agreements

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share

'

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Share Purchase Agreement

'

'

'

'

'

'

'

'

'

'

'

375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Additional Shares Issued Under Purchase Agreement

'

'

'

'

'

'

'

'

'

'

'

375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

'

$0.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercise Price

'

$0.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Placement Fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

350,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expense Reimbursement Limit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

52,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant Exercise Price Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

120.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

6,363,638

'

'

'

'

200,000

100,000

'

'

'

'

266,666

533,334

266,666

'

'

'

'

'

'

136,364

250,000

'

'

1,079,137

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

1.42

'

'

0.46

1.5

0.37

'

'

'

'

0.7

0.7

0.7

'

'

'

'

'

'

'

0.7

'

'

0.7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.25

1.5

1.75

0.51

'

0.54

0.6

'

0.5

'

'

'

'

'

1.42

1.42

'

'

'

'

'

'

'

'

'

'

'

0.7

0.7

0.7

0.75

0.66

1.42

1.42

0.68

Royalty Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future Annual Royalty Limitation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

625,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercisable

'

'

'

'

'

'

'

'

'

'

'

'

250,000

500,000

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercised Upon Default In Payment Of Note On Fourth Anniversary

'

'

'

'

'

'

'

'

'

'

'

'

133,333

'

'

266,667

133,333

266,667

133,333

57,143

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Guarantor Obligations, Current Carrying Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercised Upon Default In Payment Of Note On Fifth Anniversary

'

'

'

'

'

'

'

'

'

'

'

'

133,333

107,143

'

'

'

266,667

'

'

57,143

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note payable

'

'

'

3,620,593

2,100,000

'

'

'

'

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Condition For Purchase By Accredited Investor Minimum Share Price

'

'

'

'

'

'

'

'

'

'

'

0.45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued In Private Placement Maximum Percentage

'

'

'

'

'

'

'

'

'

'

'

9.99%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Remitted Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

370,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Investors

'

9,090,911

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

'

'

'

200,000,000

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Liquidation Preference Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

8.00%

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Conversion Basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Each share of Series A stock may be converted into Common stock at a conversion rate equal to 90% of the twenty-day average closing price of the Companys Common stock, but in no case shall this price be less than $3.00 per share.

'Each share of Series B stock may be converted into Common stock at a conversion rate equal to 90% of the twenty-day average closing price of the Companys Common stock, but in no case shall this price be less than $3.00 per share.

'The Series D stock also provided that with limited exceptions as discussed below, in no event would the Company effect any conversion of the Series D stock and the holder of the Series D stock would not have the right to convert the Series D stock, to the extent that such conversion would result in beneficial ownership by the holder of the Series D stock and its affiliates in excess of 9.99% of the then outstanding shares of Common stock (after taking into account the shares to be issued to the holder upon such conversion). The Series D stock holder could decrease the foregoing threshold upon 61 days notice of such decrease to us. The Series D stock was not listed on any securities exchange or automated quotation system.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Redemption Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The Company may redeem Series A stock for cash at a price per share equal to 104% of the liquidation preference amount plus all accrued but unpaid dividends, by providing proper notice of not less than 10 days nor more than 60 days prior to a redemption date set by the Company.

'The Company may redeem Series B stock for cash at a price per share equal to 103% of the liquidation preference amount plus all accrued but unpaid dividends, by providing proper notice of not less than 10 days nor more than 60 days prior to a redemption date set by the Company.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Redeemable Percentage

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

104.00%

103.00%

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Conversion Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.44

'

'

'

'

$0.44

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Right Remaining Exercise Term

'

'

'

'7 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price Of Options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.45

$0.72

'

$0.53

$2.28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued During Period In Lieu Of Dividends

'

'

'

'

76,461

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period On Private Offering

'

'

'

'

4,231,192

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share

'

'

'

'

$1.18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13,399,986

'

7,460,350

'

'

'

'

7,460,350

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period On Inducement To Remaining Shareholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

330,000

'

'

'

'

330,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135,398

'

'

'

207,000

'

'

'

'

'

135,398

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13,539,816

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Release Of Stock Held In Escrow Account

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

139,830

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Redemption Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

170,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends, Preferred Stock, Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value Of Warrant Exercise Agreements

$2,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Dividend Payment Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The Series D stock earned cumulative dividends at the rate of 10% per annum, payable quarterly in cash in arrears on January 15, April 15, July 15 and October 15, beginning on July 15, 2010, or, in the Companys sole discretion, in shares of Common stock valued at the 5-day volume weighted average price ending 3 days immediately preceding the dividend due date, but in no case at a price less than $0.40 per share.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Warrants Vested One

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

Percentage Of Warrants Vested Two

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Warrant Vest On Issuance

'

'

30.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Warrant Vest On Milestones Acheivement

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Shares Designated

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrants Or Rights Expiry Date

'

'

'

'

'

'

24-Feb-14

15-Oct-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9-Apr-15

7-Apr-16

'

28-Apr-16

'

'

'

'

'

31-Dec-14

'

'

'

'

'

'

'

'

'

'

'

'

19-Feb-20

19-Feb-18

19-Feb-20

22-Feb-18

22-Feb-18

31-Dec-14

31-Dec-14

8-Dec-18

[1]

These warrants were issued in connection with the August 2009 financing, are voluntarily exercisable at $0.51 per share and expire in February 2014. These amounts reflect adjustments for an additional 420,896 warrants due to anti-dilutive provisions. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.

[2]

These warrants were issued in connection with the October 2010 financing. They have an exercise price of $0.60 and expire on April 7, 2016. These warrants were previously accounted for as a derivative liability through January 28, 2011. At that time, they were modified to remove non-standard anti-dilution clauses and the associated derivative liability and related deferred financing costs were reclassified to APIC.

[3]

These warrants were issued pursuant to the Guaranty Agreements executed in connection with the Promissory Note issued in April 2011. These warrants have an exercise price of $0.50 per share and expire on April 28, 2016.

[4]

These warrants were issued in connection with the February 2012 warrant exercise agreements executed with certain existing Cytomedix warrant holders. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.

[5]

These warrants were issued to consultants and other professional service providers in exchange for services provided. A warrant for 200,000 Common shares has an exercise price of $1.50, expires on February 24, 2014, and is vested and voluntarily exercisable. A warrant for 100,000 Common shares has an exercise price of $0.37, expires on October 15, 2015, and is voluntarily exercisable upon vesting (50% vested as of December 31, 2013 and 100% vested by February 15, 2014). There is no call provision associated with either of these warrants.

[6]

These warrants were issued in February 2012 in connection with the warrant exchange agreements between Cytomedix and various warrant holders of Aldagen. These warrants have an exercise price of $1.42 per share and expire on December 31, 2014.

[7]

These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share and expire on February 19, 2020.

[8]

These warrants were issued in connection with the February 2013 financing, have an exercise price of $0.70 per share, and expire on February 19, 2018. They are only exercisable if the JPNT Note remains outstanding on or after 04-28-2015 (50% of total) and 04-15-2016 (remainder).

[9]

These warrants were issued in connection with the February 2013 financing. They are voluntarily exercisable, have an exercise price of $0.70 per share, and expire on February 19, 2020.

[10]

These warrants were issued in connection with the February 2013 registered direct offering. They are voluntarily exercisable, have an exercise price of $0.75 per share, and expire on February 22, 2018.

[11]

These warrants were issued to the placement agent in connection with the February 2013 registered direct offering. They are exercisable on or after August 21, 2013, have an exercise price of $0.66 per share, and expire on February 22, 2018.

LongTerm_Incentive_Plan_Equity2

Long-Term Incentive Plan, Equity Incentive Plan and Other Compensatory Awards (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Long-term Purchase Commitment [Line Items]	'	'
Granted - Shares	1,038,000	2,271,500
Exercised - Shares	'	-35,602
Long Term Incentive Plan [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Granted - Shares	2,271,500	35,602
Outstanding at December 31, 2013 - Shares	8,520,816	'
Long Term Incentive Plan [Member] | Equity Incentive Plan [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Outstanding at January 1, 2013 - Shares	7,866,953	'
Granted - Shares	1,038,000	'
Exercised - Shares	0	'
Forfeited or expired - Shares	-384,137	'
Outstanding at December 31, 2013 - Shares	8,520,816	'
Exercisable at December 31, 2013 - Shares	7,258,925	'
Outstanding at January 1, 2013 - Weighted - Average Exercise Price	1.28	'
Granted - Weighted - Average Exercise Price	0.5	'
Exercised - Weighted - Average Exercise Price	0	'
Forfeited or Expired - Weighted - Average Exercise Price	1.19	'
Outstanding at December 31, 2013 - Weighted - Average Exercise Price	1.19	'
Exercisable - Weighted - Average Exercise Price	1.26	'
Options Outstanding - Weighted Average Remaining Contract Life	'5 years	'
Exercisable - Weighted - Average Remaining Contractual Term	'4 years 3 months 18 days	'
Outstanding - Aggregate Intrinsic Value	61,018	'
Exercisable - Aggregate Intrinsic Value	58,163	'

LongTerm_Incentive_Plan_Equity3

Long-Term Incentive Plan, Equity Incentive Plan and Other Compensatory Awards (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013
Exercise Price Range One [Member]	'
Long-term Purchase Commitment [Line Items]	'
Exercise Price Upper Range Limit	$1.50
Exercise Price Lower Range Limit	$0.30
Options Outstanding - Shares	6,859,483
Options Outstanding - Weighted Average Remaining Contract Life	'5 years 7 months 6 days
Options Outstanding - Weighted - Average Exercise Price	$0.92
Options Exercisable - Shares	5,644,594
Options Exercisable - Weighted - Average Exercise Price	$0.95
Exercise Price Range Two [Member]	'
Long-term Purchase Commitment [Line Items]	'
Exercise Price Upper Range Limit	$3
Exercise Price Lower Range Limit	$1.51
Options Outstanding - Shares	1,591,333
Options Outstanding - Weighted Average Remaining Contract Life	'2 years 6 months
Options Outstanding - Weighted - Average Exercise Price	$2.19
Options Exercisable - Shares	1,544,331
Options Exercisable - Weighted - Average Exercise Price	$2.18
Exercise Price Range Three [Member]	'
Long-term Purchase Commitment [Line Items]	'
Exercise Price Upper Range Limit	$4.50
Exercise Price Lower Range Limit	$3.01
Options Outstanding - Shares	0
Options Outstanding - Weighted Average Remaining Contract Life	'0 years
Options Outstanding - Weighted - Average Exercise Price	$0
Options Exercisable - Shares	0
Options Exercisable - Weighted - Average Exercise Price	$0
Exercise Price Range Four [Member]	'
Long-term Purchase Commitment [Line Items]	'
Exercise Price Upper Range Limit	$6
Exercise Price Lower Range Limit	$4.51
Options Outstanding - Shares	70,000
Options Outstanding - Weighted Average Remaining Contract Life	'2 years
Options Outstanding - Weighted - Average Exercise Price	$5.20
Options Exercisable - Shares	70,000
Options Exercisable - Weighted - Average Exercise Price	$5.20

LongTerm_Incentive_Plan_Equity4

Long-Term Incentive Plan, Equity Incentive Plan and Other Compensatory Awards (Details 2) (Long Term Incentive Plan [Member], Equity Incentive Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Long Term Incentive Plan [Member] | Equity Incentive Plan [Member]	'
Long-term Purchase Commitment [Line Items]	'
Outstanding at January 1, 2013 - Shares	1,175,000
Granted - Shares	486,364
Exercised - Shares	0
Forfeited or expired - Shares	0
Outstanding at December 31, 2013 - Shares	1,661,364
Exercisable at December 31, 2013 - Shares	1,611,364
Outstanding at January 1, 2013 - Weighted - Average Exercise Price	$1.50
Granted - Weighted - Average Exercise Price	$0.62
Exercised - Weighted - Average Exercise Price	$0
Forfeited or expired - Weighted - Average Exercise Price	$0
Outstanding at December 31, 2013 - Weighted - Average Exercise Price	$1.24
Exercisable - Weighted - Average Exercise Price	$1.27
Outstanding - Weighted-Average Remaining Contractual Term	'2 years
Exercisable - Weighted-Average Remaining Contractual Term	'2 years
Outstanding - Aggregate Intrinsic Value	$10,400
Exercisable - Aggregate Intrinsic Value	$5,200

LongTerm_Incentive_Plan_Equity5

Long-Term Incentive Plan, Equity Incentive Plan and Other Compensatory Awards (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013
Exercise Price Range One [Member]	'
Long-term Purchase Commitment [Line Items]	'
Number of Outstanding Shares, Warrants Outstanding	1,336,364
Weighted Average Remaining Contract Life, Warrants Outstanding	'2 years 3 months 18 days
Weighted Average Exercise Price, Warrants Outstanding	$1.12
Number Exercisable, Warrants Exercisable	1,286,364
Weighted Average Exercise Price, Warrants Exercisable	$1.15
Exercise Price Range One [Member] | Minimum [Member]	'
Long-term Purchase Commitment [Line Items]	'
Range of Exercise Prices	$0.37
Exercise Price Range One [Member] | Maximum [Member]	'
Long-term Purchase Commitment [Line Items]	'
Range of Exercise Prices	$1.50
Exercise Price Range Two [Member]	'
Long-term Purchase Commitment [Line Items]	'
Number of Outstanding Shares, Warrants Outstanding	325,000
Weighted Average Remaining Contract Life, Warrants Outstanding	'1 year 1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding	$1.75
Number Exercisable, Warrants Exercisable	325,000
Weighted Average Exercise Price, Warrants Exercisable	$1.75
Range of Exercise Prices	$1.75

LongTerm_Incentive_Plan_Equity6

Long-Term Incentive Plan, Equity Incentive Plan and Other Compensatory Awards (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Long-term Purchase Commitment [Line Items]	'	'
Share-based Compensation, Total	$717,863	$2,047,731
Awards under the 2002 LTIP [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Share-based Compensation, Total	679,433	2,027,031
Awards under the 2013 EIP [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Share-based Compensation, Total	117	0
Awards outside the equity-based plans [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Share-based Compensation, Total	38,313	20,700
Salaries and wages [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Share-based Compensation, Total	564,737	1,389,001
Consulting expense [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Share-based Compensation, Total	16,278	275,924
General and administrative [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Share-based Compensation, Total	$136,848	$382,806

LongTerm_Incentive_Plan_Equity7

Long-Term Incentive Plan, Equity Incentive Plan and Other Compensatory Awards (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Long-term Purchase Commitment [Line Items]	'	'
Compensation Cost Recognition Period	'1 month 6 days	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	1,038,000	2,271,500
Equity Incentive Plan [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Shares authorized, shares available for grant	3,000,000	'
Ending Balance, shares available for grant	2,990,000	'
Long Term Incentive Plan [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Shares authorized, shares available for grant	10,500,000	'
Ending Balance, shares available for grant	1,457,382	'
Number Of Share Options Exercised	531,802	'
Balance Outstanding (Number of shares)	8,520,816	'
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	'Option terms are set by the Board of Directors for each option grant, and generally vest immediately upon grant or over a period of time ranging up to three years, are exercisable in whole or installments, and expire ten years from the date of grant.	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	0.45	1.19
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	2,271,500	35,602
Long Term Incentive Plan [Member] | Equity Incentive Plan [Member]	'	'
Long-term Purchase Commitment [Line Items]	'	'
Balance Outstanding (Number of shares)	8,520,816	7,866,953
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	675,000	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'10 months 24 days	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	712,000	1,828,000
Share Based Compensation Arrangement By Share Based Payment Award Unamortized Compensation Granted	6,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	1,038,000	'

Supplemental_Cash_Flow_Disclos2

Supplemental Cash Flow Disclosures - Non-Cash Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Conversion of convertible debt to common stock	$523,927	$924,904
Preferred dividends paid by issuance of stock	0	82,500
Business combination:	'	'
Issuance Of Contingent Consideration	0	11,109,020
Issuance of replacement warrants	0	1,883,751
Common stock issued in satisfaction of subscription receivable	0	2,790,107
Effect of cancellation of escrowed shares	0	195,132
Obligation to issue shares for professional services	0	30,000
Effect of modification of convertible debt	151,032	0
Common Stock issued for committed equity financing facility	204,015	0
Warrants issued for loan modification	151,758	0
Warrants issued for term loan	568,324	0
Common stock and warrants issued for release of security interest in patents	325,693	0
Warrants issued in connection with convertible debt	1,353,842	0
Derivative liability for embedded conversion option	965,484	0
Common stock issued for professional services	17,850	0
Common stock issued for settlement of contingency	39,150	0
Series E Preferred Stock [Member]	'	'
Business combination:	'	'
Issuance of Series E liability	$0	$18,955,742

Supplemental_Cash_Flow_Disclos3

Supplemental Cash Flow Disclosures - Non-Cash Transactions (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Interest Paid, Total	$564,000	$342,000

Operating_Leases_Details

Operating Leases (Details) (USD $)	Dec. 31, 2013
Operating Leases [Line Items]	'
2014	$360,000
2015	360,000
2016	360,000
2017	340,000
2018	0
Thereafter	0
Total future minimum lease payments	$1,420,000

Operating_Leases_Details_Textu

Operating Leases (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Leases [Line Items]	'	'
Operating Leases, Rent Expense, Net, Total	$324,000	$289,000
Gaithersburg, Maryland [Member]	'	'
Operating Leases [Line Items]	'	'
Area Of Operating Lease Property	7,200	'
Gaithersburg, Maryland [Member] | Lease Two [Member]	'	'
Operating Leases [Line Items]	'	'
Operating Leases, Rent Expense, Net, Total	10,000	'
Gaithersburg, Maryland [Member] | Lease One [Member]	'	'
Operating Leases [Line Items]	'	'
Operating Leases, Rent Expense, Net, Total	$20,000	'
Durham, North Carolina [Member]	'	'
Operating Leases [Line Items]	'	'
Area Of Operating Lease Property	16,300	'

Geographic_and_Customer_Concen2

Geographic and Customer Concentration information (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Geographic Areas, Revenues from External Customers [Line Items]	'	'
Product sales	$10,498,726	$7,241,392
U.S. product sales [Member]	'	'
Geographic Areas, Revenues from External Customers [Line Items]	'	'
Product sales	9,549,015	6,179,050
Non-U.S. product sales [Member]	'	'
Geographic Areas, Revenues from External Customers [Line Items]	'	'
Product sales	$949,711	$1,062,363

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	12 Months Ended			12 Months Ended				3 Months Ended
	Feb. 28, 2013	Dec. 31, 2013	Jun. 30, 2012	Jul. 31, 2009	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Sep. 30, 2008	Sep. 30, 2008
					Gaithersburg, Maryland [Member]	Gaithersburg, Maryland [Member]	Durham, North Carolina [Member]	Durham, North Carolina [Member]	Minimum [Member]	Maximum [Member]
					acre	October 2017 [Member]	acre	December 31, 2018 [Member]
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Estimated Research Development Cost	'	'	'	'	'	'	'	'	$500,000	$700,000
Research And Development	'	368,000	'	'	'	'	'	'	'	'
Letter Of Credit	'	'	'	50,000	'	'	'	'	'	'
Deposit Interest Rate	'	0.10%	'	'	'	'	'	'	'	'
Shares Issuable Contingent Condition Description	'	'This exchange was contingent on the Companys attaining aggregate gross revenues for four consecutive quarters of at least $10,000,000 and if met would result in the issuance of 325,000 shares of the Companys Common stock.	'	'	'	'	'	'	'	'
Contingently Issuable Shares	'	325,000	'	'	'	'	'	'	'	'
Contingently Issuable Shares Amount	'	'	471,000	'	'	'	'	'	'	'
Operating Leases, Rent Expense	'	'	'	'	'	10,000	'	20,000	'	'
Operating Leases, Area	'	'	'	'	7,200	'	16,300	'	'	'
Business Acquisitions Contingent Consideration Shares Issuable	'	20,309,723	'	'	'	'	'	'	'	'
Operating Expense Recognized Value	$1,006,000	'	'	'	'	'	'	'	'	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 10, 2013

Feb. 19, 2013

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 28, 2013

Apr. 30, 2011

Dec. 31, 2013

Feb. 28, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Chief Commercial Officer [Member]

Chief Science Officer [Member]

Dec 2013 Convertible Subordinated Debt [Member]

April 2011 secured promissory note [Member]

MidCap Note [Member]

JPT Warrants [Member]

Private Placement [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Jp Nevada Trust Note [Member]

Midcap Financial Llc [Member]

Worden [Member]

BTIG, LLC [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Equity Incentive Plan [Member]

Chief Commercial Officer [Member]

Chief Commercial Officer [Member]

Chief Commercial Officer [Member]

Chief Science Officer [Member]

Chief Science Officer [Member]

Chief Science Officer [Member]

Chief Science Officer [Member]

Deerfield Warrants [Member]

Deerfield Facility Agreement [Member]

Private Placement [Member]

Placement Agent [Member]

Midcap Financial Llc [Member]

Period One [Member]

Period Two [Member]

Period One [Member]

Period Two [Member]

Equity Incentive Plan [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

0.46

'

1.42

'

'

'

'

'

0.52

'

0.7

0.7

0.7

0.7

0.7

'

'

'

'

'

'

'

'

'

'

'

0.52

'

'

Proceeds From Issuance Of Shares Distribution Percentage

'

'

'

'

'

'

'

'

'

'

'

75.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance Of Common Stock

$5,462,132

$9,493,906

'

'

'

'

'

'

'

'

'

$3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Conversion Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.46

Notes Outstanding Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110.00%

Stock Issued During Period Conversion Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75.00%

Stock Issued During Period Exercise Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.68

Debt Instrument, Convertible, Conversion Price

$0.46

'

'

'

'

'

'

$0.46

'

'

'

'

'

'

'

'

'

$0.46

'

'

'

'

'

'

'

'

'

'

'

'

'

Subsequent Offering Participation Rights Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued During Period Value To Placement Agent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

194,133

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash Commission Issued During Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

240,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,000,000

'

'

'

Initial Draw Disbursement Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,000,000

'

'

'

Second Draw Disbursement Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,000,000

'

'

'

Common Stock Holding Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30.00%

'

'

'

Common Stock Price Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'the average VWAP of the Company’s stock price for the five days immediately after the public announcement of the results of the stroke trial is at least 50% greater than the average VWAP for the five day period immediately preceding the announcement of the results of the stroke trial, and (iv) the average VWAP for the five day period preceding the announcement of the results of the special meeting of the Company’s shareholders is at least 200% of the Conversion Price of $0.52 or $1.04

'

'

'

Senior Secured Convertible Notes Interest Rate Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.75%

'

'

'

Principal Payment Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

Percentage Of Beneficial Ownership Limitation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.98%

'

'

'

Conversion Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.52

'

'

'

Redeemption Share Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

Proceeds Percentage For Equity Raising Transaction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

'

Exemption Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

Event Of Default Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

Warrants Issue For Common Stock Acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,115,384

'

'

4,797,692

'

Exercise Price

'

'

'

'

'

'

'

'

'

'

$0.52

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.52

'

'

'

'

Warrants Issue For Common Stock Acquisition On Second Draw

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

67,500,001

'

'

1,272,692

'

Exercise Price On Second Draw

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.52

'

'

'

'

Additional Warrants Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

92,615,385

'

'

'

'

Warrants Limitation Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The seven-year Deerfield Warrants also contain certain limitations that prevent the holder of any Warrants from acquiring shares upon exercise of a warrant that would result in the number of shares beneficially owned by it and its affiliates to exceed 9.98% of the total number of shares of our common stock then issued and outstanding

'

'

'

'

Proceeds From Private Placements Expected Funding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,000,000

'

Total Cash Compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,450,000

'

Cash Compensation On InItial Draw

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

720,000

'

Interest And Fee On Initial Draw Prepayment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,800,000

'

'

'

Convertible Notes Amount Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

339,000

'

'

'

Net Proceeds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,100,000

'

'

'

Secured Debt

'

'

'

'

'

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Term

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

Repayments of Secured Debt

'

'

'

'

'

'

'

'

'

3,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued

107,164,855

93,808,386

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,846,154

'

'

Proceeds from Issuance or Sale of Equity, Total

5,462,132

13,560,862

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

Warrant Issued To Purchase Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,884,615

201,923

'

Class Of Warrant Or Right Expriry Date Of Warrants Or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Mar-19

'

'

Payments for Commissions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

160,000

'

Debt Instrument Accrued Interest Convertible Conversion Price1

'

'

'

'

'

'

'

$0.53

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Salary Amount Annually

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

290,000

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

1,038,000

2,271,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'0 years

'

'0 years

'0 years

'

'36 years

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

'

'

'

'

'

'

1.06%

'

'

'

'

'

'

'

'

'

'

'

'

'

40.00%

60.00%

'

25.00%

75.00%

'

'

'

'

'

'

Bonus Percentage Of Annual Salary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$40

'

'

'

'

'

'

'

'

Convertible Debt instrument, Accrued Interest Percentage

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

1,600,219

'

'

'

'

'

'

5,981,859

'

'

750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation award, outstanding common stock acquisition percentage

'

'

'

'

'

1.27%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'